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This thesis is divided into two main sections. The introductory section comprises 
studies one and two, while the pilot RCT section comprises studies three and four. The 
initial two studies were carried out to inform the latter two. 
Injecting behaviour in people who inject drugs (PWID) is a significant risk factor for 
hepatitis C virus (HCV) infection. Self-efficacy has been shown to be associated with 
injecting risk behaviour. The risk of HCV re-infection in people who inject drugs (PWID) 
treated for HCV remains high when sharing of injecting equipment continues post-
treatment.  
The first study aimed to assess the effectiveness of forming implementation intentions 
to reduce substance use. Implementation intentions are self-regulatory processes 
which help achieve health-related behaviour change. A systematic search of published 
literature was conducted to gather evidence on the effectiveness of the use of 
implementation intentions for substance use behaviours from existing studies. The 
findings of studies selected from this search were collated to carry out a meta-analysis 
in order to produce evidence for the effectiveness of implementation intentions within 
substance use behaviours, informing study 3. Significant effects were found of 
implementation intentions on alcohol use and tobacco smoking. A small non-
statistically significant result was reported for self-efficacy. No studies were found in 
the systematic search on the use of implementation intentions for the reduction of 
illicit drug use. 
The second study aimed to investigate possible injecting behaviour changes associated 
with clinical treatment of HCV. The chapter reports the results from a data analysis 
exercise completed in January 2018 on participants of Eradicate-C, a clinical trial of 
HCV treatment in PWID. A significant reduction in weekly injecting frequency was 
reported by participants on treatment (n=84).  
The third study, ADAPT, represents the main study of this thesis. ADAPT is a pilot 
randomised controlled trial testing the use of implementation intentions with people 
who inject drugs on treatment for hepatitis C to increase self-efficacy and reduce 
sharing of injecting equipment. It involved four visits over the course of participants’ 
HCV treatment. The intervention was carried out during the second visit. Psychosocial 
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factors measured during visit 1 of ADAPT (n=50) were explored as predictors of the 
primary outcome, injecting risk behaviour. A regression analysis was performed with 
bootstrapping to test a predicting model of injecting risk behaviour as explained by 
injecting frequency, identification with family and identification with drug network. 
Identification with drug network was the only significant predictor of injecting risk 
behaviour. Correlation analyses showed strong correlations between self-efficacy, 
injecting risk behaviour, injecting frequency and group identification with drug 
network. No significant differences were found between control and intervention 
groups on self-efficacy and injecting risk behaviour (n=32).  
The fourth study is a sub-study of ADAPT. This study was a qualitative investigation of 
the lived experience of PWID who are infected with HCV.  Thematic analysis was used 
to analyse the findings of the study. It was run concurrently with ADAPT. Three 
overarching themes were identified in the interview transcripts: 1. “Changing illness 
perception”; 2. “Shifting agency”; 3. “Treatment adherence”. 
The last chapter of the thesis aims to integrate the findings of study 3 and 4 into one 
final discussion. It also aims to provide a narrative reflection on the lessons learnt 
whilst planning and conducting the research with a hard-to-reach population, 
concluding with implications of the findings, the limitation of the studies and the 
suggestions for future research. 
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Chapter One: Introduction 
This chapter presents a literature review exploring definitions and characteristics of 
the disease and the population under investigation. It will provide an introduction to 
hepatitis C virus, its progression, transmission, diagnosis, treatment and costs; it will 
explore injecting drug use risk behaviour and its psychosocial predictors. The 
numerous harm reduction strategies utilised in Scotland will then be briefly discussed. 
The current challenge of hepatitis C reinfection, facing health care systems around the 
world, will be presented, followed by the role health psychology can play in the 
context of substance use and hepatitis C care. Finally, an overview of the thesis will 
conclude the chapter. 
1.1 The Hepatitis C Virus 
1.1.1 Definition and epidemiology 
Hepatitis C is a blood-borne infectious disease which primarily affects the liver. The 
Hepatitis C Virus (HCV) can cause both acute and chronic infections of the liver. An 
acute hepatitis C infection typically presents itself as a mild, usually asymptomatic 
infection lasting for a few weeks which is spontaneously cleared without any 
treatment. A chronic infection (lasting longer than six months) can become a very 
serious long-term and life-threatening condition (British Medical Journal - BMJ, 2017), 
yet still remain asymptomatic for years or decades. There are 6 major genotypes and 
more than 50 subtypes, with genotypes 1, 2 and 3 being predominant, yet prevalence 
of different genotypes varying extensively by continent (BMJ, 2017). In Scotland and 
the UK, the most prevalent genotypes are genotypes 1 and 3 (Public Health England - 
PHE, 2014). 
The World Health Organization (WHO) estimates that, globally, 71 million people are 
chronically infected with HCV, accounting for 1% of the global population, with the 
Mediterranean and Eastern European regions showing the highest prevalence (WHO, 
2017a). In the UK, it is estimated that rates of HCV positivity have fallen from 214,000 
people (PHE, 2017a) to 143,000 people (PHE, 2019). Two-thirds remain undiagnosed, 
and around 1% of the Scottish population remains affected (Health Improvement 
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Scotland, 2017). As of the last day of December 2016, 40,154 cases of HCV antibody-
positivity had been diagnosed in Scotland (Health Protection Scotland - HPS, 2017a).  
 
1.1.2 Progression of the disease 
Between 20 and 50% (in special populations) of people acutely infected with HCV, 
usually presenting an asymptomatic infection, will spontaneously clear the virus and 
will not require any treatment (Gerlach et al 2003; Pawlotsky, 2004). Up to 80% of the 
infected population, however, will develop a chronic infection (Figure 1), resulting in 
variable progression rates and levels of hepatic inflammation and fibrosis. The 
progression of fibrosis to cirrhosis will occur in about 20% of chronic infected patients 
in 20 years of infection (Figure 1). The prevalence of chronic infection in clients of 
needle exchanges in Scotland is estimated to be 31% (HPS, 2019). 
Of those who develop cirrhosis, approximately half will die as a consequence of liver 
disease, with an annual 1 to 4% risk of developing hepatocellular carcinoma and a 
similar risk of developing end-stage liver disease (Figure 1) (Pawlotsky, 2004).  
 
Figure 1.1: HCV disease progression 
 
 
Figure 1.1  HCC – Hepatocellular Carcinoma; ESLD – End-Stage Liver Disease 
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1.1.3 Transmission 
HCV is a blood-borne virus, therefore transmission happens through percutaneous 
exposure to infected blood (BMJ, 2017). The most common transmission risk factor for 
HCV infection is injecting drug use, with around a half of all people who inject drugs 
(PWID) infected with HCV (PHE, 2017a). The latest figures provided by the Needle 
Exchange Surveillance Initiative (HPS, 2019) in Scotland, report 57% HCV antibody 
positivity in PWID. 
Infection transmission can also occur due to unsafe sex, in particular in people with 
multiple partners or at risk of sexually transmitted infections  (0.4-1.8 per 100 person 
years) (Terrault, 2002), and due to unsafe medical practices, in particular in low and 
middle-income countries. In 2000, in 10 out of 14 sub-regions (according to WHO 
categorisation), an estimated 2 million HCV infections were caused by unsafe medical 
practices, accounting for 40% of new infections (Hauri et al. 2003). Percutaneous 
exposure to HCV-infected blood can also occur amongst healthcare staff through, for 
example, needle-stick injury (BMJ, 2017). Male sex is associated with lower likelihood 
of spontaneous clearance and with faster progression of disease compared to females. 
Perinatal transmission rate of the virus from HCV-infected mother to child is around 
2.4%, with risk of transmission increased if the mother is co-infected with HIV (Human 
Immunodeficiency Virus) or has high serum titer of HCV RNA (BMJ, 2017). 
Identification of HCV was scientifically challenging. Burgeoning success was only 
achieved in 1988, when the Chiron Corporation in the USA announced that they had 
discovered the virus, although details of the discovery were not published until 1989. It 
was then recognised that this virus was the cause of most cases of non-A non-B 
hepatitis (NANB) Hepatitis. Tests for the virus were developed and screening of 
donated blood for HCV was introduced (The Penrose Enquiry, 2015). 
Prior to 1991, when screening became available due to development of the first 
antibody tests, blood transfusions and organ transplant had been a major risk factor 
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1.1.4 Screening and diagnosis 
Testing is offered in Scotland to people most at risk of HCV infection, namely people 
who inject drugs and men who have sex with men. Prevalence of HCV is higher in 
people who inject, people with HIV (Human Immunodeficiency Virus), people on 
dialysis, those incarcerated, people with tattoos, people with multiple sex partners 
and/or those who perform rough sex practices (BMJ, 2017). 
In Scotland, testing for HCV mainly takes the form of intravenous blood samples or dry 
blood spot tests (DBS). Both methods will also test for HIV and hepatitis B (HBV) 
infections. With intravenous blood samples antibodies can be detected and, if positive, 
an active infection can also be diagnosed, followed by a viral count and a genotype test 
to characterise the virus.  
DBS testing instead requires a small prick to the finger and drops of blood are 
deposited on a DBS card.  In this way, a patient can be tested for antibodies. This has 
allowed testing to be exponentially increased and performed in a variety of settings, as 
minimal clinical skills are required to carry out the test. Support workers, nurses, 
needle exchange and pharmacy staff have been extensively trained in Scotland to carry 
out DBS testing in order to scale up testing, yearly re-testing and to find undiagnosed 
cases. The intensity of testing in Scotland is enabled by a positive and flexible approach 
and a commitment to eliminating HCV by the Scottish Government. 
A reactive DBS test is usually followed by an intravenous blood sample in order to 
check for active infection and viral load by conducting a polymerase chain reaction 
(PCR) test. As mentioned above, at least 20% of people will spontaneously clear an 
HCV infection, which would produce a reactive DBS test result given the presence of 
anti-HCV antibodies but would show no active infection when checked with an 
intravenous blood sample. 
Recent advances in testing make it now possible to test for HCV RNA PCR (active 
infection) from DBS tests when they are saturated with blood. This allows for a quicker 
diagnosis and it eliminates the need for a full blood sample unless a genotype needs to 
be determined. Guidelines about genotyping are in the process of changing given the 
introduction of pan-genotypic DAA treatment.  
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1.1.5 Treatments and costs to the NHS 
Interferon (IFN) has been the first treatment available since the discovery of HCV. With 
advances in the field, HCV treatment success rate has improved throughout the 
decades. Sustained Virological Response (SVR), refers to the success of the treatment 
by measuring the level of detectable virus in the blood. Usually after a minimum of 12 
weeks post treatment, blood is checked for viral load. When undetectable, the patient 
is regarded as treated successfully and cured. Treatment efficacy for genotype 1 (the 
most difficult genotype to treat) has increased steadily throughout the years: cure 
rates were around 10% in 1994 (IFN-only), around 30% in 1998 (IFN + Ribavirin), 44% in 
2001 (Pegylated-IFN + Ribavirin), around 70% in 2011 (Peg-IFN + Ribavirin + 1st 
generation of Direct Acting Antivirals), and an outstanding 93-100% from 2014/2015 in 
the Interferon-free area of Direct Acting Antivirals (DAAs) (Pawlotsky et al. 2015). 
When they were first released in the UK, DAAs were extremely expensive, with a 
course of treatment costing around £35,000 per patient (Hurley, 2018). Access to 
these drugs was therefore limited, with DAAs only offered to a specific few, while 
others continued to be treated with Peg-IFN, notwithstanding its inferiority in terms of 
SVR rates and harsh side effects. The NHS have worked tirelessly to secure deals with 
pharmaceutical companies producing DAAs, reducing the cost of a course of treatment 
to around £5,000 per patient (Hurley, 2018). With NHS boards often capping supply 
arrangements and treatment expenditure, lower treatment costs are essential for 
treatment scale up. SVR rates of close to 100% coupled with a scale up of treatment 
available theoretically equates to cost savings to the NHS because of substantial 
reductions in advanced liver diseases such as cirrhosis, decompensated liver or 
hepatocellular carcinoma, and related mortality (Hurley, 2018). 
 
1.1.6 Tayside in comparison to rest of Scotland 
There has been an exponential increase in HCV treatment across NHS Tayside, with 
clinical trials and NHS working towards the mutual goal of HCV elimination in a 
geographic area. Data provided by the NESI study, the Needle Exchange Surveillance 
Initiative that measures and monitors prevalence of BBV and characterises injecting 
risk behaviour in PWID in Scotland, shows that NHS Tayside and the rest of Scotland 
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are quite similar in terms of population characteristics, such as homeless levels and 
drugs used (Table 1.1) (HPS, 2019). High-risk injecting behaviours and lower Hepatitis B 
vaccination rates show Tayside to have slightly worse rates than the rest of Scotland 
(HPS, 2019). The data also shows NHS Tayside to be leading in Scotland for HCV care 
outcomes. In the last 12 months, the rates of testing and dispensed HCV therapy were 
the highest in Scotland, while the rates  for needle exchange users never having been 
tested for HCV were the lowest in Scotland (Table 1.1) (HPS, 2019) 
 
Table 1.1 NESI 2017/18 data comparing Tayside versus Scotland 
Description Tayside (N=211) Scotland (N=2,130) 













Groin Injecting 59% 45% 
Injecting for 15 years + 42% 58% 
Hep B vaccination ever 59% 71% 
HCV test in last 12 months 68% 56% 
Never tested for HCV 1% 6% 
HIV test in last 12 months 50% 49% 
Prescribed Naloxone in last 12 months 66% 61% 
Carrying Naloxone at interview 6% 13% 
Prescribed methadone in last 6 months and 
collecting injecting equipment 
49% 69% 
Cleared HCV after treatment (self report) 24% 13% 
Received HCV therapy 77% 50% 
Received HCV therapy in community 74% 30% 
Estimated Chronic HCV Prevalence 22% 31% 
Soft Tissue Infection in last 12 months 22% 20% 
Overdose in last 12 months 13% 15% 
Source: HPS (2019) data, Mrs Donna Thain, Sexual Health & BBV MCN Manager, NHS Tayside. 
 
1.2 Injecting risk behaviour 
In Scotland, heroin continues to be the most injected substance, albeit in recent years 
there has been a substantial spike in the injecting use of cocaine, at times both 
substances being used together (HPS, 2019). Benzodiazepine use is also very common 
(Johnson et al. 2016), and it is associated with a number of risk-taking behaviours such 
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as frequent heroin injecting, cocaine injecting, non-fatal overdose, unsafe sex and 
syringe sharing (Tucker et al. 2016). 
Injecting drug use is the principal means of transmission of HCV (PHE, 2017a), as the 
infection is not spread solely when sharing needles, but can be transmitted via all 
injecting paraphernalia: needles, barrels, pots or spoons, filters, water and 
tourniquets. 
Despite being aware of injecting-related risks, PWID continue to carry out potential 
harmful injecting behaviours. Research suggests harm reduction strategies might be 
tackling the wrong factors, such as health motivation, as many individuals are not 
concerned with the health risk related to injecting, and delay discounting is common 
practice in PWID (Reynolds, 2006).  
 
1.2.1 Injecting sharing behaviour at the individual level 
At an individual level, different mental health and psychosocial factors have been 
investigated in relation to the sharing of injecting equipment. Depressive symptoms 
and high anxiety assessment scores have both been associated with receptive syringe 
sharing (Bailey et al. 2007; Perdue et al. 2003). Negative affectivity and feelings of 
hopelessness also influence injecting risk behaviour and reduce self-efficacy to avoid 
sharing (Cheng et al. 2012; Mackesy-Amiti et al. 2014). Difficulty in avoiding or refusing 
sharing of injecting equipment can also be a result of lack of emotional regulation, high 
delay discounting and impulsivity, especially when the individual is experiencing 
negative emotions, intoxication or withdrawal (Cheng et al. 2012; Mackesy-Amiti et al. 
2014). 
Self-efficacy has been found to play an important role in injecting risk behaviour 
among PWID (Bonar & Rosenberg, 2011; Cox et al. 2008; Gagnon & Godin, 2009; 
Gibson et al. 1993; Nasir & Rosenthal, 2009; Thiede et al. 2007; Wagner et al. 2010a). 
Different types of self-efficacy have been investigated, such as self-efficacy to always 
use new equipment (Gagnon & Godin, 2009), self-efficacy to avoid sharing (Thiede et 
al. 2007), self-efficacy to convince others to inject more safely (Cox et al. 2008). Whilst 
assessing constructs related to self-efficacy, Gagnon and Godin (2007) found that 
intention to always use new equipment was also predicted by perceived behavioural 
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control and attitudes towards new equipment and its perceived benefits (Cox et al. 
2008;  Gagnon & Godin, 2007). Perceived benefits of safer injecting is often influenced 
by subjective norms and the perception of peers’ attitudes, as well as perceived 
benefits of safe behaviours. Social norms, such as believing that peers engage in 
injecting equipment sharing, predicted sharing of injecting equipment (Bonar & 
Rosenberg, 2011; Davey-Rothewell et al. 2010; Davey-Rothewell et al. 2015; Shaw et 
al. 2007). 
Social norms, perceived susceptibility to risky consequences, such as HIV or HCV 
infection, and attitudes to these risks also influence individual behaviour (Bailey et al. 
2007; Bonar & Rosenberg, 2011; Rhodes & Treloar, 2008; Skeer et al. 2018). HCV in 
particular can be perceived by PWID as an unavoidable infection, as ubiquitous and 
omnipresent (Rhodes & Treloar, 2008) and sometimes described as a ‘common cold’ 
for PWID by PWID (Skeer et al. 2018). These attitudes ‘normalise’ HCV infection. Yet, 
regardless of the normalisation of HCV infection in PWID, stigma towards HCV is still 
present both in the general population and the PWID population itself (Brener et al. 
2014; Krzeczkowska et al. 2019; Treloar et al. 2013a). 
Stigma is a social construct that occurs in a defined sociocultural and historical context 
(Becker & Arnold, 1986). It can impact both the mental and physical health of 
individuals (Ahern et al. 2007; von Hippel et al. 2018). Although it is considered as a 
phenomenon which occurs at societal level, when individuals from stigmatised groups 
are exposed to stigma overtime, they can start to internalise the negative attitudes 
towards them, thereby beginning to self-stigmatise and producing an individual-level 
phenomenon (von Hippel et al. 2018). Literature has previously described the 
relationships between internalised stigma and poor mental health and lower self-
esteem (Cama et al. 2016), as well as lessened use of injecting equipment provision 
sites to access sterile equipment (Rivera et al. 2014), and less likelihood of disclosure 
of blood-borne virus status (von Hippel et al. 2018). However, a recent study found an 
association between high levels of implicit internalised stigma and lower rates of 
injecting equipment sharing (von Hippel et al. 2018). When drug users had a more 
positive drug using identity, internalising a positive view, they were more likely to 
share equipment (von Hippel et al. 2018). The influence of stigma and discrimination 
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on injecting behaviour practices has not only been investigated from the point of view 
of the individual’s internalised self-stigma. PWID are a stigmatised population, and 
stigmatising attitudes can translate into discriminatory behaviours; but the way 
individual PWID perceive stigma and discrimination differs depending on who is the 
discriminating actor. Although PWID often report perceiving themselves as being the 
target of discrimination from the general population and general health workers 
(Brener et al. 2014; Treloar et al. 2013a; Wilson et al. 2014), this type of discrimination 
is not associated with injecting risk behaviour (Wilson et al. 2014). In contrast, the 
perception of discrimination by harm reduction staff, who are expected to be more 
knowledgeable, understanding and empathic about addictive behaviours, is associated 
with an increase in reports of sharing behaviour (Wilson et al. 2014).   
 
1.2.2 Injecting sharing behaviour at the social level 
As exemplified by the individual’s own perception and consequent behaviour of wider 
social level factors such as stigma and discrimination, the social nature of drug use, and 
injecting drug use, creates a complex interplay of inter and intrapersonal factors which 
influence decision making and motivation in regards to injecting behaviour and 
injecting sharing behaviour (European Monitoring Centre for Drugs and Drug Addiction 
- EMCDDA, 2001).  Macro-environmental and social factors such as housing and 
benefits policies, or the availability and purity of heroin, can affect social relationships 
maintained or newly formed, influencing the individual’s social network, place of drug 
purchase, preferred dealer, use of different substance and way in which these 
substances are used (EMCDDA, 2001; Fraser & George, 1988; Rhodes, 2008). Micro-
environmental factors such as accessibility of Injecting Equipment Provision (IEP), for 
example opening hours and geographical location or locations where the injecting take 
place, such as secluded public places or ‘trap houses’, will influence risk injecting 
practices  (Adamson et al. 2017; Cloud et al. 2019; Fraser et al. 2016).  
Social networks play an important role in the sharing of injecting equipment (Day et al. 
2005; Fraser et al. 2016; Latkin et al. 2011; Nasir & Rosenthal, 2009; Shaw et al 2007).  
Networks can be formed of close friends, family and partners, or be simply convenient 
acquaintances that pool resources. The characteristics of these networks are predictive 
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of injecting risk practices. Sharing behaviour is more common in networks which are 
larger in size (De et al. 2007; Heimer et al. 2014a; Smith et al. 2017) and in social 
environments that present acceptability of sharing or social pressure related to the 
expectancy of sharing of injecting equipment (Bailey et al. 2007; McGowan et al. 2013; 
Neaigus et al. 2006). Refusing to share equipment in these networks might produce 
negative social consequences and individuals might therefore feel pressurised in 
sharing (McGowan et al 2013). Increasing resistance to peer pressure to share 
equipment (Magura et al 1989) and reducing the importance of the perceived negative 
social consequences of sharing (Thiede et al. 2007) might help promote safe injecting 
and might be achieved through increasing self-efficacy to refuse sharing (Cox et al. 
2008; Nasir et al 2009; Thiede et al. 2007).  
Interactional network characteristics, such as norms or trust between members, have 
been defined in the literature as social capital when they assist in enhancing action and 
cooperation for mutual benefits to members (Putnam, 2001). Social capital that 
generates from social networks such as social support has been found to be an 
important factor in the prevention of risk-taking in substance use (Neaigus et al. 1996). 
In a 2016 study (Kumar et al. 2016), members of networks who reported higher social 
capital, such as material aids, emotional support and social participation, were less 
likely to share equipment compared to individuals reporting low social capital.  
However, social support, such as emotional or instrumental support, has also been 
positively associated with injecting equipment sharing (Lakon et al. 2006; Zapka et al. 
1993). In particular, multiplex relationships such as drug using sexual partners present 
a variety of factors influencing injecting risk behaviour. Evidence suggests that people 
with an injecting drug using partner are more likely to start using illicit drugs and to be 
initiated to injecting (Cox et al. 2008; Fraser et al. 2016; Gossop et al. 2002; Medić et 
al. 2008; Roux et al. 2014). Couples who are more intimate, report having instrumental 
support and pool money for drugs are more likely to share injecting equipment 
(Shahesmaeili et al. 2018). Couples featuring intimate partner violence also show an 
association with sharing equipment, with recepting syringe sharing being associated 
with experience of psychological and physical abuse (Stoicescu et al. 2019). 
Although the literature suggests social networks impact risk-taking behaviour for 
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injecting drug use, evidence is not clear on whether this impact is positive or negative, 
and the direction of this impact might be produced by individual network structural 
and interactional characteristics (Lakon et al. 2006). A deeper understanding of these 
characteristics is necessary to identify the mechanism influencing injecting sharing 
behaviour. 
 
1.2.3 Theory of Planned Behaviour 
One of the dominant health behaviour models which highlights the influence of 
attitudes, societal norms and perceived behaviour control on behaviour is the Theory 
of Planned Behaviour (TPB) (See Figure 1.2; Ajzen & Madden, 1986; Ajzen, 1991).  
According to the TPB, behaviour is predicted by behavioural intention, which in turn 
can be predicted using attitudes, subjective norms and perceived behavioural control 
towards the behaviour (Sutton et al. 1999). Perceived behavioural control also has a 
direct influence on behaviour, omitting the mediating effect of the behavioural 
intention (Ogden, 2012). Perceived behavioural control can be divided into two main 
constructs: controllability and self-efficacy. Controllability refers to the external 
control factors, the level of control an individual has over not using shared 
equipment, such as accessibility to clean equipment. Self-efficacy refers to the 
individual’s confidence in their own ability to perform an action, their internal control 
factors, skills and abilities to refuse sharing of equipment (Ogden, 2012). 
Self-efficacy was a construct introduced by Bandura (1986) as a central feature of 
Social Cognitive Theory. Social cognitive theory proposes that behaviour is a result of 
expectancies (including self-efficacy expectancies), incentives (consequences of 
change in behaviour) and social cognitions (and an individual’s representation of the 
social world (Ogden, 2012).  
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The TPB and other social cognitive models use social cognitive theory as the basis of 
their theoretical framework. The TPB has been widely applied to inform health 
behaviour research in a variety of settings and health topics, as explored by well-cited 
meta-analyses (Armitage & Conner, 2001; Trafimow et al. 2002).The TPB has also 
been widely criticised for being too simplistic as a social cognitive model, for not 
predicting behaviour when tested experimentally, for its focus on rational thinking 
and decision making and its lack of emotional and unconscious influences on 
behaviour (Ogden, 2012; Sniehotta et al. 2014). 
1.2.3.1 Self-efficacy and implementation intentions 
As mentioned in the paragraphs above, self-efficacy has been found to play an 
important role in injecting risk behaviour among PWID (Bonar & Rosenberg, 2011; Cox 
et al. 2008; Falck et al 1995; Gagnon & Godin, 2009; Gibson et al. 1993; Kang et al. 
2004; Rácz et al 2007; Thiede et al. 2007; Wagner et al. 2010a). Intervening on self-
efficacy can influence overall sharing practices, therefore reducing individuals’ risks of 
HCV infection (Copenhaver & Lee, 2006; Latka et al .2008; Robles et al. 2004). 
PWID are usually aware of the risks they incur in sharing equipment, yet when the 
sharing situation occurs, they are unable or unwilling to refuse (Rhodes & Treloar, 
Figure 1.2: Adapted from Ogden (2012) 
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2008; Skeer et al. 2018). Previous research shows that by increasing self-efficacy and 
planning actions, injecting risk behaviours can be reduced (Copenhaver & Lee, 2006; 
Latka et al .2008; Robles et al. 2004). 
Given part of the focus of the TPB is to predict behaviour from behavioural intention, 
the theory has been used extensively as the basis to design interventions which 
explore and intervene on the intention-behaviour gap. Implementation intentions 
have been used as an extension of the TPB to intervene on the gap between intention 
and behavioural action (Higgins & Conner, 2013). 
 Implementation intentions are self-regulatory processes that allow individuals to plan 
how they will perform a behaviour when a certain situation occurs, in the form of if-
then plans (Gollwitzer & Sheeran, 2006; Prestwich et al. 2006). Questions have been 
posed about the possible effectiveness of implementation intentions in individuals 
under the influence of drugs (Nydegger et al. 2013), such as people presenting with a 
high cognitive load when in opiate withdrawal (Brandstätter et al. 2001). Brandstätter 
and colleagues (2001) tested the use of implementation intentions on such a 
population for everyday activities and found that both low and high cognitive load 
patients showed ‘automatised’ action initiation when they had formed 
implementation intentions. 
Systematic reviews and meta-analyses assessing the effectiveness of implementation 
intentions to increase health-related behaviours such as healthy eating, physical 
activity, reducing alcohol use or smoking, have shown variable effects size, with 
reported standardized mean differences varying between 0.24 and 0.65 (Adriaanse et 
al. 2011; Bélanger-Gravel et al. 2013; Gollwitzer & Sheeran, 2006). However, some 
research has shown that forming implementation intentions can have negligible 
effects on both goal intentions and self-efficacy (Webb & Sheeran, 2008). The 
accessibility of the components of plans mediated the effect of implementation 
intentions on goal achievement (Webb & Sheeran, 2008). Using a volitional help sheet 
can provide participants with a structured approach to creating effective 
implementation intentions (Arden & Armitage, 2012). This has been shown to be an 
effective intervention for binge drinking and smoking cessation in student populations 
(Arden & Armitage, 2012).  
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Forming if–then plans specifying situations and associated solutions to achieve a 
particular goal could make an individual feel more confident about succeeding in such 
a task (Webb & Sheeran, 2008). The impact of implementation intentions on self-
efficacy, as well as the role of self-efficacy within implementation intention 
interventions has been investigated by various researchers with mixed findings (Milne 
& Sheeran, 2002; Murray et al. 2005; Rodgers et al. 2002). Self-efficacy was 
investigated as a potential mediator (Armitage & Arden, 2012) and also as a 
moderator of the effects of the intervention (Wieber et al. 2010). 
A more in depth investigation of the use of implementation intentions to change risk 
behaviour and self-efficacy will be presented in Chapter 2. No published study to date 
has investigated the use of implementation intentions to increase self-efficacy and 
reduce injecting sharing behaviour.  
 
1.3 Harm Reduction 
Harm reduction is a term that encompasses policies, programmes and services 
established to reduce harm (health, social and economic harms) to individuals and 
their communities associated with substance misuse (Newcombe, 1992; Scottish 
Parliament Information Centre - SPICe, 2017).  Harm reduction interventions and 
services form part of the controllability aspect of individual behaviour, the external 
factors that influence perceived behavioural control, behavioural intention and 
behaviour itself. The harm reduction budget is controlled and decided by the Scottish 
Government. In recent years, the budget for drug and alcohol treatment and related 
services has been reduced quite significantly (Audit Scotland, 2019; Scottish 
Government, 2017; SPICe, 2017). Table 1.2 shows funding allocation for Alcohol and 
Drug Partnerships (ADP) in the NHS Tayside board and in Scotland between 2015 and 
2018.  
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Table 1.2 ADP Funding allocations for Alcohol and Drug Treatment and related 
services in Tayside and the whole of Scotland 
NHS Board 2015-16 (£) 2016-17 (£) 2017-18 (£) 
Tayside 5,363,523 4,158,654 4,158,654 
Total Scotland 69,209,071 53,800,001 53,800,001 
Source: Scottish Government, 2017; SPICe, 2017; Audit Scotland, 2019 
 
When the most recent drug and alcohol strategy was published in November 2018, an 
additional £20million per year was announced for drug and alcohol services in 
Scotland. The annual funding for 2018-19, 2019-20 and 2020-21 was therefore 
increased to a total of £73.8 million (Audit Scotland, 2019; Scottish Government, 2017; 
SPICe, 2017).  Of the extra £20 million, £17m were specifically ring-fenced to invest in 
patient/peer-led service design, support families affected by addiction, to improve 
retention rates in treatment and reduce waiting times (Audit Scotland, 2019; SPICe, 
2017). Out of the full allocation, £3 million was subdivided between a challenge fund 
to invest in innovative ways of working with this population and to prevent 
homelessness (Audit Scotland, 2019; SPICe, 2017). 
Harm reduction strategies, policies, programmes and services for drug misuse which 
are currently being offered or considered in Scotland are hereby briefly presented and 
discussed. 
 
1.3.1 Opiate Substitution Therapy 
Opiate Substitution Therapy (OST) is a pharmacological intervention used to substitute 
illicit opiates with synthetic prescribed alternatives. They are used to treat opioid 
dependency to prevent withdrawals and reduce craving for illegal substances, with the 
aim of reaching stability and reducing prescribed amount overtime (National Institute 
for Health and Care Excellence - NICE, 2007a; SPICe, 2017). The British National 
Formulary (the BNF) recommends the use of methadone and buprenorphine as 
synthetic opioids for the pharmacological treatment of substance misuse (NICE, 
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2007a). They provide milder, less euphoric and longer lasting effects compared to 
heroin.  
Methadone is a synthetic opioid receptor agonist with effects on the body similar to 
that of morphine. The usual maintenance dose that patients will receive is 60-120mg 
daily as an oral solution (NICE, 2007a). An oral concentrate solution, tablets and 
injectable solution of methadone are also available but the oral solution is the most 
commonly prescribed. Methadone is the most prescribed drug used for OST in 
Scotland at 12.13 daily doses per 1000 population per day (Information Services 
Division - ISD, 2018a). 
Buprenorphine is both a partial opioid agonist and antagonist, and provides less 
euphoric and sedating effects than methadone (NICE, 2007a). It is recommended for 
the treatment of substance misuse with the support of medical, psychological and 
social care. It is available as sublingual tablets, injectable solution or transdermal 
patches. Sublingual tablets are the most commonly prescribed, with a maintenance 
dose of between 12-24mg daily (NICE, 2007a). Buprenorphine differs from methadone 
as it has a higher affinity with opioid receptors, occupying them for longer and 
rendering the use of other opioids (synthetic and heroin alike) somewhat futile. NICE 
(2007a) reports the potential for abuse of buprenorphine, as tablets can be crushed 
and injected. In Scotland, buprenorphine is prescribed at a rate of 0.56 daily doses per 
1000 population per day (ISD, 2018a). 
Literature comparing fixed doses of methadone maintenance therapy (MMT) and 
buprenorphine maintenance therapy (BMT) suggests fixed MMT doses have higher 
retention rates (NICE, 2007a). Literature on illicit opiate use produced mixed results on 
comparing MMT and BMT doses, with flexible doses showing no significant differences 
between the two therapies (NICE, 2007a). However, lower levels of mortality, 
especially related to opioid overdose, have been associated with BMT compared to 
MMT (NICE, 2007a; SPICe, 2017).  
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1.3.2 Heroin-assisted treatment 
Heroin–assisted treatment was introduced in the 1990s in Switzerland and has since 
become an important treatment option for people for whom standard therapies such 
as OST or residential rehabilitation programmes have not been successful (EMCDDA, 
2012). It is also referred to as supervised injectable heroin, because all doses (most 
typically 200mg of diacetylmorphine) are supervised by nursing staff to ensure 
compliance and safety, and prevent prescribed heroin entering the illicit market 
(EMCDDA, 2012).  
A number of RCTs have been conducted on the effectiveness and safety of heroin-
assisted treatment. Five were conducted in Europe (van den Brink et al. 2003; March 
et al 2006; Haasen et al. 2007; Perneger et al. 1998; Strang et al. 2010) and one in 
Canada (Oviedo-Joekes et al. 2009). The evidence from all 6 RCT supports the use of 
heroin-assisted treatment. All studies showed that participants in the supervised 
injectable heroin group, compared to the control groups, reduced their illicit heroin 
use, improved their physical and mental health and were involved in less criminal 
activity (EMCDDA, 2012). 
The first heroin-assisted treatment service in Scotland opened in Glasgow at the end of 
2019 and the Chief Scientific Office has funded an evaluation project to run alongside 
its launch (Scottish Drugs Forum - SDF, 2019). In the UK, heroin-assisted treatment has 
been trialled in London, Brighton and Darlington (SDF, 2019). The aim for the service in 
Glasgow is to treat 20 patients in year 1 and 40 patients in year 2, and once stabilised 
onto treatment, patients will gradually progress from intravenous prescribed heroin to 
an oral prescription which will allow more patients to be treated (Glasgow City Council, 
2019). 
 
1.3.3 Injecting Equipment Provision (IEP) 
The provision of injecting equipment promotes safe injecting and reduces incidences 
of viral and bacterial infections. The first dedicated outlets were operating in the UK in 
1986 as a measure to reduce the epidemic spread of HIV infections. IEP is free of 
charge in these outlets and is often accompanied by the provision of other harm 
reduction services such as dry blood spot testing or naloxone provision. The World 
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Health Organization defines high coverage needle and syringe provision as 60% of all 
people estimated to inject drugs receiving more than 200 sterile syringes per person 
per annum (O’Keefe et al. 2019; WHO, 2012). This target was devised by means of 
mathematical modelling and real-life studies to reduce the spread of HIV. The WHO 
has acknowledged these recommendations were calculated to limit the spread of HIV 
but might not be adequate to reduce newly acquired HCV infections and support the 
current 2030 WHO HCV elimination targets (discussed in subsequent paragraphs). An 
increase to 300 syringes per person per annum should instead be distributed and 
would be considered high coverage in order to achieve such a target (O’Keefe et al. 
2019; WHO, 2016a). 
The WHO targets are extremely high compared to real-life data on equipment 
distribution. Data on Scottish coverage in 2014/15 shows an average of 72 sterile 
syringes per person was distributed (ISD, 2018b). Despite equipment being free of 
charge and the presence of around 5 IEP outlets per 1000 people who use drugs (ISD, 
2018b), levels of reported equipment sharing remains a problem. In the NESI survey, 
10% reported sharing a needle and syringe in the past six months in 2017/18, whilst 
26% reported sharing other injecting paraphernalia such as spoons, filters or water, 
down from 48% in 2008/09 (HPS, 2019). Albeit the number of people reporting sharing 
of equipment has reduced in the last decade, this behaviour remains the biggest 
concern for blood-borne virus infection transmission and one of the major challenges 
faced by the WHO in achieving its target for global HCV elimination by 2030. 
 
1.3.4 National Naloxone programme 
Naloxone is an opioid antagonist which reverses the effects of opioids in cases of a 
potential overdose. It is of paramount importance in the action taken by Scotland to 
tackle the rising trend of drug-related deaths (National Records Scotland - NRS, 2019). 
Scotland was a worldwide pioneer in introducing the National Take Home Naloxone 
Programme (Scottish Government, 2019). In 2011/12, only 8% of the NESI study 
participants had been prescribed naloxone in Scotland, increasing to 61% in 2017/18 
(HPS, 2019). Despite this increase in take-home naloxone prescriptions, increases in 
drug-related deaths have been steadily recorded since 1996 (NRS, 2019). In Tayside, 
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there has also been an increase in non-fatal overdoses, which might infer the number 
of take-home naloxone kits prescribed to the affected population which are used. Data 
collected in Tayside between the 1st January 2017 and the 22nd September 2019 show 
a month by month increase in incidents. In 2017 there was an average of 0.77 non-
fatal overdose incidents per day, with an increase to 1.8 incidences per day in 2019 
(Unpublished NHS Tayside data, September 2019). 
When the take-home naloxone programme was introduced, naloxone could only be 
prescribed by nurses, pharmacists, GPs and other healthcare staff working with the 
substance use population. Since the introduction of new legislation in October 2015, 
all staff working in drug services can administer naloxone but also provide and supply 
take-home naloxone, which allows a much greater number of kits to be distributed via 
third sector organisations. It remains a prescription only medicine, but is exempt from 
certain prescription only medicine requirements because it is a life-saving intervention 
in case of emergency. The change in legislation also allows family members to access 
take-home naloxone for a person at risk, without the person’s knowledge or consent 
(PHE, 2017b). 
 
1.3.5 Residential detoxification and rehabilitation 
Residential detoxification and rehabilitation centres are an additional measure of 
support for people trying to become substance-free and for whom other community-
based interventions have not been successful. The information provided by the 
Scottish Government on residential detoxification and rehabilitation facilities is not 
particularly current, with the last review having been carried out in 2004 (Scottish 
Government, 2004). Twenty-one facilities were present in Scotland with 352 beds for 
drug treatment (Scottish Government, 2004).  
Residential detoxification aims to provide safe and humane withdrawal from the drug 
of dependence (Scottish Government, 2004; SPICe, 2017). It constitutes short-to-
medium programmes, lasting between a few days to a few weeks (usually 1 week in 
NHS Tayside) and provides different types of interventions such as clinically-supervised 
detoxification, counselling and relapse prevention, crisis support and practical help 
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with housing and benefits. Completion rates are high (75-80%), yet relapse is very 
common (Scottish Government, 2004; SPICe, 2017). 
According to Scottish Government documentation, residential rehabilitation aims to 
provide individuals with long-term abstinence, a drug-free lifestyle and re-integration 
into society (Scottish Government, 2004; SPICe, 2017). Given the more complex nature 
of these goals compared to detoxification facilities, these programmes tend to be 
medium to long-term, lasting from a couple of months to one year and providing 
clinically-supervised detoxification, intensive psychological support and therapeutic 
interventions such as counselling, group therapy and cognitive behavioural therapy, as 
well as employability interventions, such as upskilling and employment preparation 
(Scottish Government, 2004; SPICe, 2017). Completion rates are not as high, with 25% 
of individuals choosing to be discharged within 2 weeks and 40% within 3 months 
(Scottish Government, 2004; SPICe, 2017). 
 
1.3.6 Supervised consumption facilities 
Supervised consumption facilities, also referred to as drug consumption rooms or safe 
injecting facilities, have been implemented across European countries, Canada and 
Australia since 1986 (Hedric et al.2010).  The aim of supervised consumption facilities 
is to provide a safe and hygienic place for people to inject drugs. They have been 
evidenced to reduce disease transmissions, as sterile injecting equipment is provided, 
and fatal overdoses, as emergency care is available immediately in case of need 
(EMCDDA, 2018). There is also an opportunity to engage and refer clients to other 
services such as social healthcare and substance use services (EMCDDA, 2018).  
In April 2018, EMCDDA audited the number of supervised consumption rooms, with a 
total of 90 across Switzerland, Netherlands, Germany, Spain, Luxembourg, Norway, 
Denmark and France. Facilitative laws were passed in Ireland and Portugal for 
supervised consumption rooms to open in 2019. Belgian policy makers were also 
presented results from a feasibility study on drug consumption facilities in five major 
Belgian cities which supported the introduction of these facilities (EMCDDA, 2018). The 
UK government, however, continues, in spite of the available evidence, to refuse to 
permit this harm reduction measure. 
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Data published in 2019 showed that Scotland has the highest rates in Europe for drug-
related deaths, at 0.16 per 1000 population, and Greater Glasgow & Clyde showing the 
highest rate in Scotland (0.23 per 1000 population) (National Records of Scotland, 
2019). In response to this rising number of drug-related deaths and to a significant 
outbreak of HIV in Glasgow since 2015, the Glasgow City Integration Joint Board 
approved the development of a business case for piloting a safe consumption facility in 
Glasgow. Although health policy is a devolved power, drug laws are reserved to the UK 
Government in Westminster (Nicolls et al. 2019). After the business case was 
supported by Glasgow City Council, it was debated in April 2018 in Holyrood where 
MSPs voted in favour, calling Westminster to make legislation changes to the 1971 
Misuse of Drugs Act or to declare a health emergency in Scotland, therefore granting 
Holyrood emergency powers to introduce the facility in Glasgow. The UK government 
blocked such an initiative (Nicolls, 2019; SDF, 2018). 
 
1.4 Reinfection 
In 2016, the World Health Organization set targets for the elimination of hepatitis B 
and C by 2030 (WHO, 2018a). The treatment targets set diagnostic coverage at 90%, 
treatment coverage at 80% of those eligible to be treated, 90% reduction in incidence 
of viral hepatitis chronic infections and a 65% reduction in mortality caused by viral 
hepatitis (WHO, 2018a). The introduction of highly effective DAA for the treatment of 
HCV infection has improved the perception of the WHO targets being achievable 
(Falade-Nwulia et al. 2018). 
However, cure from HCV infection does not provide protective immunity against 
future infections, so people who have been treated or have spontaneously cleared the 
virus, can become reinfected (Falade-Nwulia et al. 2018). HCV reinfection could 
therefore hamper optimistic predictions on HCV elimination. Reinfection rates vary 
dramatically according to population. The two main populations which are being 
monitored for reinfection are PWID and men who have sex with men (MSM) as 
evidence suggests they are at the highest risk of reinfection (Islam et al. 2017). In PWID 
who have not injected since being treated for HCV, incidence rate is of 1.7 per 100 
person-years (Midgard et al. 2016a). For PWID with ongoing risk (e.g. currently 
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injecting drugs) post-treatment rates vary between 4.9 per 100 person-years in 
Norway (Midgard et al. 2016a), to 16.7 per 100 person-years in a Spanish population 
who reported injecting in the past 6 months, and 18.9 per 100 person-years amongst 
those who reported injecting in the previous 30 days (Valencia et al. 2019). The highest 
rate was reported in Dundee (Scotland), a city under the remit of NHS Tayside, where 
those treated in the largest IEP outlet in the city was recorded as 21.5 per 100 person-
years (Schulkind et al. 2019).  
Among MSM, the incidence varied between 9.02 per 100 person-years in a German 
sample (Ingiliz et al. 2019) and 15.2 per 100 person-years in a Dutch sample of HIV-
infected MSM (Lambers et al. 2011). 
More recently, a meta-analysis was conducted which found the overall rate of HCV 
reinfection from 36 included studies was 5.9 per 100 person-years in people with 
recent drug use, 6.2 per 100 person-years in people who recently injected drugs and 
3.8 per 100 person-years in those on OST (Hajarizadeh et al. 2020). Reinfection rates 
were similar among individuals treated with interferon-based therapy (5.4 per 100 
person-years) and those treated with DAAs (3.9 per 100 person-years) (Hajarizadeh et 
al. 2020). 
The risk of reinfection is not only a danger to the efforts carried out internationally to 
achieve viral hepatitis elimination by 2030. At an individual level, becoming reinfected 
would compromise the benefits of the previous treatment, such as the prevention of 
HCV-related liver disease (Midgard et al. 2016b) and possible psychological 
consequences associated with a renewed diagnosis, such as anger, depression and 
stigma (Janke et al. 2008). It is extremely important for healthcare professionals not to 
stigmatise and discriminate people who present with reinfection, as this might add 
barriers to accessing treatment (Midgard et al. 2016b). Healthcare professional should 
acknowledge reinfection, and use education and counselling coupled with harm 
reduction to address the risk of reinfection with patients, and by post-SVR screening, 
retreat HCV reinfected patients as soon as possible (Midgard et al. 2016b). The 
decreasing costs of DAAs have led to more health systems allowing re-treatment of 
people who present with HCV reinfections. 
At a systemic level, reinfections alter the cost-effectiveness calculations of treatment 
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as prevention, with continued high costs for the NHS associated with chronic infections 
and HCV-related liver disease and increasing the pressure for prevention of HCV on 
harm reduction strategies. Therefore, acknowledgement and education on reinfection 
is important on a systemic level as well, with post-SVR surveillance and harm reduction 
still being pivotal in the fight for HCV elimination (Midgard et al. 2016b). 
Reinfections can be perceived as the proof the most at-risk population is being 
targeted and treated and efforts should continue to diminish the virus pool present in 
such networks. However, sustained presence of reinfections might also highlight the 
disconnect between approved evidence-based governmental HCV elimination 
strategies and their effective implementation on the frontline. Such an example is the 
Scottish Government commitment to eliminate HCV by 2024 by upscaling treatment, 
investing financial and intellectual resource in case-findings (Scottish Health Protection 
Network, 2019) and ensuring people have access to optimal harm reduction services, 
such as access to 300 syringes per person per annum (O’Keefe et al. 2019; WHO, 
2016a) to lower transmission, yet only having an average coverage of 72 syringes per 
person per annum (ISD, 2018b). 
 
1.4.1 The role of health psychology  
A multi-stakeholder approach must be taken if both domestic and international 
elimination targets are to be achieved (Lazarus et al. 2018). Combining treatment and 
prevention is essential (WHO, 2018a). Both of these individual strategies require 
different degrees of behaviour change, which is the reason health psychology can 
contribute to elimination efforts.  
Health psychology aims to improve, promote and maintain health of individuals and 
populations by applying theories and models of behaviour change to practice and 
therefore providing an evidence-based approach to the management of illnesses 
(British Psychological Society, 2019). It is often applied in a multidisciplinary setting 
and can be helpful both at a population and an individual level. 
At a systemic level, treatment scale up, testing scale up and harm reduction measures 
are being implemented with the help of national strategies. Thirty-six countries have 
developed national plans and 33 are in the process of developing such plans (WHO, 
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2018a). Health psychology can be applied to carry out needs assessments in a 
population; gather and analyse evidence to produce public health interventions; test 
the effectiveness of these interventions as well as strategies that are already in place; 
configure efficacious implementation plans and help evaluate them; train healthcare 
and third sector staff in behaviour change and low-tier interventions. 
At an individual level, it will be difficult to achieve and maintain HCV elimination if the 
primary behaviour and route of transmission, sharing of injecting equipment, does not 
change.  The roles of health psychology at a systemic level mentioned above can also 
be applied at an individual level for one-to-one behaviour change work with patients. 
This type of application of health psychology is the focus of this thesis. 
 
1.5 Overview of the Thesis 
1.5.1 Aims  
In light of the higher HCV reinfection rate for people who continue to inject drugs and 
the role that health psychology can play in the management of HCV, the main aim of 
this research is to test the effectiveness of a behaviour change intervention at an 
individual level to reduce rates sharing rates of injecting equipment, and 
consequentially of HCV reinfection, by intervening on patients’ self-efficacy and 
injecting risk behaviour.   
The full thesis presents a series of studies that aim to: a) understand the current use of 
implementation intentions in substance use populations (Chapter 2); b) explore 
injecting behaviour changes, and psychosocial factors associated to these, in people 
who inject drugs on HCV treatment from a previous study to help inform the current 
intervention (Chapter 3); c) investigate the effectiveness and feasibility of 
implementation intentions with people who inject drugs for reducing sharing of 
injecting equipment and associated HCV reinfection rates and increasing self-efficacy 
to refuse sharing (Chapter 6); d) explore psychosocial predictors of injecting sharing 
behaviour (Chapter 5); e) examine patients’ experience of HCV treatment and their 
perception of HCV as an illness (Chapter 7).  
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1.5.2 Research questions  
Table 1.3 Research questions of this thesis 
Research question Specification 
of centrality 
Study number & 
Design 
Are implementation intentions effective in 
reducing substance use? 
Primary Study 1:  
Meta-Analysis 
Does injecting behaviour change during HCV 
treatment? What psychosocial factors are 
associated with such change? 




Will implementation intentions produce 
changes in self-efficacy to refuse sharing of 
injecting equipment and injecting risk behaviour 
in active PWID on treatment for hepatitis C at 1-
month follow-up? 
Primary Study 3:  
Pilot Randomised 
Controlled Trial 
 Is there longevity of the intervention 
effectiveness 4 months post-intervention 
(and 12 weeks post-treatment)? 
 What type of relationship exists, if any, 
between measured psychosocial factors and 
injecting risk behaviour? 
 Are there any differences in psychosocial 
factors pre- and post-treatment? 
Secondary 
 
What is the lived experience of patients on HCV 
DAA treatment? 
Primary Study 4: 
Qualitative study 
What is the patients’ illness perception? Secondary 
 
1.5.3 Structure of the thesis 
The research project was subdivided into 4 studies. The initial two studies were carried 
out to inform the latter two. 
The first study is presented in Chapter 2. The aim of this study is to assess the 
effectiveness of forming implementation intentions to reduce substance use. The 
chapter briefly explores epidemiological data on substance use in general, including 
alcohol use, tobacco smoking and illicit drug use. It continues by presenting 
implementation intentions as self-regulatory processes which help achieve health-
related behaviour change. A systematic search of published literature was conducted 
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to gather evidence on the effectiveness of the use of implementation intentions for 
substance use behaviours from existing studies. The findings of studies selected from 
this search were collated to carry out a meta-analysis in order to produce evidence for 
the effectiveness of implementation intentions within substance use behaviours, 
informing study 3. 
The second study is presented in Chapter 3. The aim of this study is to investigate 
possible injecting behaviour changes associated with no intervention other than 
clinical treatment of hepatitis C. The chapter reports the results from a data analysis 
exercise completed in January 2018. The data was collected and provided by the 
Eradicate-C study group and the Chief Investigator, Professor John F. Dillon, also 
second supervisor to this PhD project. Eradicate-C was a single-centre clinical trial 
investigating the effectiveness of hepatitis C treatment in current injecting drug users 
(primary outcome) between 2012 and 2017. Secondary outcomes, such as behavioural 
and social measures, were collected during the trial to analyse any changes during 
treatment. These outcomes were used to characterise the population and examine any 
relationship between these factors and injecting behaviour change. The participants of 
Eradicate-C are directly comparable with the population chosen for the studies 
included in this thesis, as they were also current injecting drug users on treatment for 
hepatitis C in the same Scottish Health Board region where study 3 and 4 of this thesis 
took place. It was therefore considered important to analyse this data in order to 
inform our protocol for study 3 and 4.  
The third study, ADAPT, represents the main study of this thesis. It was the study that 
required most resources in terms of planning, statutory and regulatory approvals, 
recruitment, analysis and dedicated time. Three chapters of this thesis are therefore 
dedicated to ADAPT: Chapter 4, 5 and 6. 
Chapter 4 presents the design and methodology of the randomised controlled trial 
(ADAPT). It is reported in accordance with the CONSORT (The Consolidated Standards 
of Reporting Trials) 2010 statement for transparent reporting of trials (Schultz et al. 
2010), in conjunction with the TIDieR checklist (Template for Intervention Description 
and Replication) for better reporting of interventions (Hoffmann et al. 2014). This 
chapter required updating throughout the course of the study, as three substantial 
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amendments were submitted during the study life. It includes a description of all the 
assessment scales collected and analysed for ADAPT, namely those reported in 
chapters 5 and 6. 
In chapter 5 psychosocial factors measured during visit 1 of ADAPT (RCT) are explored 
as predictors of the primary outcome, injecting risk behaviour. Only measures taken on 
visit 1 are considered in this analysis. The chapter presents the characteristics of the 
sample, the mean variable score, normality testing, correlation testing to check the 
relationship between injecting risk behaviour and psychosocial secondary outcomes. A 
regression analysis is then performed with bootstrapping to test a predicting model of 
injecting risk behaviour as explained by injecting frequency, identification with family 
and identification with drug network. 
Chapter 6 presents the main findings of ADAPT. This chapter explores attrition rates 
and randomisation, and it focuses on presenting and describing the intervention data 
in detail, using simple inferential statistics to investigate the effects on the use of 
implementation intentions with the specified population on self-efficacy and sharing of 
injecting equipment. 
The fourth study is presented in Chapter 7. This study is classified in the ADAPT study 
protocol as a sub-study, as it is directly linked to the RCT and its recruitment took place 
from the same study sample of ADAPT. It is presented in the thesis as a separate 
chapter and study because of its concurrent design with the RCT and because it was 
answering a related but different set of research questions. This study is a qualitative 
investigation of the lived experience of people who inject drugs who are infected with 
hepatitis C.  Thematic analysis was used to analyse the findings of this study. The 
concurrent design of study 3 and 4 was selected to ensure the qualitative data was not 
influenced by the quantitative study findings or vice versa.  
Lastly, Chapter 8 aims to integrate the findings of study 3 and 4 into one final 
discussion. The concurrent design of these two studies allows the analysis of the 
convergence, divergence or contradiction of the findings of the two datasets in an 
overall discussion. It aims to provide a narrative reflection on the lessons learnt whilst 
planning and conducting the research with a hard-to-reach population. It will also 
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present the implication of the findings, the limitation of the studies and the 
suggestions for future research. 
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CHAPTER TWO: Study 1 - Meta-analysis  
Effectiveness of the use of implementation intentions on reduction of 
substance use. 
This chapter presents the first study of the thesis. It explores epidemiological data on 
the effects of substance use, such as alcohol, tobacco and illicit drugs, on health and 
mortality. It presents implementation intentions as self-regulatory processes which 
help achieve behaviour change. A systematic search was carried out to identify studies 
testing the effectiveness of implementation intentions on substance use behaviour 
change. Data was extracted and a meta-analysis carried out to produce pooled 
evidence on the effectiveness of implementation intentions. The findings of this study 
were used to inform Study 3 of this thesis. 
 
2.1 Abstract  
Background: Substance use, such as alcohol drinking, tobacco smoking and illicit drug 
injecting, has been associated to severe health conditions and an annual estimated 
12% of all deaths worldwide. Implementation intentions are self-regulatory processes 
which help achieve health-related behaviour change. Objectives: To investigate the 
effectiveness of forming implementation intentions to reduce substance use and 
increase self-efficacy.  
Design: Data sources: PsycINFO, MEDLINE, Psychology and Behavioural Science 
Collection, clinicaltrials.gov, UK Clinical Trials Gateway, Reference lists. Inclusion 
criteria: RCT of substance users forming implementation intentions to reduce 
consumption (active or passive control condition present). Study appraisal and 
synthesis methods: the SIGN checklist for RCT quality was used for quality appraisal, 
data was extracted by two reviewers.  
Results: Twenty-one studies were included in the meta-analysis. The overall effect size 
for alcohol use was g=0.31 (95% CI: 0.21, 0.42), p< .001; for tobacco smoking g=0.31 
(CI: 0.12, 0.50), p=.002; for self-efficacy g=0.16 (CI: -0.02, 0.34), p=.087); no studies 
were retrieved for the use of implementation intentions on illicit drug use. The 
interventions revealed stronger effects in the general population compared to 
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students for both alcohol and smoking, and when delivered in person rather than 
online on screen for alcohol only.  
Conclusions: This review suggests that implementation intention interventions are 
effective in reducing some forms of substance use (alcohol and tobacco smoking), 
albeit revealing small effect sizes, among the general population and students in 
secondary and higher education. Implementation intentions also have a small non-
significant effect on self-efficacy. Review registration number: CRD42018116170. 
 
2.2 Background 
Commonly consumed psychoactive substances such as alcohol, nicotine (within 
tobacco) and opioids have been linked to an astonishing amount of health conditions 
(World Health Organization - WHO, 2018b) and an estimated yearly 12% of all deaths 
worldwide (Hodder et al. 2016), amounting to around 11 million deaths a year.  In the 
paragraphs below, the association between substance use and health is investigated 
and categorised by substance. 
 
2.2.1  Alcohol use 
In 2016, 43% of the worldwide population aged 15 and over had drunk alcohol in the 
previous year (WHO, 2018b). The WHO European Region sees the highest level of 
individual consumption of alcohol worldwide, with the global average of 6.4 litres of 
pure alcohol per capita having been consumed in 2016 in over 15s (WHO, 2018c). 
In the same year, around 5.3% of deaths worldwide (equivalent to 3 million people) 
and 5.1% of disability-adjusted life years (DALYs) were a result of harmful alcohol use. 
Alcohol consumption is linked to both acute and chronic poor health outcomes (and 
related mortality) such as injuries, hepato-gastroenterological diseases, cardiovascular 
disease, infectious diseases and cancers (Bahorik et al. 2017; Schuckit, 2009; WHO, 
2018b0). In addition to this, alcohol related DALYs are attributable to non-
communicable conditions, mental health and injuries (WHO, 2018c). Some meta-
analytical research suggests that light to moderate alcohol consumption could reduce 
the risk of cardiovascular disease, stroke and coronary heart disease and their related 
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mortality (Ronksley et al. 2011). However, health departments of countries around the 
world define light, moderate and harmful drinking as widely different, with 
recommended drinking guidelines ranging from 8g of pure alcohol mass a day in 
Guyana to 40g a day in Estonia, Republic of Korea, Romania, Spain and Uruguay 
(International Alliance for Responsible Drinking, 2018). It is therefore difficult to 
globally specify a consistent threshold of health-protective light to moderate drinking, 
leaving the debate wide open on how, if at all, to integrate this information into public 
health messages (Ronksley et al. 2011). 
 
2.2.2  Tobacco smoking 
Smoking of tobacco is the single leading cause of preventable deaths around the 
world. Cardiovascular disease, cancers, chronic respiratory disease, diabetes have all 
been linked to first-hand tobacco use, smoke and smokeless, and second-hand smoke 
exposure (WHO, 2014a). Albeit tobacco use is reported in both smoke and smokeless 
forms, data for smokeless use is rarely captured, with data and information reported 
by WHO relating almost exclusively to smoking in over 15 year olds. Globally, 7% of 
female deaths and 12% of male deaths are related to tobacco use. The World Health 
Organization had estimated that, worldwide, tobacco will be the cause of 8 million 
deaths per year by 2030. From 6 million deaths in 2014 (WHO, 2014a), we are now on 
course to reach and surpass this threshold with an estimated 7.2 million deaths related 
to smoking reported in 2016 (WHO, 2017b). Eight million deaths in 2030 would be 
equivalent to 10% of all-cause deaths (WHO 2014a). 
In 2016, smoking was estimated to be prevalent in 21.9% of the global population in 
people over 15 years of age. Once again, the highest population average in the world is 
reported in the WHO European region, with a 28.7% prevalence of smoking in over 15s 
(WHO, 2018c). 
Aside from mortality, in 2015 smoking-attributable DALYs were mainly due to 41.2% of 
cardiovascular disease, 27.6% cancers and 20.5% chronic respiratory diseases. Smoking 
remains one of the worse contributors to DALYs, with an overall 6% global estimate 
(Global Burden of Disease, 2015). 
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2.2.3  Illicit drug use 
A United Nations report estimated that 275 million people in 2016 had used illicit 
drugs at least once, a prevalence of 5.6% of the population aged 15 to 64 years (United 
Nations Office for Drugs and Crime - UNODC, 2018). It suggested 192 million people 
had used cannabis, 34 million opioids, 34 million amphetamines and prescription 
stimulants, 21 million ecstasy, 19 million opiates and 18 million cocaine. Around 31 
million of these people have drug use disorders and are undergoing, or requiring, 
treatment. These people will use drugs via different administration routes, with 11 
million estimated to be injecting them. One in 8 people who inject are living with HIV 
and one in 2 with hepatitis C, 1 million co-infected with both (UNODC, 2018). 
Illicit drug use has severe health consequences. In 2015, around 450 thousand people 
died as a consequence of their drug use. Just under 168 thousand deaths were 
associated to drug use disorders, 69 thousand people dying from opioid overdose 
alone each year (UNODC, 2018; WHO, 2014b); the remaining deaths are often 
associated to HIV and HCV infections acquired mainly via sharing of injecting 
equipment (UNODC, 2018). 
As well as mortality, opioid use disorders have been linked to other poor health 
outcomes, such as arthritis, chronic pain, musculoskeletal disorders, bacterial and viral 
infections, cardiovascular disease, limb amputations, poor mental health (e.g. 
suicidality, anxiety and depression), poor oral health (Bahorik et al. 2017). Similarly, 
cannabis use is linked to cognitive impairment, poor mental health (e.g. psychosis, 
suicidality, anxiety and depression), cardiovascular disease, chronic pulmonary disease, 
respiratory and other cancers (WHO, 2016b). 
 
2.2.4  Implementation intentions to promote health behaviour 
Implementation intentions are self-regulatory processes which take the form of ‘if-
then’ plans and facilitate the attainment of goals and behaviour change (Gollwitzer, 
1993). The role of intentions in behaviour change has been explored within a variety of 
theories and models of behaviour change, e.g.  Ajzen’s Theory of Planned Behaviour 
(1991). The behavioural intention variable has been largely discussed and criticised as 
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it can be perceived as both an excellent and poor predictor of behaviour given the 
‘notorious’ intention-behaviour gap (Prestwich, et al. 2006; Sheeran, 2002; Sutton, 
1998). The intention-behaviour gap is the relation between intending to carry out a 
certain behaviour and actually performing that behaviour (Hagger & Luszcynska, 2014). 
Correlational studies suggest a medium-to-large effect size of intention-behaviour 
relations, which however don’t seem to translate to the same level of effects in 
experimental studies, which is why the relation is referred to as having a “gap” 
(Armitage & Conner, 2001; Hagger & Luszcynska, 2014; Webb & Sheeran, 2007). The 
gap might be explained by dividing into intention activation and intention elaboration 
(Sheeran et al. 2005). Intention activation refers to characteristics of the context in 
which a goal is set. A goal intention “I intend to do X” might be the victim of change of 
salience, direction or reprioritisation depending on how achievable the goal itself is in 
a particular context; intention elaboration refers to the lack of detail of action planning 
that people usually provide for their goals (Bélanger-Gravel et al. 2013). Previous 
research shows that action planning interventions (implemented either as a once-off 
or as repeated sessions) can be helpful in reducting substance use behaviour in both 
populations with diagnosed addictions (Latka et al., 2008; Robles et al., 2004) and the 
general population (Bolman et al., 2015). Implementation intentions are hypothesised 
to offer a solution to the intention-behaviour gap (Hagger & Luszcynska, 2014). 
Implementation intentions have been used to recognise contextual barriers and to 
plan in detail how to achieve a goal: when, where and how to perform a specific 
behaviour. They take the form of if-then plans: “if Y happens then I will perform Z”, 
which commits individuals to behave in a particular way (Z) when they are presented 
with a certain situation (Y) (Gollwitzer, 1993). This provides the individual with self-
regulatory strategies that create heightened accessibility of environmental cues, 
allowing individuals to automatically respond to contextual cues by unconsciously 
initiating their planned behaviour (Aarts et al. 1999; Gollwitzer, 1993; Hagger & 
Luszcynska, 2014).  Implementation intentions are specifically mentioned in the 
Behaviour Change Technique Taxonomy (Michie et al. 2013) as a theoretical 
framework within action planning. Action planning in the taxonomy is the technique 
1.4, part of Group 1: Goals and planning. It requires prompt detailed planning, 
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including context, frequency, duration and/or intensity, of the performance of a 
behaviour; the context can be environmental or internal (Michie et al. 2013). 
Implementation intentions have similarities with coping planning, which is included in 
the taxonomy as part of the problem solving technique 1.2 (Michie et al. 2013). Both 
techniques specify cues-to-action relevant to the individual or population, the when 
and where the behaviour will be enacted, and both can take the format of if-then 
plans; yet coping planning involves more conscious processing in decision-making and 
self-evaluation (Hagger & Luszcynska, 2014). 
Implementation intention interventions can assume a variety of different formats. 
They can be oral or in writing, on paper or on screen (sometimes online), self-
generated by people completing the intervention or pre-specified by the researchers 
or clinicians, or pre-specified situations with self-generated solutions (Armitage 2009; 
Armitage 2015; Caudwell et al. 2018; Hagger et al. 2012a). 
A number of studies have investigated the effects of implementation intentions on 
health-related behaviours, but none have been solely focused on substance misuse 
(Adriaanse et al. 2011; Bélanger-Gravel et al. 2013; Gollwitzer & Sheeran, 2006). In 
fact, implementation intentions have rarely been applied to addictions. Addiction-
related behaviours are notoriously difficult to change and for any change to be 
maintained. The automaticity aspect of implementation intentions discussed above, 
however, would suggest that this type of intervention could successfully be applied to 
substance use behaviours such as alcohol consumption, smoking and illicit drug use. 
Questions have been posed about the possible effectiveness of implementation 
intentions in individuals with a high cognitive load, such as people in opiate withdrawal 
(Brandstätter et al. 2001). Albeit implementation intentions were formed for a 
behaviour unrelated to their substance use, Brandstätter and colleagues (2001) found 
that both low and high cognitive load patients showed ‘automatised’ action initiation 
when they had formed implementation intentions.  
Forming if–then plans specifying situations and associated solutions to achieve a 
particular goal could make an individual feel more confident about their ability to 
achieve behaviour change (Webb & Sheeran, 2008). The impact of implementation 
intentions on self-efficacy, as well as the role of self-efficacy within implementation 
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intention interventions has been investigated by various researchers with mixed 
findings. Some studies found implementation intentions increased self-efficacy 
(Murray et al. 2005, Rodgers et al. 2002), whilst others found no differences between 
intervention and control groups (Milne & Sheeran, 2002). In addition, some research 
has shown that forming implementation intentions can have negligible effects on 
both goal intentions and self-efficacy (Webb & Sheeran, 2008). The accessibility of the 
components of plans mediated the effect of implementation intentions on goal 
achievement (Webb & Sheeran, 2008).  
Given no previously published meta-analyses have focused on the effectiveness of 
implementation intentions on substance use reduction at the time of this study, this 
review aims to fill this gap in the literature. 
 
2.2.5  Objectives 
This review’s objective was to investigate the effectiveness of forming implementation 
intentions to reduce substance use. It aimed, in more detail, to answer the following 
questions: 
1. Does forming implementation intentions reduce alcohol consumption? 
2. Does forming implementation intentions reduce cigarette smoking? 
3. Does forming implementation intentions reduce illicit drug use? 
A secondary question which the review aimed to answer was: 
4. Does forming implementation intentions increase self-efficacy? 
 
2.3 Methods 
The methodology and reporting of this review comply with the PRISMA statement 
checklist for the reporting of systematic reviews and meta-analyses (Moher et al. 
2009), with the Meta-Analysis Reporting Standards – MARS (American Psychological 
Association, 2008) and with the Scottish Intercollegiate Guidelines Network (SIGN) 
checklist 1: systematic reviews and meta-analysis (SIGN, 2018). The review protocol 
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with methods and inclusion criteria was registered in advance on the University of 
York’s Centre for Reviews and Dissemination PROSPERO register, as CRD42018116170. 
 
2.3.1  Eligibility criteria 
Only studies written in English were considered for selection, with no limit on 
publication dates on the first searches carried out between April and September 2018. 
An update search was run in January 2019, to which restricted publication dates were 
applied between 2018 and 2019 only. No geographical restrictions were applied. 
2.3.1.1 Participants  
No restrictions were applied to study participant characteristics 
2.3.1.2 Interventions 
The intervention under review was the formation of implementation intentions for the 
reduction of substance use behaviours, such as tobacco smoking, drinking alcohol, and 
other drug use. Trials with more than one intervention were selected when the 
implementation intention was reported independently so that the effect could be 
measured independently. 
2.3.1.3 Comparisons 
All studies had to present a control group. This included passive control groups (not 
performing any task) and active controls (performing an unrelated time-controlled task 
such as filling in an extra questionnaire or creating implementation intentions for an 
unrelated behaviour). 
2.3.1.4 Outcomes 
All studies were required to report on substance use as their main outcome measures. 
Outcomes such as weekly consumption of alcohol units, binge drinking occasions, 
quantity of cigarettes smoked, nicotine dependence and other drug use consumption 
were all accepted primary outcomes. Secondary outcomes, such as self-efficacy, were 
not necessary for inclusion in the systematic review.  
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2.3.1.5 Study design 
Randomised controlled trials (RCTs) were selected for review. Intervention follow-up 
length was left unrestricted for selection. 
 
2.3.2  Information sources 
The following databases were searched between April 2018 and September 2018 via 
EBSCOhost: PsycINFO, MEDLINE and Psychology and Behavioural Science Collection. 
Reference lists of all selected papers for screening were searched by hand between 
September and October 2018. The following clinical trial registers were searched in 
November 2018: Clinicaltrials.gov and UK Clinical Trials Gateway.  
 
2.3.3  Search and study selection 
The search strategy was similar across all databases, adjusting for database-specific 
headings. An example of the search strategy for PsycINFO is provided in 
Supplementary File 2.1. Reference lists were searched by hand for relevant titles; 
whilst research registers were searched with “implementation intentions” in the title 
or trial description.  
One reviewer carried out the full search on the three different databases via 
EBSCOhost between April and September 2018. Searches were saved in an EBSCOhost 
folder. All selected title items were transferred into the reviewer’s personal EBSCOhost 
list.  
 
2.3.4  Data collection process and items 
Data was extracted by 2 reviewers, both chartered health psychologists, and input into 
a summary table then transferred into the Comprehensive Meta-Analysis Software 
v3.3. The data extracted (See Table 2.2) were study design (including control group 
format), follow-up period, sample characteristics (size, type, age, sex), theoretical 
approach, behavioural goal (reduce alcohol consumption, reduce tobacco smoking), 
implementation intentions format (online or pen & paper, pre-specified or self-
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generated, number of plans), outcome measures of substance use reduction 
(units/day, binge drinking occasions, cigarettes/day, tobacco smoking quitting status), 
and effect size (Hedge’s g with specified 95% Confidence Intervals, see section 2.7 for 
effect size calculation). For 10 studies, the authors were contacted for data or data 
clarification. Authors for 8 of these studies replied, 5 of which provided the requested 
information. 
 
2.3.5  Risk of bias in individual studies 
Risk of bias in individual studies was assessed with the SIGN checklist 2 for randomised 
controlled trials (SIGN, 2018). The checklist assesses selection bias, ascertainment bias, 
measurement bias, attrition bias and reporting bias. Agreement for assessment of 
individual studies by different reviewers was calculated using Cohen’s kappa 
coefficient of inter-rater reliability (McHugh, 2012). 
 
2.3.6  Summary measures 
2.3.6.1 Statistical analyses  
The Comprehensive Meta-Analysis software (version 3.3) was used to perform all 
calculations, test for heterogeneity and generate forest plots. Given the assumed 
heterogeneity in interventions, populations and outcomes, a random-effects model 
was selected (Hedges & Vevea, 1998). Using a random-effect model allows for a more 
conservative interpretation of the findings, given the confidence intervals (CIs) for the 
average intervention effects obtained in this way are wider compared to CIs obtained 
with fixed-effect models (Sutton, 2001).   
2.3.6.2 Effect size calculations  
For continuous outcomes (e.g. units alcohol/day, cigarettes/day and self-efficacy 
score) Hedges’ g with 95% confidence intervals (CIs) were calculated as the difference 
between the intervention groups’ mean follow-up scores and the comparison groups’ 
mean follow-up score divided by the pooled standard deviation and adjusted for 
sample size. Hedges’ g corrects for small sample sizes, and its results are very close to 
Cohen’s d for 20 or more samples (Borenstein et al. 2009).   
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For dichotomous outcomes (e.g.percentage of people who quit smoking, group 
differences in abstinence) the risk ratio (RR) and 95% CIs were calculated on the basis 
of the number of events and the number of participants in the intervention and 
control groups. The RR were then transformed into Hedge’s g statistic, using the 
Comprehensive Meta-Analysis Software v3.3, to allow for comparisons across studies 
(Borenstein et al. 2009) 
In studies where the primary outcome was investigated with more than one measure 
(i.e. alcohol units consumed per week and binge drinking occasions or cigarettes 
smoked per day and nicotine dependence score) results were combined into one 
overall outcome effect size (i.e. alcohol use or smoking) using the Comprehensive 
Meta-Analysis Software v3.3. This allowed for a more comprehensive meta-analysis, 
and heterogeneity checks were performed during the analysis to ensure validity of 
outcomes (Puhan et al. 2006). 
Alternative statistics (e.g. t-test, F-statistic, odd ratio or p-value and sample size) were 
used to calculate Hedge’s g when studies did not provide means, standard deviations 
and proportions (Borenstein et al., 2009).  
Effect sizes were coded so that positive scores signified favourable intervention effects 
such as lower alcohol use or smoking, with values of 0.20 considered small effects, 
0.50 as medium and 0.80 as large (Cohen, 1988).  
Separate analyses were conducted for studies that targeted alcohol, smoking or self-
efficacy and those that included adjusted or unadjusted effect estimates, as some 
studies adjusted for baseline differences.  
 
2.3.7  Synthesis of results 
2.3.7.1 Assessment of heterogeneity  
The I² and Q statistic tests were used to analyse heterogeneity between studies. I² 
indicates the heterogeneity percentage across the studies. The magnitude of 
heterogeneity was categorised as 1) I² =0% -25%, low heterogeneity; 2) I² =26% -50%, 
moderate heterogeneity; 3) I² =51%=75%, substantial heterogeneity; and 4) I² =76%-
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100%, considerable heterogeneity (Higgins, 2011). Sensitivity analyses were performed 
to explore potential sources of heterogeneity.  
 
2.3.8  Risk of bias across studies 
2.3.8.1 Assessment of publication bias  
Three techniques were used to determine the extent to which publication bias 
impacted on the results of the overall sample. Funnel plots were created to explore 
the presence of publication bias. The Egger regression asymmetry test and the Begg 
and Mazumdar adjusted rank correlation test (Begg & Mazumdar, 1994) were 
performed to measure the extent of the funnel plot asymmetry, with p<0.05 indicating 
a statistically significant publication bias. Finally, the Duval and Tweedie’s trim-and-fill 
method (Duval & Tweedie, 2000), in which the studies are ‘trimmed’ from the right of 
the funnel plot and entered on the left side to address funnel plot asymmetry, was 
used to formalise the result of the funnel plot. 
 
2.3.9  Additional analyses 
2.3.9.1 Subgroup analyses  
Subgroup analyses were conducted to explore potential sources of heterogeneity 
among studies for the alcohol and smoking outcomes using the following 
characteristics: quality of the study, type of implementation intention (self-generated 
or pre-specified), format of implementation intention (in person or online) and 
population (students or general population). In the alcohol use outcome, 2 of the 16 
studies presented adjusted data. Unadjusted data of 14 studies was analysed for the 
main analyses, whilst the 2 studies presenting unadjusted data were analysed as a 
subgroup. The 16 studies were then combined to check for similarity of results. No 
subgroup analyses were performed for self-efficacy due to the small number of 
studies. 
2.3.9.2 Sensitivity analyses 
Sensitivity analyses were performed to determine the robustness of intervention 
effects by evaluating whether the overall effect size was sensitive to inclusion of any 
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individual study (Higgins and Green, 2011). One sensitivity analysis was carried out. 
Effects were explored to determine robustness when only studies with low risk of bias 
scores were retained in the analyses. These analyses were carried out by excluding 
studies with high risk of bias (Borenstein et al., 2009; Cooper et al. 2009). 
 
2.4 Results 
2.4.1  Study selection 
AM carried out the full search on the three different databases via EBSCOhost between 
April and September 2018 (for full database search strategy see Supplementary File 2.1 
at the end of chapter). Searches were saved in an EBSCOhost folder. Duplicates were 
removed manually. The reviewer screened 1756 titles and selected 79 relevant results 
for abstract selection. All selected title items were transferred into the reviewer’s 
personal EBSCOhost list. Duplicates were removed manually before the abstract 
screening process. Abstracts were again screened by the same reviewer, who selected 
29 relevant studies according to the eligibility criteria. Full texts were downloaded and 
divided by database. Twelve studies were excluded with reason (See Table 2.1) and 18 
were selected for quality appraisal and inclusion in the analysis. A further 9 studies 
were found via reference list searches, 2 excluded after abstract screening, 3 excluded 
after full-text assessment with reason (See Table 2.1), and 4 selected for quality 
appraisal. An extra 2 studies were selected for abstract screening after searching 
Clinicaltrials.gov and UK Clinical Trials Gateway. One was retained for full-text 
assessment and included in the study. 
After re-running the searches in January 2019, an extra 104 studies were screened by 
title, 8 selected for abstract screening, 4 were removed as duplicates and 3 selected 
for full-text screening. All 3 were excluded with reason (See Table 2.1). 
Overall, a total of 1906 were identified in the search for this review: 94 were screened 
through their abstract, 40 selected for full-text assessment, 18 excluded with reason 
(See Table 2.1), 22 selected for quality appraisal, and 21 included in the meta-analysis 
(See Figure 2.1).  
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Table 2.1 Full-text reasons for exclusion 
Reason for Exclusion Paper 
Protocol paper Caudwell et al. 2016  
Creation of implementation 
intention not completed by all 
intervention participants 
Epton et al. 2014  
Cameron et al. 2015  
No formation of 
implementation intentions 
(e.g. coping skills training) 
Steven & Hollis, 1989 
Avants et al. 2000 
Borlard et al. 2015 
Dolan et al. 2013 
Sugarman et al. 2010 
Walters et al. 2014 
Zetterlind et al. 2001 
Elfeddali et al. 2012 
No Control group Elfeddali et al. 2013 
Buitenhuis et al. 2018 
Leightely et al. 2018 
Not an intervention study Hooper et al. 2013 
Implementation intentions if-
then plans not formed 
substance use 
Brown et al. 2019 
Chatzisarantis and Hagger, 2010 
Unsuitable Implementation 
intention format 
DeStasio et al. 2018 
 
One study was included in the qualitative synthesis but excluded from the meta-
analysis (Conner & Higgins, 2010). The study presented interval follow-up period of 4 
to 48 months; however, the authors, after being contacted for unadjusted 4 month 
follow-up data, suggested the exclusion of their paper on the basis of the multi-level 
nature of their data. 
 
2.4.2  Characteristics of the studies 
Among the 22 studies selected for the review, 15 studies were RCTs on interventions 
to reduce alcohol consumption, whilst the remaining 7 RCTs aimed to reducing 
cigarette smoking (Table 2.2). One paper (Armitage & Arden, 2016) reported 2 
different studies which were treated as separate studies for the analysis, whilst 
another divided results by nationality of the sample (Hagger et al. 2012b) bringing the 
total number of studies reviewed for the alcohol use outcome to 18. All studies had 
suitable explanation about the randomisation procedure, albeit details on which online 
software or website was missing when papers described their randomisation as being 
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online. All studies reported behavioural outcomes; some studies (k= 6) reported self-
efficacy comparison outcomes at follow-up. 
The three main outcome analyses were run on studies with a follow-up of between 2 
weeks and 3 months (k= 19), with a mean follow-up period of M= 5.68 weeks (SD= 
4.8). These were all considered short follow-up timeframes, given healthy habits tend 
to require around 6 months to become established (Armitage et al. 2011).  
Two studies with, respectively, 1 week and 6 months follow-up (Norman & Wrona-
Clarke, 2016; Norman et al. 2018) were included in the meta-analysis in the subgroup 
analyses of adjusted data on alcohol use (k=2).  
The papers selected for the meta-analysis (k=21) reported an initial sample total of N= 
6655. The analysed sample total was 2758, with some papers performing an intention-
to-treat analysis (k= 13). 
This meta-analysis only analysed the effect of implementation intentions on substance 
use behaviour. Some of the studies selected were comparing control conditions to 
implementation intention groups and other intervention groups, such as Theory of 
Planned Behaviour messages (Table 2.2). The participants included in these groups do 
not feature in this analysis, increasing the difference between total and analysed 
sample. In total, a sample of 2055 was analysed for the alcohol use outcome, 703 for 
the smoking outcome, and 468 for the self-efficacy outcome (albeit the self-efficacy 
outcome had included repeated participants from the alcohol and smoking studies but 
for a different outcome).  
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Figure 2.1: PRISMA flow diagram of study selection 
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Note: RCT - Randomised Controlled Trial; II - Implementation intentions; SOC - Stages of Change Model; TPB - Theory of Planned 
Behaviour; HAPA - Health Action Process Approach; SDT - Self-Determination Theory; VHS - Volitional Help Sheet; NR – Not reported. *= 
Study included in the review but not included in the meta-analysis. 
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2.4.2.1 Characteristics of the participants 
The two main populations recruited within the selected studies were adolescents and 
undergraduate students (k=11), and the general population (k=10). The total mean age 
of the sample ranged from 16.6 to 43.7 (M= 26.97, SD= 8.69, k= 20). A slightly higher 
percentage of women was generally included in the studies, ranging from 43 to 76% 
(M= 59.03%, SD=9.95, k= 22). 
2.4.2.2 Characteristics of substance use outcomes 
Most studies measuring alcohol use outcomes used self-reported weekly or daily 
consumption or binge drinking occasions (k=14). One study (Ehret & Sherman, 2018) 
used the Daily Drinking Questionnaire (Collins et al. 1985). The studies measuring 
smoking outcomes tended to use a mixture of self-report on cigarettes a day and 
quitting status (k=6), nicotine dependence score (k=3) and objective carbon monoxide 
(CO) breath tests (Matcham et al. 2014), a non-invasive procedure used for data 
validation.  
2.4.2.3 Characteristics of implementation intention interventions 
All studies referred to Gollwitzer’s (1993) principles of implementation intentions. 
Implementation intentions were characterised mainly by two features. All 
implementation intentions were delivered after other questionnaires, such as 
demographic information or self-affirmation messages. The first feature to 
characterise the intervention was the type of implementation intention: self-generated 
(k=10) or pre-specified plans (k=12). The second feature was the mode of delivery: 
online on a computer screen (in person or remotely; k=5) or delivered in person on 
paper (k=17). 
 
2.4.3  Risk of bias within studies 
Risk of bias in individual studies was assessed with the SIGN checklist 2 for randomised 
controlled trials (SIGN, 2018). One reviewer (AM) completed the quality appraisal for 
all studies. A second reviewer (R2) appraised 13 studies, whilst a third reviewer (R3) 
appraised 10 studies (Table 2.3).  
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Table 2.3: Risk of bias of selected studies 
 





















































































































































































































Arden & Armitage 2012 + + ? + ? + + ++ 
Armitage 2007 + + + + + + + ++ 
Armitage 2008 + + + + + + + ++ 
Armitage 2009 + + + + + + ? ++ 
Armitage 2015 + + + + + + + ++ 
Armitage 2016 + + + + + + + ++ 
Armitage & Arden 2008 + + + - + + + ++ 
Armitage & Arden 2012 + + + + + + ? ++ 
Armitage & Arden 2016 + + ? + + ? ? ++ 
Armitage et al. 2011 + + + + + + + ++ 
Armitage et al. 2014 + + + + + + + ++ 
Caudwell et al. 2018 + + ? + + - + ++ 
Conner & Higgins, 2010 + + - - + - + + 
Ehret et al. 2018 + + ? + + + - + 
Hagger et al. 2012a + + + - + - ? - 
Hagger et al. 2012b + + + + + - ? + 
Matcham et al. 2014 + - - ? + ? + + 
Murgraff et al. 2007 + - ? ? ? - ? - 
Norman & Wrona-Clarke 2016 + + + + + + - + 
Norman et al. 2018 + - - + + - + + 
Rivis & Sheeran, 2013 + ? ? + ? - ? - 
Webb et al. 2009 + + + + + + + ++ 
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A Cohen’s Kappa coefficient (K) was calculated for the reviewers to assess inter-rater 
agreement (McHugh, 2012). There was a substantial inter-rater agreement between 
AM and R2, with K=0.64, p<.001 (n=143), and a moderate inter-rater agreement 
between AM and R3, with K=0.54, p<.001 (n=110). Disagreement or discrepancies 
were resolved by discussion (See Table 2.3).  
 
2.4.4  Synthesis of results 
The effectiveness of implementation intention was analysed by behavioural outcome 
and described in the paragraphs below. The intervention effectiveness was calculated 
between-groups at follow-up.  
2.4.4.1 Alcohol consumption 
Firstly, data was pooled from 16 studies that reported unadjusted data (Arden & 
Armitage, 2012; Armitage, 2009; Armitage, 2015; Armitage & Arden, 2012; Armitage & 
Arden, 2016a; Armitage & Arden, 2016b; Armitage et al. 2011; Armitage et al. 2014; 
Caudwell et al. 2018; Ehret & Sherman, 2018; Hagger et al. 2012a; Hagger et al. 2012b 
(3 samples); Murgraff et al. 2007; Rivis et al. 2013) and included 2055 individuals 
(students and general population). The effect size for alcohol use was g=0.31 (CI: 0.21, 
0.42), p< .001, indicating that implementation intentions had a small but significant 
effect in reducing alcohol consumption (Figure 2.2). The statistical heterogeneity 
across the studies was not significant (Qstatistic= 18.39; df=15; I
2 = 18.41 %; p= .24).   
2.4.4.2 Tobacco smoking  
Data was pooled from 6 studies (Armitage, 2007; Armitage, 2008; Armitage, 2016; 
Armitage & Arden, 2008; Matcham et al. 2014; Webb et al. 2009) and included 703 
individuals. A small effect size was detected, with g=.31 (CI: 0.12, 0.5), p=.002, 
indicating that implementation intentions had a small effect on reducing smoking 
(Figure 2.3). The homogeneity analysis suggested a moderate, yet non-significant 
degree of statistical heterogeneity (Qstatistic= 9.9; df= 5; I
2 = 49.49%; p= .08).  
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Figure 2.2: Forest plot of the effect of implementation intentions on alcohol use at follow-up. 
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2.4.4.3 Illicit drug use 
No studies that fitted the inclusion criteria were found in the present systematic 
search for the use of implementation intentions on reduction of illicit drug use. 
Literature suggests implementation intentions should be employed to prevent and 
treat addiction (Prestwich et al. 2006), yet more research is undoubtedly needed in 
this area. The lack of literature on this topic could also be due to publication bias, 
favouring publication of significant results.  
2.4.4.4 Self-efficacy  
Six studies evaluated the impact of implementation intentions on self-efficacy scores, 
with g ranging from -0.2 to 0.494 (Armitage, 2008; Armitage & Arden, 2012; Armitage 
& Arden, 2016a; Armitage & Arden, 2016b; Armitage et al. 2014; Murgraff et al. 2007). 
The pooled studies, which included 468 individuals (adult and student population), 
resulted in an effect size of g=0.16 (CI: -0.023, 0.342, p=.087), indicating that 
implementation intentions had a very small, non-significant effect in improving self-
efficacy scores. One study (Norman et al. 2018) provided adjusted data so it was not 
included in this analysis (Figure 2.4). The statistical heterogeneity across the studies 
was neither important nor significant (Qstatistic= 5.07; df= 5; I
2 = 1.373%; p= .407).  
 
2.4.5  Risk of bias across studies 
2.4.5.1 Assessment of publication bias 
Funnel plots for the studies reporting alcohol, smoking and self-efficacy follow-up 
effect sizes were visually inspected to assess publication bias, with no bias detected 
(see Figures 2.5, 2.6 and 2.7). Eggers regression test (Egger et al. 1997) also showed no 
evidence of publication bias among the studies reporting alcohol use (intercept=0.4; 
SE=1.25; CI= 2.28, 3.08), among those reporting tobacco smoking (intercept=-2.33; 
SE=1.89; CI= -7.57, 2.91) and those reporting self-efficacy (intercept=-2.64; SE=1.14; 
CI= -0.28, 5.57). The trim and-fill method (Duval & Tweedie, 2000) suggested that no 
missing studies were needed to make the plot symmetric for the smoking outcome, 
yet it suggested the inclusion of an extra 2 studies for greater symmetry for both the 
alcohol and self-efficacy outcomes.  
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This simply estimates that the addition of 2 unpublished studies would increase the 
symmetry of the funnel plot, showing slight publication bias towards studies with 
positive medium effect sizes. 
 
2.4.6  Additional analysis 
2.4.6.1 Sensitivity analyses 
Sensitivity analyses were used to remove individual studies with high relative weight to 
investigate the robustness of the overall results. For the alcohol outcome, one study 
(Rivis et al 2013) was found to influence the meta-analysis results more than other 
studies. When Rivis et al. (2013) was omitted from the analysis, a slight increase in the 
pooled effect size was observed, g=0.33 (0.21, 0.44), p<.001.  
For the tobacco smoking outcome, one study (Armitage and Arden 2008) was omitted, 
providing a slightly smaller effect size, g=0.25 (CI: 0.02, 0.48), p=.031. 
For the self-efficacy, one study (Murgraff et al. 2007) was omitted, resulting in a very 
slight reduction in effect size, g=0.15 (CI: -0.09, 0.39), p=0.23.  
2.4.6.2 Subgroup analyses  
Subgroup analyses were run where possible (k≥2 in each subgroup) for all outcomes 
(Table 2.4). Self-efficacy did not present a sufficient number of studies per subgroup to 
allow any comparison. Subgroup analyses on the alcohol outcome showed that the 
effect of implementation intentions differed according to mode of delivery (in person 
or online), type of implementation intention (self-generated or pre-specified), 
population (general population or students) and by the studies’ methodology quality 
(with high quality differing from acceptable or low quality). The two studies (Norman & 
Wrona-Clarke, 2016; Norman et al. 2019) presenting adjusted data revealed a lower 
effect size compared to the unadjusted analysis reported in the main results, resulting 
in a slightly lower overall effect size when all studies were combined. 
The only two subgroup analyses obtainable for the smoking outcome were population 
and type of implementation intention. Both revealed differences in effect sizes 
between subgroups (Table 2.4). 
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Table 2.4: Effect sizes at follow-up using moderators of effect of implementation 
intention on alcohol use and tobacco smoking.  
 Alcohol use Tobacco smoking  
Factor  No. of 
studies 
Pooled g (95% CI) No. of 
studies 
Pooled g (95% CI) 
Mode of delivery     Number of studies per subgroup 
not sufficient to allow comparison. 
In person 13 0.335** (0.211, 0.458)   




    
Pre-specified 9 0.389** (0.258, 0.520) 3 0.229 (-0.158, 0.616) 
Self-generated  7 0.232** (0.082, 0.383) 3 0.352* (0.119, 0.584) 
Population      
Students  10 0.254** (0.129, 0.379) 2 0.097 (-0.154, 0.348) 
General  6 0.447** (0.278; 0.615) 4 0.406** (0.199, 0.613) 
Quality     Number of studies per subgroup 
not sufficient to allow comparison. 
Low 3 0.281* (0.089, 0.473)   
Acceptable 4 0.201 (-0.02, 0.422)  
High 9 0.413** (0.271, 0.556)  
Effect estimate      
Adjusted analysis  2 0.115 (-0.011, 0.241)   
Unadjusted analysis  16 0.312** (0.209, 0.416)   
Overall 18  0.272** (0.175, 0.369)   
Note: *p< .05; **p≤ .001 
 
2.5 Discussion 
This meta-analysis reviewed the evidence of the effectiveness of implementation 
intention on the reduction of substance use. It found a small, yet significant, effect size 
for both alcohol use and tobacco smoking. The Hedges’ g values reported in this meta-
analysis are smaller than the medium effect size of d = 0.65 reported in a highly cited 
meta-analysis of behaviour change studies (Gollwitzer & Sheeran, 2006). The results 
are, however, similar to other meta-analyses investigating the effectiveness of 
implementation intentions on specific health behaviour, such as promoting physical 
activity, SMD= 0.24 (Bélanger-Gravel et al. 2013), and reducing unhealthy eating, 
d=0.29 (Adriaanse et al. 2011).  
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The results of this meta-analysis suggest that implementation intentions have been 
successfully applied to some substance use behaviours such as alcohol consumption 
and tobacco smoking, implying that the automaticity aspect of implementation 
intentions could function as the mechanism of behaviour change. The results for the 
alcohol use outcome were consistent throughout the subgroup and sensitivity 
analyses, suggesting a degree of confidence in the strength of the findings. The 
number of studies included for this outcome (k=16) and the general high quality of the 
studies presented, contributed to the strength of the findings.  
The strength of the findings on the tobacco smoking and self-efficacy outcomes were 
less consistent due to the low number of studies identified for the meta-analysis (k=6 
for either outcome). The tobacco smoking results were mostly homogeneous, with 
only one study reporting a negligible effect of implementation intentions on the 
outcome (Armitage, 2016). The results for the self-efficacy outcome, however, 
presented a small effect size with confidence interval overlapping zero. Not only was 
the number of studies small, but the degree of variation in the promotion of action-
specific self-efficacy was obvious in these results. As with previous studies investigating 
self-efficacy and implementation intentions (Milne et al. 2002; Murray et al. 2005, 
Rodgers et al. 2002; Webb & Sheeran, 2008), the findings of this study show 
inconsistency and further research on this area is recommended. However, the overall 
findings on alcohol use and tobacco smoking remain in line with previously published 
literature on implementation intentions (Adriaanse et al. 2011; Bélanger-Gravel et al. 
2013; Kwasnicka et al., 2013). 
In some studies, implementation intention interventions were coupled with other 
behaviour change techniques (BCTs), such as self-affirmation manipulations, social 
comparisons and information about social and environmental consequences or mental 
rehearsal of successful performance. Since the introduction of the Behaviour Change 
Technique Taxonomy (Michie et al. 2013) and the TIDieR checklist (Template for 
Intervention Description and Replication) for better reporting of interventions 
(Hoffmann et al. 2014), there have been advances in the way behaviour interventions 
are reported. However, it is possible that the effect sizes reported in the findings of 
this review might have been influenced by more than one BCT. This is the nature of 
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social and health psychological research, which includes research with possible 
confounders given ‘laboratory’ experimental conditions are unnatural and arguably 
lack ecological validity (Orne, 1962). 
Regrettably, this review was unable to analyse whether implementation intention 
interventions can reduce illicit drug use. The lack of identifiable studies on this subject 
is surprising, highlighting a need for this type of research to be conducted. Given the 
interest this topic had raised in previous years (Brandstätter, Lengfelder & Gollwitzer, 
2001; Churchill & Jessop, 2010; Prestwich, Conner & Lawton, 2006; Verdejo-García, 
Lawrence & Clark, 2008), it is possible studies have been conducted, but have been 
victim of publication bias, where studies with no significant effects have failed to be 
published and distributed to the wider scientific community. 
 
2.5.1 Subgroup analyses 
Subgroup analyses revealed little difference between subgroups, with most effect sizes 
remaining small to medium and significant (Table 2.4). The most notable differences 
were observed in the target population subgroups. For both alcohol use and smoking, 
implementation intentions showed a much stronger medium effect size in the general 
population compared to student/adolescent populations. These results might be due 
to adolescents usually being less future-orientated than adults (Siu et al. 2014), 
suggesting planning future actions results in weaker plans and greater observed 
delayed discounting in the present moment (Steinberg et al. 2009). 
 
2.5.2  Implications for policy and practice 
The damaging effects on health of substance use and misuse, such as alcohol and 
tobacco smoking, and their related mortality rates, were explored in detail at the start 
of this chapter. Implementation intentions are a brief, one-off and inexpensive 
intervention that can be provided by primary and secondary care healthcare providers 
alike. They provide individuals with self-regulatory strategies to automatically initiate 
action planning after experiencing environmental cues. Given the small significant 
effect sizes, and the characteristics of study participants, it is unclear what the 
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implications from this review may be for clinical practice. Therefore future research on 
implementation intentions should test them as part of clinical practice with patients in 
alcohol use, smoking cessation settings and with people in substance misuse services. 
 
2.5.3 Limitations 
At a study level, this review did not exclude studies with high risk of bias. Only RCTs 
were included in the review, in order to minimise risk of bias and increase confidence 
in the overall findings. However, studies which were found to have low methodological 
quality were retained in the review, which could have increased the risk of bias at 
review level. Equally, excluding these studies might have increased the risk of bias at 
review level by reporting only high-quality studies. A decision was made to keep all 
studies despite their individual risk of bias, as there was an identified need to translate 
the findings into real-world clinical application, allowing therefore for some 
methodological imperfections. 
At review level, other limitations were also identified. Only 3 databases were searched 
for literature, no grey literature was reviewed and only one reviewer conducted the 
searches and identified the studies for quality appraisal. Grey literature is not peer 
reviewed and therefore was purposefully not included. Two clinical trial databases 
were searched for ongoing RCTs, yet only published trials were identified with this 
search. Reference list searches were conducted and proved fruitful.  
All populations included in the studies analysed were from Western societies. High-
income Western countries may have a very different cultural relationship with 
substance use compared to low- and middle-income countries in other parts of the 
world. Further research which elucidates whether the automaticity of action planning 
initiation following environmental cues can differ between cultures should be 
conducted.  
Lastly, the reviewers observed some heterogeneity with regards to implementation 
intentions intervention delivery (e.g. pen and paper, paper and oral repetition, online 
self-generation), yet when I2 and Qstatistic tests were run to assess heterogeneity 
between studies, two of the outcomes did not demonstrate any heterogeneity, whilst 
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the smoking outcome showed a somewhat moderate level of non-significant 
heterogeneity. Subgroup analyses clearly showed that the population targeted in the 
intervention (students or general population) was the source of this heterogeneity. All 
data was checked to be correct and this analysis was reported, as some degree of 
heterogeneity is to be expected in meta-analysis (Higgins, 2008). 
 
2.5.3 Conclusions 
This meta-analysis suggests that implementation intention interventions show 
significant small effects in reducing some forms of substance use (alcohol use and 
tobacco smoking) among the general population and students in secondary and higher 
education. The evidence of the effectiveness of this intervention could be improved by 
standardising implementation intention interventions (oral or written, self-generated 
or pre-specified, implementation intention seen once or with repeated exposure). 
Generalisability could be improved by conducting interventions in clinical populations 
and in low- to middle-income countries with different cultural views on substance use. 
Future research efforts should also be applied on the use of implementation intentions 
to reduce illicit drug use, whether or not the effect of this intervention is significant 
and on the use of implementation intentions in clinical practice.  
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Supplementary File 2.1: Systematic review searches 
PsycINFO via EBSCOhost - 23 April 2018 
Search ID Search terms Hits 
S1 TI (implementation 
intention* OR coping 
strateg* OR goal planning) 
OR AB (implementation 
intention* OR coping 
strateg* OR goal planning)  
18384 
S2 TI (action OR goal OR plan) 
OR AB (action OR goal OR 
plan)  
390,959 
S3 AB (coping OR cop* OR 
barrier* OR obstacle* OR 
shield*) OR TI (coping OR 
cop* OR barrier* OR 
obstacle* OR shield*)  
188327 
S4 S1 OR S2 OR S3 556753 
S5 TI ( (subtance OR drug) ) 
AND TI ( (abuse OR misuse 
OR use OR disorder* OR 
addict* OR dependen*) ) 
OR AB ( (subtance OR drug) 
) OR AB ( (abuse OR misuse 
OR use OR disorder* OR 
addict* OR dependen*) )  
1,281,538 
S6 TI (alcohol OR drink* OR 
bing*) OR AB (alcohol OR 
drink* OR bing*) 
125138 
S7 TI ( (smok* OR cigarette* 
OR cannabis OR marijuana 
OR grass OR pot OR dope) ) 
OR AB ( (smok* OR 
cigarette* OR cannabis OR 
marijuana OR grass OR pot 
OR dope) )  
66,963 
S8 TI ( (drug* OR heroin OR 
opioid OR opiate OR opium 
OR cocaine OR stimulant* 
OR methamphetamine OR 
amphetamine OR crack OR 
hash OR brown OR gear) ) 
OR AB ( (drug* OR heroin 
OR opioid OR opiate OR 
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amphetamine OR crack OR 
hash OR brown OR gear) )  
S9 TI ( (inject* OR 
intravenous*) ) OR AB ( 
(inject* OR intravenous*) )  
65,215 
S10 TI ( (reduc* OR impair* OR 
decreas* OR eliminat* OR 
diminish* OR cut* OR quit* 
OR cessation OR stop OR 
moderat*) ) OR AB ( 
(reduc* OR impair* OR 
decreas* OR eliminat* OR 
diminish* OR cut* OR quit* 
OR cessation OR stop OR 
moderat*) )  
924,587 
S11 S5 OR S6 OR S7 OR S8 OR S9 
OR S10  
1,926,788 
S12 S4 and S11 265,373 
S13 TX ( (randomi?ed control* 
trial OR trial OR rct) ) OR TI ( 
(randomi?ed control* trial 
OR trial OR rct) ) OR AB ( 
(randomi?ed control* trial 




S12 AND S13 15,007 
S15 
 
S1 AND S14 360 
Selected through Title   35 
Minus duplicates  n/a (first database search) 
Selected through Abstract  19 
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Medline via EBSCOhost - 04 May 2018 
Search ID Search terms Hits 
S1 TI (implementation 
intention* OR coping 
strateg* OR goal planning) 
OR AB (implementation 
intention* OR coping 
strateg* OR goal planning)  
11,961 
S2 TI (action OR goal OR plan) 
OR AB (action OR goal OR 
plan)  
906,226 
S3 AB (coping OR cop* OR 
barrier* OR obstacle* OR 
shield*) OR TI (coping OR 
cop* OR barrier* OR 
obstacle* OR shield*)  
711,540 
S4 S1 OR S2 OR S3 1,584,771 
S5 TI ( (subtance OR drug) ) 
AND TI ( (abuse OR misuse 
OR use OR disorder* OR 
addict* OR dependen*) ) 
OR AB ( (subtance OR drug) 
) OR AB ( (abuse OR misuse 
OR use OR disorder* OR 
addict* OR dependen*) )  
4,726,923 
S6 TI (alcohol OR drink* OR 
bing*) OR AB (alcohol OR 
drink* OR bing*) 
313,307 
S7 TI ( (smok* OR cigarette* 
OR cannabis OR marijuana 
OR grass OR pot OR dope) ) 
OR AB ( (smok* OR 
cigarette* OR cannabis OR 
marijuana OR grass OR pot 
OR dope) )  
309,815 
S8 TI ( (drug* OR heroin OR 
opioid OR opiate OR opium 
OR cocaine OR stimulant* 
OR methamphetamine OR 
amphetamine OR crack OR 
hash OR brown OR gear) ) 
OR AB ( (drug* OR heroin 
OR opioid OR opiate OR 
opium OR cocaine OR 
stimulant* OR 
methamphetamine OR 
amphetamine OR crack OR 
1,557,128 
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hash OR brown OR gear) )  
S9 TI ( (inject* OR 
intravenous*) ) OR AB ( 
(inject* OR intravenous*) )  
912,742 
S10 TI ( (reduc* OR impair* OR 
decreas* OR eliminat* OR 
diminish* OR cut* OR quit* 
OR cessation OR stop OR 
moderat*) ) OR AB ( 
(reduc* OR impair* OR 
decreas* OR eliminat* OR 
diminish* OR cut* OR quit* 
OR cessation OR stop OR 
moderat*) )  
5,796,228 
S11 S5 OR S6 OR S7 OR S8 OR S9 
OR S10  
9,776,504 
S12 S4 and S11 884,035 
S13 TX ( (randomi?ed control* 
trial OR trial OR rct) ) OR TI ( 
(randomi?ed control* trial 
OR trial OR rct) ) OR AB ( 
(randomi?ed control* trial 




S12 AND S13 76,559 
S15 
 
S1 AND S14 964 






Selected through Abstract 
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Psychology and Behavioural Science Collection via EBSCOhost - 06 September 2018 
Search ID Search terms Hits 
S1 TI (implementation 
intention* OR coping strateg* 
OR goal planning) OR AB 
(implementation intention* 
OR coping strateg* OR goal 
planning)  
2917 
S2 TI (action OR goal OR plan) 
OR AB (action OR goal OR 
plan)  
64882 
S3 AB (coping OR cop* OR 
barrier* OR obstacle* OR 
shield*) OR TI (coping OR 
cop* OR barrier* OR 
obstacle* OR shield*)  
47442 
S4 S1 OR S2 OR S3 108419 
S5 TI ( (subtance OR drug) ) AND 
TI ( (abuse OR misuse OR use 
OR disorder* OR addict* OR 
dependen*) ) OR AB ( 
(subtance OR drug) ) OR AB ( 
(abuse OR misuse OR use OR 
disorder* OR addict* OR 
dependen*) )  
238255 
S6 TI (alcohol OR drink* OR 
bing*) OR AB (alcohol OR 
drink* OR bing*) 
24086 
S7 TI ( (smok* OR cigarette* OR 
cannabis OR marijuana OR 
grass OR pot OR dope) ) OR 
AB ( (smok* OR cigarette* OR 
cannabis OR marijuana OR 
grass OR pot OR dope) )  
16383 
S8 TI ( (drug* OR heroin OR 
opioid OR opiate OR opium 
OR cocaine OR stimulant* OR 
methamphetamine OR 
amphetamine OR crack OR 
hash OR brown OR gear) ) OR 
AB ( (drug* OR heroin OR 
opioid OR opiate OR opium 
OR cocaine OR stimulant* OR 
methamphetamine OR 
amphetamine OR crack OR 
hash OR brown OR gear) )  
55410 
S9 TI ( (inject* OR intravenous*) 12253 
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) OR AB ( (inject* OR 
intravenous*) )  
S10 TI ( (reduc* OR impair* OR 
decreas* OR eliminat* OR 
diminish* OR cut* OR quit* 
OR cessation OR stop OR 
moderat*) ) OR AB ( (reduc* 
OR impair* OR decreas* OR 
eliminat* OR diminish* OR 
cut* OR quit* OR cessation 
OR stop OR moderat*) )  
159363 
S11 S5 OR S6 OR S7 OR S8 OR S9 
OR S10  
358745 
S12 S4 and S11 47976 
S13 TX ( (randomi?ed control* 
trial OR trial OR rct) ) OR TI ( 
(randomi?ed control* trial OR 
trial OR rct) ) OR AB ( 
(randomi?ed control* trial OR 




S12 AND S13 13472 
S15 
 
S1 AND S14 408 
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CHAPTER THREE: Preliminary behavioural analysis of equivalent 
population  
Change in injecting behaviour among people treated for hepatitis C virus.  
This chapter reports the results from a data analysis exercise completed in January 
2018, which informed a substantial amendment to the study protocol. The data was 
collected and provided by the Eradicate-C study group and the Chief Investigator, 
Professor John F. Dillon, also second supervisor to this PhD project. Albeit the 
Eradicate-C was a single-centre clinical trial investigating the effectiveness of hepatitis 
C treatment in current injecting drug users (primary outcome), behavioural and social 
measures were taken as secondary outcomes to analyse any changes during 
treatment. The participants of Eradicate-C are directly comparable with the population 
chosen for this PhD project. It was therefore considered important to analyse this data 
in order to inform our protocol. Below is the research paper report of the data 
analysis, published in the Journal of Viral Hepatitis. 
 
3.1 Abstract  
Background: Injecting behaviour in people who inject drugs is the main risk factor for 
hepatitis C virus (HCV) infection. Psychosocial factors, such as having a partner who 
injects drugs and living with other drug users, have been associated with increases in 
injecting risk behaviour. This study aimed to investigate injecting behaviour changes 
during treatment for HCV infection whilst exploring the role of psychosocial factors on 
patients’ injecting behaviour. 
Methods: Eradicate-C was a single centred clinical trial investigating the effectiveness 
of HCV treatment within the injecting drug use population between 2012 and 2016. A 
total of 94 participants completed up to 24 weeks of treatment, with social and 
behavioural measures taken at different intervals throughout. Data for 84 participants 
was analysed retrospectively to explore mechanisms of potential behavioural changes 
which had occurred during treatment. 
73 
Chapter 3   
Results: Injecting frequency reduced significantly between baseline (week 1) and every 
4-weekly interval until week 26. Not being on Opiate Substitution Therapy (OST) was 
associated with a statistically significant decrease in injecting frequency, χ2 (1) = 
10.412, p=.001, as was having a partner who also used drugs, in particular when that 
partner was also on treatment for HCV infection, Z= -2.312, p=.021. 
Conclusions: Treating a ‘chaotic’ population for HCV infection is not only possible, but 
also bears health benefits beyond treatment of HCV alone. Enrolling couples on HCV 
treatment when partners are sero-concordant has shown enhanced benefits for 
reduction in injecting behaviour. Implications for practice are discussed. 
 
3.2 Introduction 
Over 170 million people worldwide are infected with the hepatitis C virus (Hanafiah et 
al. 2013; World Health Organization - WHO, 2011). The burden is axiomatic, with an 
estimated HCV-related mortality rate of 350 thousand people a year (Mann et al. 2013; 
Palmateer et al. 2007; Public Health England, 2014; WHO, 2010). The most common 
transmission route remains injecting drug use, with an estimated 60-80% of the HCV-
positive population having acquired the virus via injecting risk behaviour (Aspinall et al. 
2013; Mcdonald et al. 2014; Nelson et al. 2011). A variety of psychosocial factors have 
been associated with injecting risk behaviour: injecting frequency, poly-drug use, 
having a sexual partner who also injects, trust and risk perception to name a few (De et 
al. 2007; Dunn et al. 2010; Shaw et al. 2007). Despite the continued injecting risks 
carried out by people who inject drugs, many studies have shown that fears of non-
adherence and low sustained-virological response (SVR) rates are unjustified, with 
people who inject drugs (PWID) showing both successful adherence and high SVR rates 
(Aspinall et al. 2013; Hellard et al. 2009; Wolfe et al. 2015). 
Psychosocial factors such as social support, romantic partnerships and living situation 
seem to have conflicting effects on injecting risk behaviour and HCV treatment 
success. Published literature reports an association between HCV treatment success 
rates and social support (Janda et al. 2017). Peers help to increase motivation, self-
care, feelings of hope and strength to complete treatment, feelings of being listened 
to, accepted and understood, as well as decreasing internalised stigma and shame 
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related to HCV and substance misuse and reducing use of substances itself (Batchelder 
et al. 2015; Rance et al. 2017). Yet, historically, close relationships with other PWID, 
such as romantic partnerships and living with other drug users, are among the factors 
most strongly linked to continued injecting risk behaviour (De et al. 2007; Dunn et al. 
2010; Shaw et al. 2007). These polar effects of psychosocial factors on injecting risk 
behaviour and HCV treatment might be due to the function of romantic, and other, 
partnerships of PWID as sources of social care and protection, in a hostile and ‘chaotic’ 
environment where the behaviours of vulnerable adults are influenced negatively by 
partners, whilst also increasing a sense of acceptance, belonging and self-worth (Rance 
et al. 2017). Integrated models of behaviour change attempt to explain how couple 
dynamics can influence risk and health behaviours (Lewis et al. 2006). 
HCV treatment itself seems to have a wider effect on PWID than curing hepatitis C 
alone. It has been associated with a decrease in ancillary injecting equipment sharing 
after treatment completion (Alavi et al. 2015), suggesting treatment might impact the 
HCV as well as impacting injecting behaviour. Midgard and colleagues (Midgard et al. 
2017) investigated changes in behaviour during and after treatment, and reported a 
decrease in recent injecting drug use and alcohol use and an increase in opiate 
substitution therapy (OST) uptake throughout HCV treatment and at follow-up. 
However, they found no changes in daily injecting, use of sterile or shared equipment 
(Midgard et al. 2017).  
Only a few studies have investigated the effects of HCV treatment on risk behaviour 
(Alavi et al. 2015; Midgard et al. 2017) and no literature to date has investigated the 
role of psychosocial factors such as romantic partnerships and living situation on risk 
behaviour during and following HCV treatment. 
The Eradicate-C study was carried out to investigate the effectiveness of interferon-
based HCV treatment on current PWID, characterised by a ‘chaotic’ lifestyle and erratic 
engagement with healthcare services. This study aimed to investigate changes in 
injecting behaviour during treatment, examining the role of psychosocial factors on 
hypothesised injecting behaviour change.  
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3.3 Methods 
3.3.1 Study design 
Eradicate-C was a single centred clinical trial investigating the effectiveness of HCV 
treatment within the injecting drug use population between 2012 and 2017. 
Participants were seen on a weekly basis for 26 consecutive weeks. The nurses, 
starting on visit 2 of treatment, provided a weekly injection of 180µg pegylated 
interferon α (PEG-IFNα) and supplied participants with a week’s worth take-home daily 
dose of between 400 – 1400 mg (weight based) of self-administered ribavirin.  Patients 
presenting with a genotype 1 infection also received protease inhibitors: telaprevir or 
simiprevir. The study treatment mirrored the standard of care treatment duration of 
24 weeks for genotype 1 infections and of 16 weeks for genotypes 2 and 3 infections. 
All participants completed behavioural and social measures at different time points 
during the 26 visits of treatment.  
The study was conducted in accordance with the Declaration of Helsinki and the 
principles of good clinical practice. The study was co-sponsored by the University of 
Dundee and NHS Tayside, and was ethically reviewed and approved by the East of 
Scotland Research Ethics Service REC 2. It was also registered with the National 
Institute for Health Research (NIHR) on UK Clinical Trials Gateway as ISRCTN27564683. 
 
3.3.2 Outcomes 
The primary outcome of the Eradicate-C study was to analyse SVR12 in the PWID 
population, which resulted in 84.2% genotype 1 and 85.2% genotype 2 & 3 achieving 
SVR (Johnston et al. 2017). The total SVR12 rate for all participants was 84.8%. The 
abstract hereby referenced shows a slightly lower SVR12 rate of 83.1% because it was 
submitted before the end of the study, with 5 patients SVR12 results still pending.  
In this paper, the outcomes of interest were the behavioural and social measures 
collected during treatment. The primary outcome was injecting frequency throughout 
treatment (collected at visit 1, 4, 8, 12, 20, 24 and 26). Independent variables analysed 
were OST, living situation, living with other drug users, having children, having a 
partner, having a partner who used drugs/alcohol and the EQ5D scores. These 
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measures were taken at visit 1 and visit 26, with the exception of OST which taken 
every visit from visit 2 to follow-up (visits 27 and 28). 
 
3.3.3 Study participants  
A total of 94 participants completed up to 24 weeks of treatment between January 
2013 and December 2016 within the largest Injecting Equipment Provision (IEP) service 
in Dundee (Scotland, UK). Participant inclusion criteria were: being aged between 18 
and 70; active HCV infection - genotyped and confirmed by Polymerase Chain 
Reaction; current illicit drug use (confirmed through self-report and injection sites 
inspection); if female of child-bearing age, provision of a negative pregnancy urine test 
and fitting of Long-Acting Reversible Contraception (LARC). Exclusion criteria were: 
inability to provide informed consent; aggressive or violent behaviour; features of 
decompensated liver; evidence of primary hepatocellular carcinoma; if female, being 
pregnant, breastfeeding or pre-menopausal not on LARC; contraindications to using 
PEG-IFNα or Ribavarin; previous treatment with PEG-INFα, Ribavarin or Telaprevir 
criteria; participation in other drug study within past 30 days. The current study 
analysed behavioural and social data from visit 1 and visit 8 of treatment. Not all 94 
participants who completed treatment provided data for both visits, reducing the pool 
of participants to 84 for the present analysis. 
 
3.3.4 Analysis 
Data was analysed using IBM SPSS Statistics 22. Descriptive analyses were run to 
obtain characteristics of the sample. If data was available for immediately preceding 
and subsequent weeks (e.g. visits 7 and 9), an average score was used for the required 
missing data (e.g. visit 8). If immediately preceding and subsequent visit scores were 
not available, data was considered missing.  The null hypothesis (no difference in 
injecting frequency at different time points) was tested with a non-parametric 
Friedman test, and subsequent post-hoc analyses using Wilcoxon Signed Ranked tests 
were run to identify where differences lay. Non-parametric testing was selected 
following data testing for violation of normality, which showed skewed data with 
kurtosis at all time points. A square root transformation was attempted to normalise 
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distribution and eliminate outliers, but distribution remained skewed. Outliers were 
included in analysis as non-parametric use of medians signifies outliers hold less 
influence over test results. 
Once identified that the largest injecting frequency difference was observed between 
week 1 and week 8 of the study, this difference was used to create a new dependent 
variable of injecting change, used in the analysis both as a categorical variable, to allow 
for Crosstab explorations using multiple categorical social factors, and as a continuous 
variable, to allow investigation of significant differences between the most important 
categorical social factors using Mann-Whitney U tests. 
 
3.4 Results 
A total of 106 participants consented to treatment. Two never completed baseline 
measures: 1 participant did not meet inclusion criteria and 1 participant died before 
starting treatment and completing baseline data. Of the remaining 104 consented, 94 
completed treatment, but only 84 had completed behavioural and social data. So a 
total of 20 participants were lost to follow-up for this sub-study. Ten participants never 
commenced treatment: 3 spontaneously cleared the infection, 4 were lost to follow-
up, 2 were treated on standard pathway after becoming drug-free and 1 was in prison 
outwith the catchment area. The remaining 10 consenting participants who completed 
treatment had data missing for the visit 8 follow-up. Characteristics of participants at 
enrolment are presented in Table 3.1.  
 
Table 3.1: Participants’ characteristics 
Characteristic Study population 
(N=84) 
Lost to Follow-up  
(N=20) 
Female Sex (%) 26 (31) 2 (10) 
Age, median (IQR) 34 (23-45) 33 (25.25-40.75) 
Legal situation: none (%) 49 (58.3) 11 (55) 
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Table 3.1 continued Study population Lost to Follow-up  
Living situation 
Homeless (%) 16 (19) 6 (30) 
Living in own or rented 
accommodation (%) 
61 (72.6) 13 (65) 
Living alone (%) 38 (45.2) 12 (60) 
Living with partner (%) 25 (29.8) 4 (20) 
Living with parents (%) 12 (14.3) 1 (5) 
Living with other drug users (%) 30 (35.7) 5 (25) 
Romantic relationships 
Has partner (%) 42 (50) 5 (25) 
Partner uses drugs (% of Has 
partner) 
34 (81) 4 (80) 
Has children (%) 50 (59.5) 7 (35) 
Healthcare-related measures 
EQ5D Health state score, median 
(IQR) 
50 (20-80) 45 (20-70) 
On OST (%) 60 (71.4) 4 (20) 
Methadone dose, median (IQR) 70 (45-95) 75 (61-89) 
Weekly injecting frequency, 
Mean (STD) 
9.39 (8.87) 11.35 (11.37) 
 
Only 32 of the 84 participants presented a complete set of data on injecting frequency 
at the 8 time points.  A Friedman test for differences in weekly injecting frequency 
among the time points gave a significant result, χ 
  (7) = 36.44, p< .001.  The median for 
week 1 was 4.5, for week 4 was 2, and thereafter for weeks 8 to 26 the median was 1.  
The range for the 8 time points remained between 0-14 and 0-30.  Post hoc Wilcoxon 
Signed Rank Tests were applied to the differences between Week 1 and each of the 
other 7 time points.  Bonferroni's correction reduced the significance level to p< .007.  
The results and effect sizes are shown in Table 3.2. Effect size r was calculated with 
Rosenthal’s formula   
 
  
 (Rosenthal, 1991), where Z is the post hoc Wilcoxon Signed 
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Rank Test score and N is the number of observations. The coefficient r is more 
commonly used as a correlation coefficient to measure the strength of a relationship; 
however, it is a versatile coefficient and it is used, especially within non-parametric 
testing, as a measure of experimental effect (Field, 2018). 
 
Table 3.2: Post-Hoc comparisons 
 Z p *   r † 
Weeks 1-4 -3.534 < .001* -.63 
Weeks 1-8 -5.459 < .001* -.97 
Weeks 1-12 -5.265 < .001* -.93 
Weeks 1-16 -4.759 < .001* -.84 
Weeks 1-20 -3.768 < .001* -.67 
Weeks 1-24 -3.225 .001* -.57 
Weeks 1-26 -4.495 < .001* -.80 
* Significant at p < .007 with Bonferroni correction 
† Effect size r : Small = .1, Medium = .3, Large= .5 
 
Week 8 was the time point at which the largest decrease in injecting was observed. To 
explore the decrease in injecting further, a new variable was computed. The difference 
between week 1 and week 8 injecting frequency was computed and categorised as 
‘Better’ for a difference of ≥ 7or ‘Not Better’ otherwise. This was because a reduction 
in injecting frequency of at least once a day was judged to have some clinical 
significance. Figure 5.5.1 shows the difference in injecting frequency between week 1 
and week 8 of treatment among the grouping variables analysed above. 
Chi-Square tests were run to explore associations between participant characteristics 
and injecting behaviour change as judged by the new variable Better or Not Better 
(Table 3.3). Living situation, having children and healthcare-related measures showed 
no significant association with injecting behaviour change. However, having a partner 
who used drugs was significantly associated with being ‘Better’ (i.e. to reducing of 
weekly injecting), χ2 (1) = 4.43, p =.035, Fisher’s Exact test p =.043. Not being on OST 
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on week 2 of treatment was also significantly associated with being ‘Better’, χ2 (1) = 
10.412, p =.001, Fisher’s Exact test p =.003 (See Table 3.3). 
 
Table 3.3: Chi Square Tests for association 
Characteristic χ2 (df) p * Fisher’s Exact Test 
* 
Legal situation 4.254 (4) .373 na 
Living situation 1.361 (3) .715 na 
Accommodation .04 (2) .98 na 
Living with other drug 
users 
2.007 (1) .157 .21 
Romantic relationships 
Has partner .023 (1) .880 1 
Partner uses drugs* 4.43 (1) .035* .043* 
Has children .067 (1) .795 .813 
Healthcare-related measures 
EQ5D Mobility .05 (1) .823 1 
EQ5D Self-care 1.088 (1) .297 .368 
EQ5D Activity .621 (2) .733 na 
EQ5D Pain .905 (2) .636 na 
EQ5D Anxiety 1.159 (2)  .56 na 
On OST week 2* 10.412 (1) .001* .003* 
* Significant at p < .05 
na: not available 
 
The association between having a partner who uses drugs and a reduction in weekly 
injecting frequency was quite surprising. A possible explanation may be that couple 
members were on treatment together, i.e. Partner who uses drugs is also on treatment 
study. The trial nurses identified N=22 participants as couples on the study (26.2% of 
total study sample, 52.4% of those with partner who used drugs/alcohol). 
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A Mann-Whitney U test showed that those who had a partner who used drugs and was 
also on treatment for HCV (N=22) reduced their injecting frequency significantly more 
than those whose partner was not on treatment (N=20), Z= -2.312, p=.021, medium 
effect size r =0.36. The mean weekly injecting difference was M = 5.65 (95% CI: -0.23 to 
11.54), just short of one injection per day difference between the two groups (Figure 
3.1). 
 
* Significant at p < .05 
 
These results were confirmed by analysing the association between the injecting 
frequency difference between week 1 and week 8 in couple members. Couples were 
assigned a couple ID (N=22, hence 11 couples on the study). All couples were 
heterosexual. The male-female Pearson’s correlation coefficient was r = .629, p = .038, 



























Figure 3.1: Injecting frequency change by grouping 
Overall Study population* 
Partner uses drugs/alcohol* 
Partner also on treatment* 
Partner no drug use 
Partner not on treatment 
OST week 2 
No baseline OST* 
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3.5 Discussion 
The findings of this paper show a significant reduction in injecting frequency between 
baseline, i.e. before the start of HCV treatment, and every other time point. The 
largest reduction was recorded between week 1 (baseline) and week 8, with injecting 
frequency stabilising thereafter whilst on treatment. Possible mechanisms of 
behaviour change were explored using baseline social factors. 
 
3.5.1 Benefits for non-OST patients 
Firstly, not being on OST on week 2 of treatment (first treatment visit recording this 
information) was found to be associated with a significant reduction in injecting 
frequency. It has been widely demonstrated that OST impacts injecting drug use 
(Gowing et al. 2008; Kemode et al. 2011; Kimber et al. 2010; Turner et al. 2011). Meta-
analysis and pooled analysis of the effect of OST and IEP on incidence of HCV infections 
(Turner et al. 2011) reported a mean injecting frequency reduction of 20.8 injections 
per month (95% CI: -27.3 to -14.4), though OST did not reduce lifetime timeframe 
duration of injecting (Kimber et al. 2010). So it is possible that the patients who were 
on treatment for HCV and were already enrolled on OST, had previously reduced their 
injecting frequency before starting HCV treatment. Previous studies however, have 
attributed decreases in ancilliary injecting equipment and decrease in recent injecting 
drug use to enrolment in HCV treatment (Alavi et al. 2015; Midgard et al. 2017). 
Enrolment on OST might therefore attenuate the effects of receiving HCV treatment 
on injecting behaviour. 
On the other hand, those who were not on OST on week 2 of Eradicate-C had not 
experienced the behavioural benefits of OST before their engagement with HCV 
treatment. It is well recognised that PWID are reluctant to access healthcare services, 
generally due to a lack of material resources, complicated and lengthy referral 
pathways, experience of stigma and poor relationship with healthcare providers 
(Ahern et al. 2007; Day et al. 2011; Morgan et al. 2015; Neale et al. 2008). For these 
individuals who were not on OST, engagement with HCV nurses might have been the 
only contact with any healthcare provider. Given the regular and considerate nature of 
this contact, a therapeutic relationship with the nurses providing the HCV treatment 
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might have functioned as a behaviour change mechanism these patients had not 
experienced because not enrolled on OST. Unfortunately therapeutic alliance was not 
measured in this study, but previously published literature attests for the importance 
of this factor on healthcare outcomes relating to this population (Haber et al. 2009; 
Meier et al. 2005; Schneider et al. 2004; Simpson et al. 1997). Meta-analyses have 
shown positive therapeutic alliance to increase patients’ engagement and retention 
within drug services, as well as motivation, treatment readiness and treatment 
experience (Meier et al. 2005). The results of this study show that engagement in HCV 
treatment has increased health-related benefits, i.e. reduction in injecting frequency, 
for those patients who are not in contact with other healthcare services. 
 
3.5.2 Behaviour change in intimate partnerships 
The observed reduction in weekly injecting frequency was also, and more interestingly, 
linked to drug-using status of romantic partners. Those who had a partner who used 
drugs were more likely to reduce their injecting frequency, a reduction difference of 
more than 9 injections a week, equalling more than one injection a day (mean injecting 
difference = 9.74, SE = 3.56). This finding was surprising, as previous literature 
associated having a partner who uses drugs, in particular those injecting, with 
increased frequency of injecting and of sharing of injecting equipment (De et al. 2007; 
Dunn et al. 2010; Rance et al. 2017; Shaw et al. 2007). A variety of papers have been 
published on the power imbalance and social inequalities that drive injecting risk 
behaviour in heterosexual couples, in particular in women who inject drugs, who often 
rely on their male partner to acquire, prepare and inject the drugs (El-Bassel et al. 
2014; Harvey et al. 1998; Wagner et al. 2013). Disregard of injecting risk occurs as a 
consequence of emotional closeness, intimacy, trust and commitment (El-Bassel et al. 
2014; Rance et al. 2017; Simmons et al. 2012). Yet those who were in an intimate 
partnership involving drug use on this study were the principal drivers of injecting 
frequency reduction throughout treatment.  
Given the high level of sero-concordance in people who inject drugs in intimate 
partnerships (Rance et al. 2017), the study team identified patients in dyadic intimate 
partnerships who had both been enrolled on the Eradicate-C trial. The final study 
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findings confirmed that members of couples both treated for HCV on Eradicate-C were 
significantly more likely to reduce their injecting than other individuals, i.e. those in 
drug using romantic partnership but whose partner was not on treatment for HCV and 
those who did not have a drug using partner. This effect was explored through models 
of behaviour change explaining the influence of partners on each other’s health-
related behaviour. The Interdependence model of couple communal coping and 
behaviour change (Lewis et al. 2006), explores couple dynamics and their influence on 
motivation and health behaviour change. 
In the general population, the health benefits of being married or in a committed 
intimate relationship are well documented (Lewis et al. 2006; Rance et al. 2017). 
People in romantic partnerships tend to be healthier, engage with health care services 
and show a longer lifespan (Lewis et al. 2006).  The role of intimate partnerships within 
the drug using population, however, has often been linked to increased risk-taking 
behaviour and generally as a bad influence on health (El-Bassel et al. 2014; Harvey et 
al. 1998; Rance et al. 2017; Simmons et al. 2012; Wagner et al. 2013). Qualitative 
studies have shown that HCV management within couples could help consolidate a 
relationship, introducing sentiments such as feeling valued and cared for (Rance et al. 
2017). PWID generally experience hostile social environments, and intimate 
partnership which involve sentiments such as those above might represent one of the 
only types of meaningful social support and care that PWID encounter (Rance et al. 
2017). Social support is regarded as an essential part of HCV treatment, with many 
care pathways for PWID involving the role of a peer support worker as integral part of 
the treatment (Bonnington et al. 2017), providing empathy and trustworthiness to 
patients on treatment. However, it is not simply individualistic social support 
perception that has to be considered to explain the study findings. 
Lewis’ couples’ interdependence theory (Lewis et al. 2006) explains how motivation 
transformation can occur when partners experience a health event which is not only 
significant for the self, but has cognitive and emotional significance for the 
relationship. The attribution of significance of the health event to the dyad rather than 
the individual is the result of automatic consideration of partnership roles, subjective 
norms, commitment, quality of the relationship, and trust (Lewis et al. 2006). HCV 
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infection is a health threat that has both emotional and cognitive implications on the 
relationship and on each partner. These implications help transform motivation from 
‘individual-focused’ to ‘relationship-focused’, adding a layer of complex interplay 
between intrapersonal and interpersonal behaviour change processes. Once 
motivation has become ‘relationship-focused’, couples work together through 
communal coping to achieve better health through shared action to manage the health 
threat (Lewis et al. 2006; Lyons et al. 1998). Communal coping requires shared beliefs 
that joint effort is advantageous to combat HCV, communication about HCV infection 
between partners and cooperation between partners to manage HCV and its 
treatment. Communal coping impacts health behaviour through the processes of 
outcome efficacy and couple efficacy (Lewis et al. 2006; Lyons et al. 1998). The 
couple’s belief about the effectiveness of the coping/action strategies, i.e. HCV 
treatment, coupled with the couple’s confidence about engaging in joint coping, i.e. 
reducing injecting frequency will ensure HCV is less likely to recur in the couple, will 
influence the behavioural outcome. The responsibility of the couples’ (and individual’s) 
health therefore lies equally on both partners, enabling the couple to become the unit 
for risk-reducing behaviour change (Lewis et al. 2006; Rance et al. 2017). Associations 
between changes in self-perception and self-care have been identified before 
(Batchelder et al. 2015; Jauffret-Roustide et al. 2012). Often these self-perceptions are 
intended as the ‘self’ as an ‘addict’ becoming the ‘self’ as a ‘patient worthy of HCV 
treatment’ (Batchelder et al. 2015; Rance et al. 2017). A similar process of 
psychological alteration might take place within the couple, with the couple’s identity 
changing from ‘drug-using partners’ to ‘HCV-treated partners, who coped with effects 
of treatment and achieved SVR as a unit’, presenting a shared sense of ‘self’. 
 
3.5.3 Conclusions 
This study shows that treating a ‘chaotic’ population for HCV infection is not only 
possible, but also bears health benefits beyond treatment of HCV alone. Enrolling 
people who are not on OST and/or couples on HCV treatment when partners are sero-
concordant, has shown enhanced benefits for reduction in injecting behaviour and it is 
therefore recommended for practice. A complex interplay of relationship-focused 
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motivation transformation, outcome efficacy, couple efficacy and communal coping 
might improve patients’ injecting risk-behaviour.  
A few limitations are recognised within the study. Firstly, albeit the initial sample size 
seemed promising, missing data at different time points and the selection of different 
grouping variables considerably reduced the sample size for some of the analyses 
(N=42). However, the majority of clinical trials experience missing data (Dziura et al. 
2013) and the analyses were performed taking this into consideration. Secondly, the 
effect of the results might not be as large for DAA treatment. Interferon-based 
treatment was notoriously harsh and communal coping within the couples might have 
developed strongly as a consequence of this. With the advent of DAA treatment, 
communal coping might become less necessary and prominent, therefore reducing 
health-enhancing behaviour change. However, the notion of HCV treatment alone 
might be enough to kick-start the motivational transformation within an intimate 
partnership and effects on communal coping and risk-behaviour reduction could still 
be observed in the DAA treatment era. 
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Chapter Four: Methodology  
This chapter presents the design and methodology of the pilot randomised controlled trial 
(ADAPT). It is reported in accordance with the CONSORT (The Consolidated Standards of 
Reporting Trials) 2010 statement for transparent reporting of trials (Schultz et al. 2010), in 
conjunction with the TIDieR checklist (Template for Intervention Description and 
Replication) for better reporting of interventions (Hoffmann et al. 2014).  
 
4.1 Development of the protocol 
The conceptualisation of the protocol commenced prior to the Principal Investigator’s (PI) 
enrolment onto the Psychology PhD programme. A systematic review conducted in 2015 
for the Qualifications in Health Psychology Stage 2 informed the initial development of the 
PhD proposal, submitted to the University in December 2016. The protocol was initially 
created in April 2017 and developed throughout four months under the supervision of the 
PI’s first and second PhD supervisors and the other members of the monitoring committee 
from NHS Tayside. Substantial amendments to the protocol were submitted throughout 
the lifetime of the study as informed by studies 1 and 2 of this thesis. Details of the 
substantial amendments applied to the protocol are reported in this chapter. The study 
was registered on ClinicalTrials.gov (NCT03293576). 
 
4.2 Sponsor and ethical approval 
The protocol was submitted at the start of August 2017 for sponsor comments and 
approval at Tayside Medical Science Centre (TASC). The study was registered at the same 
time with the local Research and Development (R&D) management office. The sponsor 
required clarifications and changes to be applied to the protocol and the rest of the study 
documents, such as informed consent form and participant information sheet, over the 
course of the following 3 months. At the end of October 2017 the study received 
sponsorship and insurance, study agreements were signed and the completed Integrated 
Research Application System (IRAS) form, study checklist with uploaded documentation 
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and R&D package were all submitted and the Research Ethics Committee (REC) review 
meeting was booked for the 8th December 2017. 
The PI, first supervisor and one of the members of the monitoring committee attended 
the REC review meeting at the start of December 2017. The review meeting was a good 
professional experience for the PI (PhD student), who had not attended one of these 
meetings before, to learn about typical enquiries and requirements of ethics committees 
and how to answer or query them appropriately. 
The REC provided a provisional favourable opinion a week after the review meeting, 
requiring further clarifications and a few changes. These were applied, and a full 
favourable opinion was provided on the 21st December 2017. On the same day, R&D 
approval was also obtained, therefore allowing the study to start recruitment. 
 
4.2.1 Substantial Amendment AM01 
In January 2018 a change to the participants’ case report form (questions on romantic 
partners) was applied and the PI contacted the sponsor to notify of this change. The 
sponsor suggested this would have to be submitted as a substantial amendment 
(Substantial Amendment 1 – AM01) and that changes to the protocol and participant 
information sheet had to take place. After these changes were applied, the sponsor 
approved the documents and a substantial amendment form was submitted to REC and 
R&D. R&D approval was received on the 30th January 2018, whilst REC favourable opinion 
was provided after further small clarifications on 12th February 2018. 
 
4.2.2 Substantial Amendment AM02 
In April 2018, after 2 months of recruiting, it became apparent some of the variables being 
tested were too repetitive for participants, and that 5 visits (including a 6-month follow-
up) would be hard to achieve with this population, given dropout rates between visits 
were high. So the CI, PI and first supervisor revised the structure of the trial to include 4 
visits and reduce the number of repeated measures for each construct to a maximum of 3 
times. The PI contacted the sponsor to notify of this change. The sponsor suggested this 
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would have to be submitted as a substantial amendment (Substantial Amendment 2 – 
AM02) with appropriate changes to the protocol and participant information sheet. After 
these changes were applied, the sponsor approved the documents and a substantial 
amendment form was submitted to REC and R&D. Both REC and R&D approval was 
received on the on 8th May 2018. 
 
4.2.3 Substantial Amendment AM03 
In June 2019, the research team agreed further changes to the protocol would allow the PI 
to conduct a small qualitative sub-study to explore the lived experience of people who 
inject drugs diagnosed with hepatitis C who were, or had been, on treatment. The 
concurrent design of this small qualitative study would allow a discussion of comparison 
of results with the main quantitative pilot RCT. The PI contacted the sponsor to notify of 
this change. The sponsor suggested this would have to be submitted as a substantial 
amendment (Substantial Amendment 3 – AM03) and that changes to the protocol, 
participant information sheet had to take place, plus the PI had to submit new documents: 
interview schedule, informed consent form for the sub-study, participant information 
leaflet for the sub-study. After these changes were applied, the sponsor approved the 
documents and a substantial amendment form was submitted to REC and R&D. R&D 
approval was received on the 8th August 2019, whilst REC favourable opinion was received 
on 9th August 2019. 
 
4.3 Trial Design 
The study was a single centre, longitudinal, unblinded, time-controlled, parallel-group trial 
conducted between April 2017 and January 2020 in injecting equipment provision services 
across Tayside (Scotland, UK). It was set to investigate differences in self-efficacy and 
sharing behaviour between the intervention arm compared to the control arm within the 
population.  
The data collection was carried out over four visits in private clinic rooms within the 
services, with the intervention taking place on visit 2 (See the treatment trial schedule: 
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Table 4.1). All of the visits coincided with times at which the participants were seeing 
nurses or pharmacists for their hepatitis treatment.  
On visit 1, informed consent was taken from participants and, subsequently, baseline 
measures were completed by participants with the help of the researcher (reading the 
questions). The baseline measures were: Injecting Risk Questionnaire (IRQ), Group 
Identification Scale (GIS), Patient Health Questionnaire (PHQ-9), General Anxiety Disorder 
(GAD-7), Post Traumatic Stress Disorder (PC-PTSD-5), Illness Perception Questionnaire (B-
IPQ). This visit occurred between week 0 and week 3 of participants’ HCV treatment. 
 
Table 4.1: Treatment trial schedule 
 
  
Treatment trial schedule 























Demographic information x     
Injecting risk questionnaire  x   x   x  
Self-efficacy   x  x   x  
Volitional help sheet  
(intervention)  
 x     
Time Perspective (Control)  x    
Subjective Norms Scale  x x   
Social Connectedness Scale x     
Group Identification Scale x  x  x 
Depression (PHQ-9) x  x   
Anxiety (GAD-7) x  x   
PTSD (PC PTSD-5) x     
Working Alliance Inventory (WAI)   x   
Illness Perception Questionnaire x  x  x 
Qualitative interview    x  
Approx Time 30 mins 25 mins 30 mins 30 mins 25 mins 
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On visit 2, participants were allocated to the intervention or control group. As well as the 
intervention (Volitional help sheet) or control task (Zimbardo’s Time Perspective 
Inventory), participants spent approximately 15 minutes filling in further baseline 
measures with the researcher’s help: Self-Efficacy Scale (SES), Social Connectedness Scale 
(SCS), Social Norms Scale (SNS). This visit occurred between week 3 and week 7 of 
participants’ HCV treatment as data shows injecting behaviour stabilises after 4 weeks of 
treatment (see Chapter 3: Preliminary behavioural data analysis of population).  
On visit 3, follow-up measures were captured with participants filling in measures with the 
help of the researcher: IRQ, SES, SNS, GIS, PHQ-9, GAD-7, Working Alliance Inventory 
(WAI) and B-IPQ. This visit occurred between weeks 7 and 12 of treatment, around the 
time participants terminated their HCV treatment. 
Visit 4 was the 3-month follow-up visit, when participants were seen by the nurses for the 
last blood sample, during which three measures were collected again: IRQ, SES and B-IPQ. 
A full blank Case Report Form and Questionnaire collection can be found in the 
Appendices of the thesis. 
 
4.3.1 Qualitative sub-study 
Towards the end of their treatment, 6 participants were asked to opt in for a qualitative 
interview to understand factors that led to injecting risk behaviour and HCV infection and 
explore their experience of HCV diagnosis, treatment and therapeutic alliance. Five 
participants consented. Interviews were conducted in the needle-exchange services and 
pharmacies across Tayside where participants had received treatment. The interviews 
were digitally recorded. All audio transfers were conducted via NHS encrypted USB sticks, 
and encrypted and secure software (e.g. from audio recorder to NHS encrypted laptop). 
Given the interviews were arranged for a time out with standard care, participants were 
reimbursed for the travel cost and time with £10 cash.  
  
92 
Chapter 4   
 
4.3.2 Patient and public involvement 
In May 2019, five patients on treatment for HCV were asked what type of reimbursement 
they would prefer if they were invited to attend the needle-exchange for a 30 minute 
interview outwith their standard care. Their preference was recorded using a simple 
feedback form. The options presented included: Bus fare (£3.70), Bus fare + 5 protein 
drinks, £10, Bus fare + £5 high street voucher, £5 + 5 protein drinks and £10 high street 
voucher. Three patients expressed their wish to be reimbursed with £10 cash, one patient 
express the wish to be reimbursed with £5 cash and 5 protein drinks and one to be 
reimbursed with a £10 voucher. One of the patients said cash would be easier as voucher 
for shops might be invalid since this population are sometimes banned from certain shops 
and hence might not be able to spend the voucher. In light of this, the PI decided that 




This study aimed to investigate the effectiveness of the behavioural intervention in active 
PWID who were infected with HCV in Tayside and were on HCV treatment to clear their 
infection. Eligible participants were all adults over 18 years of age, presenting with a 
chronic HCV positive infection, making use of illicit drugs (established through 
participants’ self-report), currently on treatment for HCV provided by the NHS, who spoke 
English and who provided informed consent. Exclusion criteria were inability to provide 
informed consent, aggressive or violent behaviour, presenting with a chronic HCV positive 
infection without being on treatment to clear the infection and the inability to 
communicate in English. Ineligible and non-recruited participants were thanked for their 
interest in the trial and were given a clear explanation as to why they were ineligible. 
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4.4.2 Identification and enrolment 
All study participants were recruited through standard pathways of NHS care within 
substance misuse services, IEP enhanced services and community pharmacies.  
Participants who were in the process of being enrolled onto HCV treatment were 
approached directly by the treatment nurses with information about the study. Potential 
participants were provided with information on the trial verbally and via the Participant 
Information Sheet, and were given at least 24 hours to consider participation and to ask 
any questions on the study, in line with good clinical practice. On their return visit for 
screening for their HCV treatment, the patients interested in the study were interviewed 
by the  researcher and asked to sign an informed consent form once they were satisfied 
that they had had adequate explanation about the study and had had the opportunity to 
ask any unanswered questions.   
The informed consent procedure was regarded as a continuous and ongoing process as 
part of the full study (over 4 visits), in line with good clinical practice principles, and it was 
conducted in compliance with TASC SOP07: Obtaining Informed Consent from Potential 
Participants in Clinical Research. 
 
4.5 Study settings 
Recruitment took place in the main IEP site in the Tayside region in Dundee and in the 
main IEP service in Perth from February 2018 to January 2020. Clients were seen in clinical 
rooms on a one-to-one basis. The Cairn Centre Hub where participants were recruited in 
Dundee, is a partnership between NHS Tayside, Gowrie Care, Dundee City Council and 
other voluntary sector partners. The Hub aims to support people with their recovery from 
drugs and/or alcohol, aiding with assessment for alcohol and drug treatment, BBV testing 
and treatment and IEP. It is, in fact, the IEP with the highest number of clients in Tayside, 
with 1237 registered identity codes as of 2017 and an average of 420 transactions a 
month. The total population of PWID in Tayside is estimated to be approximately 2800. A 
note of caution in reading these figures: identity codes for needle-exchanges (NEO ID) 
represent a majority of opiate injectors, but in recent years there has been a significant 
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rise in injectors of Image and Performance Enhancing Drugs (IPED), in some areas as high 
an increase as 600% since 2005 (Fast Forward, 2016), and IPED users are not included in 
the estimated 2800 PWID population. 
The study recruited patients on treatment for hepatitis C in the IEP service. During the 
recruitment period (2018-2020), the IEP was hosting a clinical trial investigating medicinal 
products for the treatment of hepatitis C called ADVANCE (Inglis et al. 2019). ADVANCE 
dispensed HCV medication on a fortnightly or daily basis according to their randomisation. 
ADAPT recruited a sub-sample from ADVANCE, irrespective of their dispensing regime. 
The Cairn Centre, where recruitment took place, is located in the city centre in Dundee. 
Patients on treatment for hepatitis C came from all over the Tayside region. Some, 
fortnightly dispensed, were keen to attend appointments, whether they lived within 
walking distance or not. Those who were on daily dispensing direct-observe therapy, had 
more difficulty attending appointments unless they lived close by, but daily travel 
expenses from outside the city centre postcode area were covered by the HCV treatment 
study (ADVANCE) which aided attendance to treatment. Participants were also 
incentivised with protein drinks, which had proven very popular with this population in 
the past. 
The IEP in Perth is located in one of the main health centres of the city, Drumhar Health 
Centre, and the IEP room is situated in the same corridor as the substance use service. 
Both the IEP service and the substance use service had recently moved to this location 
prior to the treatment trial and the ADAPT trial commencing. The dynamic between the 
services (substance use, IEP, harm reduction nursing and viral hepatitis care) was peculiar. 
This will be discussed in the later chapters of this thesis. Participants for the HCV 
treatment and ADAPT trials, some dispensed fortnightly and others daily, were 
incentivised to attend with paid travel expenses and with protein drinks. 
 
4.6 Intervention 
The intervention entailed completing the volitional help sheet with the participants on 
visit 2. This brief intervention lasted around 20 minutes in a clinic room in the needle-
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exchange services and pharmacies across Tayside. The participants and the researcher 
read through the list of real-life solutions the participants might find applicable to them. 
They then read through the list of situations one by one. The participant drew a coloured 
line between the situation and the solution which seemed more appropriate to them. This 
created implementation intentions, which are self-regulatory strategies taking the form of 
“if-then” plans (i.e. situation-solution plan). The volitional help sheet belonged to 
participants once completed; no copy was required by the researcher for data analysis as 
the volitional help sheet was the intervention and did not constitute analysable data. In 
the final visit of the study, participants were asked if they had kept (in visible or non-
visible place), discarded or lost the volitional help sheet for the duration of the study.  
To control for contact-time, participants in the control group spent approximately 20 
minutes with the researcher on visit 2 exploring Zimbardo’s time perspective constructs 
(ZTPI, Zimbardo & Boyd, 1999) and completing the short Zimbardo’s time perspective 
inventory (Orosz et al. 2017).  The inventory was selected because the cognitive processes 
involved in accessing time constructs were activated in the intervention group for the 
planning of coping strategies and goal achievement during future injecting risk situations.  
The intervention is reported below (Table 4.2) using the TIDieR checklist (Hoffmann et al. 
2014), which is an extension of the CONSORT 2010 statement (Schultz et al. 2010). The 
checklist was developed in response to Hoffman and colleagues’ (2013) analysis of 137 
non-drug interventions, which showed very poor rates of adequate intervention 
description. It is conceptualised as an extension of the CONSORT statement to improve 
the quality and completeness of reporting of more non-specific interventions, allowing for 
greater replicability of studies.  
The development of the checklist involved a panel of experts reviewing CONSORT’s 
statement, reporting items of interest, as well as relevant literature on other checklists 
and research on intervention reporting guidance, which generated a list of 34 items. The 
panel then used a modified two-round Delphi consensus survey, which involved 
international experts and stakeholders. These were authors of research, clinical trial 
experts, journal editors, statisticians and similar experts in the field. The survey 
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participants were asked to rate the 34 items in an ordinal fashion, as ‘omit’, ‘possible’, 
‘desirable’ and ‘essential’ for the final inclusion in the checklist. They were allowed to 
comment on the items and their wording and to suggest further items. The survey 
identified 13 items to be included and a further 13 items to be discussed. A consensus 
meeting was then held in person to discuss such items, with a range of experts from 
difference health disciplines in attendance. The drafted checklist was then piloted with 26 
researchers. Clarifications and elaborations were made and the final 12-item checklist was 
published (Hoffman et al. 2014). 
 
Table 4.2: TIDieR Checklist 
TIDieR Checklist (Hoffmann et al. 2014) 
Item Item No  
Brief name 1 ADAPT 
Why 2 The new HCV treatment oral regimens present a substantial reduction in side 
effects and remarkable Sustained Virological Response rates. The National 
Health Service incurs considerable costs to fund patients’ HCV treatment, since 
this is cost-effective within the model of treatment as prevention. Once 
treated, there is the chance patients may become reinfected with HCV if they 
encounter further risk of transmission. In Tayside the rate of reinfection within 
the PWID treated population reaches 10%. This study aims to deliver a 
behaviour change intervention to reduce rates of HCV reinfection by 
intervening on patients’ self-efficacy and injecting risk behaviour.   
What 3 Materials: the intervention instrument was a volitional help sheet. It was 
used to create implementation intentions, which are self-regulatory strategies 
taking the form of “if-then” plans (i.e. situation-solution plan). The volitional 
help sheet can be found in the Supplementary File 4.1 at the end of this 
chapter 
 4 Procedures: the participants and the researcher read through the list of real-
life solutions the participants might find applicable to them. They then read 
through the list of situations one by one. The participant drew a coloured line 
between the situation and the solution which seemed more appropriate to 
them. 
Who provided 5 The Principal Investigator who is also a PhD student and a qualified Health 
Psychologist, delivered both the intervention and the time-control activity. Her 
expertise and training background focus on health behaviour change, sexual 
health, substance misuse and drug-related risk behaviours.  
How 6 Describe the modes of delivery:  the intervention was provided face-to-face 
on an individual basis. Tea and coffee was offered to participants to help them 
settle and feel appreciated for their time. 
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Where 7 Describe the location(s): the intervention was delivered in the main IEP sites 
in the Tayside region. Clients were seen in clinical rooms. The Cairn Centre Hub 
where most participants were recruited from, aims to support people with 
their recovery from drugs and/or alcohol, and aids with assessment for alcohol 
and drug treatment, BBV testing and treatment and IEP. 
When and 
How Much 
8 The intervention was delivered on one occasion only during the course of the 
participant’s enrolment in the study. It was delivered on visit 2 of the 5 visits 
planned to complete the study, and it would last approximately 20 minutes. 
The volitional help sheet (intervention) would then belong to the participant, 
who could decide whether to keep it or discard it. 
Tailoring 9 No individual tailoring was required. 
Modifications 10 Although the protocol was modified during the course of the study (See 
section 4.2 Sponsor and Ethical approvals on Amendments 1, 2 and 3), the 
intervention itself was not modified in any way. 
How well 11 Planned:  intervention adherence or fidelity was not assessed, as the 
intervention was a one-off activity carried out with the researcher.  
12 Actual: N/a 
 
4.7 Outcomes 
Primary and secondary outcomes of the study are described below and are listed in Tables 
4.3 and 4.4. Most study outcomes were collected using previously developed and 
validated measures. Where previously published scales were not available or appropriate, 
adaptations of validated scales were made to ensure the quality of the measurements 
collected. It is important in healthcare research to use the best measurements available to 
ensure research funding and time is not wasted on unreliable measurements of 
constructs, and to allow more scientific evidence to be collected, disseminated and 
critically evaluated (McDowell, 2006). 
The Case Report Form also contained SVR12 and HCV reinfection clinical data as 
dichotomous outcomes collected as standard practice in NHS services providing HCV 
treatment, and were provided to this trial by the nurses and research teams delivering 
HCV treatment. 
All outcomes, apart from clinical outcomes such as SVR12 and HCV reinfection rates, were 
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Table 4.3: Primary objectives and outcome measures 
Primary Objective: Outcome Measure: Timepoint of outcome  
measured 
To assess levels of injecting risk 
behaviour and self-efficacy scores 
in patients on treatment for 
hepatitis C creating 
implementation intentions 
compared to patients assigned to 
the control group. 




Visit 2, Visit 3, Visit 4,  
 
Table 4.4: Secondary objectives and outcome measures 
Secondary Objective: Outcome Measure: Timepoint of 
outcome  measured 
To assess the variability in injecting 
risk behaviour as explained by 
mental health, illness perception, 
subjective norms, social 





Injecting Risk Questionnaire Visit 1, Visit 2, Visit 3, 
Visit 4,  
Patient Health Questionnaire Visit 1, Visit 3 
General Anxiety Disorder  Visit 1, Visit 3 
Post-Traumatic Stress Disorder Visit 1 
Illness Perception Questionnaire Visit 1, Visit 3 ,Visit 4 
Subjective Norms Scale Visit 2, Visit 3 
Social Connectedness Scale Visit 1 
Group Identification Scales Visit 1, Visit 3, Visit 4 
Qualitative interview Sub-study visit 
To assess the longevity of the 
intervention effectiveness 4 
months post-intervention (and 12 
weeks post-treatment).  
 
Injecting Risk Questionnaire Visit 1, Visit 3, Visit 4,  
Self-efficacy Scale 
 
Visit 2, Visit 3, Visit 4,  
Injecting Risk Questionnaire Visit 1, Visit 2, Visit 3, 
Visit 4,  
To assess any differences in 
psychosocial factors pre- and post-
treatment 
Patient Health Questionnaire Visit 1, Visit 3 
General Anxiety Disorder Visit 1, Visit 3 
Illness Perception Questionnaire Visit 1, Visit 3 
Subjective Norms Scale Visit 2, Visit 3 
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4.7.1 Injecting Risk Questionnaire 
The Injecting Risk Questionnaire – IRQ (Stimson et al. 1998) was selected as a primary 
outcome to evaluate the efficacy of the behavioural intervention. The European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) lists the IRQ as a validated 
instrument of evaluation. It has been referenced in a variety of published studies on HCV 
epidemiology and surveillance, harm reduction, addictions, recruitment strategies and 
behavioural interventions (Marsden et al. 1998; Platt et al. 2006; Rhodes et al. 2004; Rotily 
et al. 2001). While the scale is slightly out of date, its wording remains relevant to 
contemporary research. Contact was made with the principal author to ensure no 
copyright restrictions limited the use of the scale. 
The scale was developed by Stimson and colleagues in 1998 for drug users who had 
injected within the previous 4 weeks. It has 19 items, rated with a 4-point Likert scale, 
exploring different features of injecting equipment sharing, with questions such as: - 
During the last 4 weeks, how often have you done any of the following things: 4) given or 
lent used needles/syringes to a friend or acquaintance; 6) injected with needles/syringes 
that had already been used by a sexual partner; 12) put a used needle into a container or 
spoon that was then used by someone else; and so on. It explores both risks to self, as 
well as risks to others through a variety of risk-taking injecting practices.  
The questionnaire was checked for its acceptability with the population, test-retest 
reliability, inter-rater reliability, internal reliability and construct validity. Product moment 
correlation, principal component analysis and Cronbach’s alpha (α) were investigated as 
statistical testing. The scale items were deemed acceptable, with close to 100% response 
rate to all questions.  The test-retest correlations were all positive and significant at p < 
.001, with no differences by age, gender or main drug injected. Correlations for inter-rater 
reliability were calculated for subjects who were interviewed by both agency staff and 
field workers, showing a high degree of consensus. Internal reliability was tested at Time 1 
and Time 2 with a resulting Cronbach’s alpha value of between .88 and .90. Items loading 
was high at > .32 on one factor, accounting for 42% of the total variance.  
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Scoring: Although the questionnaire data responses varied from 1=frequently to 4=never, 
the scores for all items and all participants were reversed to 1=never to 4=frequently. This 
was executed in order to have scores in ascending order (Score=1 never shared in past 4 
weeks / Score >1 shared in past 4 weeks). The score was computed as: 
IRQ_Score= (1+2+3+4+5+6+7+8+9+10+11+12+13+14+15)/15 
A categorical score was also computed with dummy variables 0 and 1 where 0= IRQ_Score 
of 1 (participant Not Sharing) and 1= IRQ_Score>1 (participant Sharing). 
 
4.7.2 Self-Efficacy Scale 
The Self-Efficacy Scale – SES, adapted from Martin (1995) was selected as a primary 
outcome because of the relationship between self-efficacy and behaviour (Ajzen, 1991). 
Martin’s (1995) Self-Efficacy Scale for Drug Avoidance is reported on the EMCDDA as a 
validated evaluation instrument. Its adaptation for the trial was carried out because of its 
low applicability to the trial population (heroin users). It has been used to measure self-
efficacy in different populations of substance misuse: medication adherence in psychiatric 
outpatients (Magura et al. 2012), mindfulness for relapse prevention in prison settings 
(Lee et al. 2010) , cognitive  behavioural therapy for abstinence in adolescents (Jafari et al. 
2012), and for addiction severity studies (Butler et al. 2006; Heydari et al 2014). Contact 
was made with the authors to ensure permission for the use of the scale. 
The scale, developed by Martin and colleagues (1995), was created to specifically measure 
self-efficacy in drug users. The original scale had 16 items, for example “1) Imagine that 
you are going to a party where you will meet new people. You feel drug/alcohol use will 
relax you and make you more confident. Could you avoid drug/alcohol use?”, with 7-point 
Likert responses. The typology of responses was kept the same, but the scale had to be 
adapted from polydrug/stimulants-orientated scale, to a scale focused on heroin use and 
injecting equipment sharing, with items like “8) Imagine that you have run into 2 friends 
who have drugs on them they offer to share. You have no clean equipment on you. Could 
you resist the urge to join them and share their works?”. The adapted scale had 14 items, 
given some of the items from the original scale had situations which were completely 
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unrealistic for the heroin-using population. The adapted scale was first checked for validity 
with harm reduction nurses, then its validity was investigated with members of the 
population itself by piloting it for comments with clients of a needle-exchange. 
The original scales’ reliability tested high, with Cronbach’s α= .91, and showed high 
predictability, with scale scores predicting future substance use behaviour. Construct 
validity was checked through the association of the scale scores with other concurrent 
measures of drug use and self-efficacy changes, which resulted in statistically significant 
correlations. 
Scoring: The scale scored items as 1=Certainly yes to 7=Certainly no. In order to have 
ascending scores (the higher the score, the more confidence in one’s ability to avoid 
sharing), items 1, 3, 4, 5, 8 ,11, 12 were reverse-scored. The score was computed as: 
SES_Score= (1Rev+2+3Rev+4Rev+5Rev+6+7+8Rev+9+10+11Rev+12Rev+13+14)/14. 
 
4.7.3 Social Norms Scale 
The Social Norms Scale – SNS was also adapted from previous literature (Glanz et al. 2002; 
Ajzen, 2002a). This construct was important to measure as a secondary outcome because 
of its effect on behavioural intention and risk behaviour (Ajzen, 1991; Bailey et al. 2007; 
McGowan et al. 2013; Neaigus et al. 2006). Given it had to be adapted specifically to 
injecting risk behaviour, this measure is non-validated. The construct was measured with 4 
questions to ensure reliability, with a 7-point Likert scale with items such as: “1) Most 
people who are important to me think it is ok to share injecting equipment”. 
Subjective norms have been investigated in a variety of health-related behaviours and 
settings, from children’s health to adult exercise (Courneya & McAuley 1995; Walsh et al. 
2009) and has been used extensively in substance misuse populations (Hohman et al. 
2014; Latkin et al. 2003; Rivis & Sheeran, 2003), though not applied to sharing of injecting 
equipment. 
Scoring: The scale scored items as 1=Strongly Agree to 7= Strongly Disagree. In order to 
have ascending scores (the higher, the score the stronger the social norm to share 
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equipment), items 1, 2 and 3 were reverse-scored. The possible score ranged between 4 
and 28. The score was computed as: 
SocialNorms_Score= 1Rev+2Rev+3Rev+4. 
 
4.7.4 Social Connectedness Scale 
According to published literature, social connectedness is associated with injecting risk 
behaviour (Bailey et al. 2007; Bloor et al. 2008; Broz et al. 2010; Cepeda et al. 2012; 
Heimer et al. 2014b; McGowan et al. 2013; Neaigus et al. 2006; Roux et al. 2014), hence 
this construct being selected as a secondary outcome. The scale used for this construct, 
Social Connectedness Scale – SCS, was a validated instrument, published by Lee & Robbins 
(1995). The authors were contacted for permission to use the scale. 
The scale and construct has been used in a variety of settings investigating health and 
wellbeing (Hendrickson et al. 2011; Williams & Galliher, 2006), but has not been 
extensively used in substance misuse settings (Buckingham et al. 2013; Hunt & Burns, 
2017), in particular with opiate injectors. 
There are different versions of the scale, the one selected presents 8 items, such as: “2) 
Even around people I know, I don’t feel that I really belong”, with items rated on a 6-point 
Likert scale. The 8 items were selected to principal component analysis, with all selected 
items showing factor correlations of above .677, and none correlating with other factors 
above with a .261 correlation. The scale showed high internal reliability with Cronbach’s α 
= .91.  Test-retest reliability over a 2-week period also showed positive results, with a 
correlation score r of .96. 
Scoring: The scale scored items as 1=Strongly disagree to 6= Strongly agree. A high score 
meant a high sense of social connectedness. The possible score ranged between 8 and 48. 
The score was computed as: 
SocialConnectedness_Score= 1+2+3+4+5+6+7+8.  
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4.7.5 Group Identification Scale 
As well as social connectedness, the sense of an individual’s social identification to 
selected groups was regarded as a possible predicting factor of injecting risk and health. 
Therefore, the Group Identification Scale – GIS (Sani et al. 2015a), a validated instrument, 
was selected to measure this construct as a secondary outcome of the research trial. The 
senses of belonging to a family nucleus and to an injecting network were explored in the 
study. The GIS scale was therefore repeated twice to obtain results on identification with 
both groups. 
The scale has been previously used in mental health settings exploring depression in 
adolescents and post traumatic stress in cancer patients (Miller et al. 2017; Swartzman et 
al. 2017), but it has never been used with people who inject drugs. 
The GIS is a short 4-item scale, each rated on a 7-point Likert scale. The items, such as “3) I 
have a sense of belonging to my family” were adapted for the assessment of belonging to 
different groups (family and to injecting drug network), as suggested by the authors (Sani 
et al. 2015a). The scale presents good internal reliability with Cronbach’s α ranging 
between .85 and .92 depending on the population and group identification under 
investigation. It has good convergent validity, showing good correlations with other group 
identification scale, divergent validity, showing only moderate correlations with scales 
which do not measure the exact construct of group identification but measure other social 
aspects of group factors. Test-retest reliability was also high, with Pearson’s correlation r 
coefficient on family group of .91. 
Scoring: The scale scored items as 1=Strongly Agree to 7= Strongly Disagree. In order to 
have ascending scores (the higher the score, the stronger identification with a social 
group), all items were reverse-scored. A score of less than 3 signified the individual was 
not identified with the specific social group. The score was computed as: 
GIS_Family and GIS_DrugNetw computed the same way= (1Rev+2Rev+3Rev+4Rev)/4.  
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4.7.6 Brief Illness Perception Questionnaire 
Perception of HCV risk was another secondary outcome which emerged from review of 
the literature (Bailey et al. 2007; Fairnbairn et al. 2010; McGowan et al. 2013; Wagner et 
al. 2010b). The Brief Illness Perception Questionnaire – B-IPQ (Broadbent et al. 2006) is a 
validated scale adaptable to any illness. Its adaptation to hepatitis C was therefore 
straightforward, allowing the retention of the integrity and validity of the measure. 
 The published paper on the B-IPQ has been cited around 1500 times, it has been used in a 
variety of health settings with reviews concluding that illness perception is associated with 
illness and treatment outcomes (Petrie et al. 2007). Some research also focused on illness 
perception and hepatitis C, showing its influence on treatment outcomes, coping and 
adjustments (Langston et al 2016; Langston et al. 2017; Langston et al. 2018; Zalai et al. 
2015). 
The scale presents 9 total items, 8 of which require a response to a 10-point Likert scale, 
e.g. “1) How much does your Hepatitis C affect your life?”, and the 9th item asking 
participants to rank the three most important factors that cause the illness. Test-retest 
analysis showed good reliability, with Pearson’s correlations on items ranging between r = 
.42 and r = .75, and all statistically significant. Concurrent validity was tested using a 
revised version of the scale, showing statistically significant correlations. The scale showed 
good predictive validity, with variance in rehabilitation attendance in MI recovery patients 
explained by higher identity scores (F (39,1)= 5.11, p = .03).  Higher concern and treatment 
control beliefs were associated to slower return to work (r = .43, p = .03 and r = .44, p = 
.03 respectively). Discriminant validity was tested exploring differences between B-IPQ 
scores in different illnesses, showing statistically significant differences able to distinguish 
patients’ scores between different illnesses. 
Studies in which the scale has been utilised, and its properties have been tested, have 
shown good internal reliability, with Cronbach’s α in ranges between .72 and .85 (Karataş 
et al. 2017; Løchting et al. 2013). 
Scoring: Items 3, 4 and 7 were reverse-scored so that a high score signified a more 
threatening perception of the illness. The score was computed as: 
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BIPQ_Score= 1+2+3Rev+4Rev+5+6+7Rev+8. 
Scale author (Broadbent et al. 2006) assigned different sub-construct to each item: 
1=Consequences of illness; 2=Timeline; 3=Personal control; 4+ Treatment control; 5= 
Identity; 6=Concern; 7=Coherence; 8=Emotional representation. 
 
4.7.7 Mental health variables 
Mental health variables have been found, by most literature, to be associated to injecting 
behaviour and injecting risk behaviour (Bailey et al. 2007; Broz et al. 2010; Cepeda et al. 
2012; Gossop et al. 2002; Heimer et al. 2014b; Neaigus et al. 2006, Roux et al. 2014). 
Depression, anxiety and trauma are extremely common mental health issues with which 
the injecting drug use population presents. These variables could therefore show a ceiling 
effect, but given previous literature, it was important to collect them and control for their 
effects on the intervention effectiveness.  
The Patient Health Questionnaire – PHQ-9 (Spitzer et al. 1999) was selected because of its 
wide use within clinical settings as a depression screening instrument. Papers on the 
development of the PHQ-9 have been cited over 18 thousand times in literature, showing 
its vast and extended use (Kroenke et al 2001; Kroenke & Spitzer, 2002; Spitzer et al. 
1999). Pfizer lifted the copyright restricting the use of the scale in 2010, allowing free 
public access. Not surprisingly, the PHQ-9 shows excellent internal reliability, with 
Cronbach’s α of 0.89 and excellent test-retest correlations with r = 0.84. Its 9 items are 
based on the nine criteria used for diagnosis of depressive disorders in the DSM-IV 
(Diagnostic and Statistical Manual of Mental Disorders, APA, 2000). The items, such as: 
“Over the last 2 weeks, how often have you been bothered by any of the following 
problems?: 2) Feeling down, depressed, or hopeless.” 
The scale was also tested for construct validity, showing significant positive correlations 
with other depressive symptom screening tools, and criterion validity, assessed comparing 
the PHQ-9 screening results to independent mental health professional assessments in 
580 patients.  
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Scoring: All items were summed to calculate the score. Scoring instruction identified 
scores as: 0-5 Mild depression; 6-10 Moderate; 11-15 Moderately severe; 16+ Severe. The 
score was computed as: 
PHQ9_Score= 1+2+3+4+5+6+7+8+9. 
 
The Generalized Anxiety Disorder – GAD-7 (Spitzer et al. 2006) was also selected because 
of its vast use within clinical settings as a screening tool for anxiety symptoms, showing 
thousands of citations. In 2010, Pfizer lifted the copyright restricting the use of this scale, 
allowing free public access. The 7-items in the scale, such as “Over the last 2 weeks, how 
often have you been bothered by any of the following problems?: 2) Not being able to 
stop or control worrying.” showed excellent internal reliability, with a Cronbach’s α of .92. 
Test-retest reliability showed a correlation coefficient of r = .83. Construct validity was 
demonstrated with significant pairwise comparisons between GAD-7 scores and SF-20 
mental health and social functioning scale scores. Convergent validity was also reported, 
with correlations of r between .72 and 74 with other anxiety measures. 
Scoring: Exactly like the PHQ-9 scoring, all items were added for the final score. Score=0-5 




The Primary Care Post-Traumatic Stress Disorder scale – PC-PTSD-5 (Prins et al. 2016) was 
developed as an update to the previous version, PC-PTSD-4, in conjunction with the 
update of the DSM to its fifth edition (APA, 2013). The scale was developed with the help 
of military veterans, but for use in primary care. This was because of the high prevalence 
of PTSD in this population. It consists of a preliminary question “Have you ever experience 
a traumatic event?”, followed by 5 items to aid diagnostic value, for example: “1) Had 
nightmares about it or thought about it when you did not want to?”. All the items are 
answered as Yes/No, and the scale score is also treated as a dichotomous variable 
(symptoms of PTSD with scale score of 3 or more, no symptoms with score of 2 or less). 
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The scale’s use has been discussed in fields such as substance misuse (Matthieu et al. 
2017), PTSD in children victims of sexual abuse (Cummings & O’Donohue, 2018) and in the 
LGBT population (Hurley et al. 2017). 
The scale’s inter-rater reliability was tested by two independent raters who obtained 
100% agreement on diagnosis of PTSD and excellent reliability at scale-item level (k > .95). 
Weighted k coefficients are used for better agreement between scale results and 
diagnosis. The diagnostic accuracy (AUC) for the PC-PTSD-5 was .941 (95% CI: .912 to 
.969). 
Scoring: Dummy variables assigned to the questionnaire responses: Yes=1; No=0. The 
items were summed to compute the score. The higher the score the more the person was 
showing symptoms of PTSD. According to scale scoring instructions, a score of less than 3 
meant No PTSD symptomatology was present. The score was computed as: 
PTSD_Score= 1+2+3+4+5 
 
4.7.8 Working Alliance Inventory 
This questionnaire (Hovart & Greenberg, 1989; Hatcher & Gillaspy, 2006) was collected to 
inform the ADVANCE trial (a clinical trial of medicinal products to treat hepatitis C). Given 
the ADAPT researcher was independent from the ADVANCE trial the measure was 
collected in order to assess therapeutic alliance among three different treatment-
dispensed groups. This measure will therefore not be discussed or analysed in this thesis.  
 
4.7.9 Zimbardo’s Time Perspective Inventory – Short Revised 
In addition, the Zimbardo’s Time Perspective Inventory short revised version – ZTPI-SR 
(Orosz et al 2017) will be completed as the time-control activity in the control group only, 
and data will be used as a secondary outcome for this group. The full ZTPI has 56 items, so 
short versions of the scale have been tested and used in other forms of addiction, such as 
internet and social addiction (Przepiorka & Blachnio, 2016). The 17-item scale has been 
used in academic settings (Orosz et al. 2016). A short version of the inventory was 
necessary for the population in this study and considering the other tasks taking place in 
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visit 2, to keep all visits to around 30 minutes. This short version of the ZTPI was also 
selected because of the similar response time to the study’s behavioural intervention 
(around 20 minutes); this allowed the researcher to control for time and contact effect 
with the study population. 
This short version of the ZTPI had 17 items, between 3 and 4 items for each sub-construct 
dimensions. Examples of items for each dimension are as follows: Future “1) Meeting 
tomorrow’s deadlines and doing other necessary work comes before tonight’s play”; past 
positive “3) Happy memories of good times spring readily to mind”; past negative “5) I’ve 
taken my share of abuse and rejection in the past”; present fatalistic “11) My life path is 
controlled by forces I cannot influence”; and present hedonistic 8) Taking risks keeps my 
life from becoming boring”. 
Orosz and colleagues used confirmatory factor analysis to reduce the number of items 
from the original ZTPI of 56 to a minimum of 17 for the model to have a good fit (2017). 
Four items were identified for the past negative (PN) dimension, three items for past 
positive (PP), three items for present hedonism (PH), three items for present fatalism (PF) 
and four items for future (F). The internal consistency was good or borderline: αPN = 0.84; 
αPP = 0.68; αPH = 0.73; αPF = 0.69; αF = 0.70. The test-retest reliabilities of the subscales for all 
dimensions were between .70 and .80. The five dimensions were inter-correlated, with small, yet 
significant, r values.  
Scoring: The items were scored as 1= Very Untrue to 5= Very True. The higher the score 
the stronger the trait characteristic. Scale items divided into different time perspectives 
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4.8 Sample size 
A power calculation was conducted with G*Power 3.1.9.2 (Faul et al. 2007) to estimate 
the required sample size for a MANOVA between-within interaction. The desired effect 
size value of 0.35 was estimated from previous literature on psychological and 
psychosocial interventions in substance misuse (Copenhaver et al. 2006; Luty, 2015; 
Tanner-Smith et al. 2013; Webb & Sheeran, 2008). Alpha was set at 0.05 and desired 
power at 0.8. The calculation was based on the primary outcomes Self-Efficacy and 
Injecting Risk Behaviour, measures repeated 3 times during the course of the trial. The 
resulting required sample size was of 67. Dropouts and patients reinfected during the 
course of the trial were to be counted as part of the outcome as unsuccessful 
interventions. This sample will be recruited and divided into experimental and control 
groups for the psychosocial intervention on self-efficacy. The power calculations were 
checked by the PI and an honorary statistician in the School of Social Sciences at the 
University of Dundee. 
The required sample for the qualitative sub-study is of 5 (to reach theme saturation) from 
either arm of the study. 
 
4.9 Randomisation 
Eligible and consenting participants were randomised to either intervention or control 
group (See Figure 4.1: Study flowchart). A computerized random number generation to 
the two trial groups was carried out by a member of the research team external to the 
study process, using the website Randomization.com (Dallal, 2008: 
www.randomization.com ). The randomisation was generated in blocks of 20 with a 1:1 
ratio assignment to either of the two groups; the PI was aware of the block size. 
Stratification was not used for the randomisation process.  
  
110 
Chapter 4   
 
Figure 4.1: Study flowchart
 
Figure 4.1  
 
To prevent code breaking and ensure allocation concealment, sealed envelopes were 
produced and sequentially numbered by the independent research team member. The 
envelopes were opaque, brown and non-see through when held up to the light. Once the 
research team member had run the sequence generator and concealed allocation, the 
sealed envelopes were handed to the PI to bring to the recruitment site. Once a patient 
Participants given leaflet 
information (PIL) about 
qualitative assessment (sub-
study) 
Participants invited to consent 
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had consented, the PI providing the intervention or control task, opened the patient’s 
corresponding ID numbered envelope to allocate them to either intervention or control 
group. Participants and treatment nurses and pharmacists were not aware of which arm 
patients were allocated to, given the time and contact-control task for the control group 
participants.  
For the sub-study, no randomisation procedure will be necessary. Participant in their 
second visit will be given information about the sub-study and during visit 3 they will be 
asked if they wish to participate. 
 
4.10 Blinding 
Given the nature of the study, it was not possible to blind the data collector to the study 
group allocation. The PI’s role was that of study planning, sponsorship and ethical 
permissions acquirement, information provision to potential participants, participant 
enrolment, data collection, intervention provision, outcome assessment, data entry, data 
analysis and report write-up. It was therefore essential for the PI to be un-blinded to 
participant allocation in order to provide the intervention or the control task. Allocation to 
study group remained unknown to the PI until after participant enrolment, when the 
randomisation sequence was implemented by opening the sealed envelope which 
corresponded to the participant’s ID. 
 
4.11 Statistical methods 
The data was analysed on a modified intention to treat basis, meaning that those who 
performed the intervention or control task and were lost to follow-up were treated as 
no-changers. A factorial analysis to assess the validity of the scales used was not possible 
given the small sample size. Reliability analyses were run on all scales. 
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4.11.1 Primary analyses 
The primary objective was to increase self-efficacy (SES) in individuals who inject drugs 
who are on treatment for HCV in order to reduce sharing of injecting paraphernalia and 
reduce HCV reinfection rates. It was hypothesised that, by increasing self-efficacy, 
individuals who inject drugs would report a decrease in sharing instances at follow-up. 
This was achieved by using a volitional help sheet to implement intentions. A mixed 
between-within MANCOVA was performed to compare baseline, end of treatment, 1- & 
3-month follow-up data to assess the effectiveness of self-efficacy enhancement as a 
behaviour change technique to reduce injecting risk behaviour (IRQ). Mental health 
(PHQ-9, GAD-7, PTSD-5), illness perception (B-IPQ) and psychosocial factors (Subjective 
norms, SCS, GIS) were set as covariates. 
 
4.11.2 Secondary analyses 
The psychosocial predictors measured at baseline were tested as predictors of injecting 
risk behaviour using a multiple regression.  
Differences in time (baseline and follow-up) for psychosocial variables were tested in the 
sample using Wilcoxon Signed Ranks. 
 
4.11.3 Sub-study analyses 
For the qualitative sub-study, data was analysed using thematic analysis. Thematic 
analysis is one of the most widely used methods of qualitative data analysis as it allows 
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4.12 Missing data 
The nature of this trial was to assess the applicability of this model in the real world, so 
incomplete data that impacted on the primary outcome was assumed to be consistent 
with failure of the intervention. Modified intention-to-treat analysis might be required to 
exclude participants lost to follow-up after visit 1, who did not receive the intervention as 
per protocol, and for whom assumptions of intervention failure could not be made 
(Abraha & Montedori, 2010). 
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Supplementary File 4.1 
 
Situations 
1. If I am tempted to share equipment when I am in 
withdrawal and I am offered heroin 
2. If I am tempted to share equipment when I am with 
others who are injecting  
3. If I am tempted to share equipment when things are 
not going my way 
4. If I am tempted to share equipment when I am feeling 
down 
5. If I am tempted to share equipment when other people 
encourage  me to share 
6. If I am tempted to share equipment when I am very 
anxious 
7. If I am tempted to share equipment when offered 
equipment by someone 
8. If I am tempted to share equipment when things are 
going really well for me 
9. If I am tempted to share equipment when I am upset 
10. If I am tempted to share equipment when I am under 
the influence of other drugs 
11. If I am tempted to share equipment when I have no 









 Then I will avoid situations that encourage me to share 
equipment 
 Then I will reward myself when I do not give into my 
urge to share equipment 
 Then I will use alternatives to calm myself 
 Then I will do something else instead of injecting 
 Then I will seek out someone who listens when I want 
to talk about my feelings 
 Then I will seek out social situations where people 
respect the rights of others not to inject/share 
equipment 
 Then I will remember that I have strong feelings about 
how much my injecting and sharing has affected the 
people I care about 
 Then I will remember the information that people have 
personally given me on the benefits of not sharing 
equipment 
 Then I will think about how my emotions affect me 
when I think about consequences of sharing equipment  
 Then I will tell myself that I can choose to change or not 
to change 
 Then I will tell myself that if I try hard enough I can say 
no to sharing equipment 
 Then I will think about the type of person I will be if I 
am in control of my injecting 
 Then I will always make sure I have enough clean 
equipment
Volitional Help Sheet 
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CHAPTER FIVE: Study 3 – ADAPT Results 1  
The predicting role of psychosocial factors on injecting risk behaviour. 
This chapter reports the baseline results from the main study in the thesis, Study 3. 
The chapter aims to explore the RCT sample characteristics and to investigate the 
psychosocial predictors of injecting risk behaviour.  
 
5.1 Abstract 
Background: Injecting behaviour in people who inject drugs is the main risk factor for 
hepatitis C virus (HCV) infection. Psychosocial factors such as having a partner who 
injects drugs and living with other drug users have been associated with increases in 
injecting risk behaviour. The risk of HCV reinfection in people who inject drugs (PWID) 
treated for HCV remains high when sharing of injecting equipment continues to occur 
post-treatment. This study investigates the role of psychosocial factors on risk 
behaviour during HCV treatment. 
Methods: This cross-sectional study included 50 participants on treatment for HCV. 
Correlation analyses informed the association of group identification, mental health 
and illness perception with sharing injecting equipment. Only factors with a good 
correlation to sharing behaviour were included in the model. A multiple linear 
regression tested the model under investigation.  
Results: Correlation analyses showed sharing behaviour to be significantly associated 
with injecting frequency and group identification with drug network. The bootstrapped 
multiple linear regression model was statistically significant, F(3,46)= 5.67, p= .002. The 
model explained 27% (R2) of the variance in injecting risk behaviour. Group 
identification with drug network had a substantial and statistically significant impact 
on injecting risk behaviour.  
Conclusions: Identification with a social group, usually associated with improved 
health, may pose health risks depending on the type of group an individual identifies 
with. Interventions on social networks are recommended to reduce sharing of injecting 
equipment.  
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5.2 Introduction 
As explored in Chapters 1 and 3, drug injecting behaviour in Scotland continues to be 
mostly associated with heroin injecting, although concomitant use of heroin with 
cocaine and/or benzodiazepines has increased in recent years (Johnson et al. 2016; 
HPS, 2019; Tucker et al. 2016). Sharing of injecting equipment, such as needles, 
syringes, pots, filters, water and tourniquets, is the principal means of transmission of 
blood-borne viruses (Public Health England, 2017a). Literature suggests psychosocial 
factors influence injecting risk behaviour, whilst social identity isolation is linked to 
poor physical and mental health (Latkin et al. 2011; Sani et al. 2015a). A number of 
psychological and social factors have been associated with injecting risk behaviour and 
were thoroughly explored in chapters 1, 3 and 4. The rationale and theory used to 
develop this study were explored in chapters 1 and 2. The aim of this part of the study, 
and therefore this chapter, is to explore the characteristics of the study sample and 
investigate the psychosocial predictors of injecting risk behaviour. 
 
5.3 Methods  
The methodology employed to carry out Study 3 was the focus of Chapter 4, reported 
in accordance with the CONSORT 2010 statement (Schultz et al. 2010) and the TIDieR 
checklist (Hoffmann et al. 2014) so it will not be repeated here. All regulatory 
approvals (University of Dundee sponsorship, NHS East of Scotland Research Ethics 
Committee, Research & Development NHS Tayside) were received in December 2017. 
Data collection took place between February 2018 and January 2020. The total sample 
size was 52. The data and results reported in this chapter only refer to visit 1 of the 
pilot RCT, the baseline visit, allowing for cross-sectional exploration of the sample’s 
data. This section will focus on the participants and the statistical analyses carried out 
to explore the baseline data and investigate the predicting factors of injecting risk 
behaviour.  
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5.3.1 Analysis  
Data was analysed using IBM SPSS Statistics 25. Descriptive analyses were run to 
obtain characteristics of the sample at baseline and mean scores of all measured 
variables at visit 1. Cronbach’s α reliability analysis was run to check consistency of 
construct measuring on all scales used at visit 1. A correlation analysis was run to 
explore baseline factors associated to injecting risk behaviour. The variables which 
were found to be significantly correlated to injecting risk behaviour were then used in 
a regression model. A multiple linear regression was performed to investigate possible 
predictors of injecting risk behaviour. 
 
5.4 Results  
5.4.1 Sample Characteristics 
Exploration of the baseline data was carried out to characterise the sample (Table 5.1). 
 
Table 5.1: Characteristics of the sample 
Characteristics  Full sample (N=50)  
 
M                              SD 
Age (years) 37.4 6.9 
Weekly injecting frequency at baseline 7.1 9.13 
  
N                               % 






































If Yes  
1.Partner injects 
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Table 5.1 continued 
Characteristics 
 




























1Sites= Cairn Centre is the main IEP in Dundee; Drumhar is the main IEP in Perth. 
2Treatment pathways: DOT= Daily Observed Therapy; 2/52= Fortnightly observed therapy; 
2/52+ = Fortnightly observed therapy with Psychological intervention (Adherence). 
3SVR12 Achieved= Sustained Virological Response (HCV undetectable, patient cured). 
 
5.4.2 Exploration of variables  
Means, standard deviations and reliabilities of measures were calculated for all 
variables and presented in Table 5.2. An exploratory factor analysis on all the measures 
was not possible as the sample size was too small for appropriate analysis. Cronbach’s 
α for all measurement showed good reliabilities, ranging from acceptable (Illness 
perception questionnaire α= .65) to excellent (Group Identification scale for Family and 
Drug Network α values over .9). 
 
Table 5.2: Variables’ descriptives and reliability testing 
Characteristics (Range) M                               SD Cronbach’s α 
Injecting Risk Behaviour (1-4) 
 
Number Shared with (reported at start) 










Identification Family (1-7) 4.3 2.35 .93 
Identification Drug Network (1-7) 3.9 2.42 .94 
Depression (0-27) 17.36 7.86 .86 
Anxiety (0-21) 14.32 6.39 .86 
Post traumatic stress disorder 
symptomatology (1-5) 
3.22 1.69 .76 
Illness Perception (8-80) 31.44 13.49 .65 
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5.4.3 Normality testing 
The distribution of the sample was tested using Shapiro-Wilk tests for continuous and 
discrete variables, given its better suitability to test smaller samples (n<50) (Field, 
2018). Normal Q-Q Plots and Box plots were visually inspected to assess distribution. 
Most variables violated the assumption of normal distribution (Table 5.3); age was the 
only variable which did not deviate significantly from normal, W(50) = .96, p= .056.  
 
Table 5.3: Test of normality 
Tests of Normality 
 Shapiro-Wilk 
Statistic - df (50) Sig. 
Age .96 .056 
Injecting Frequency 1 .78 .000 
Injecting risk .61 .000 
Identification - Family .84 .000 
ID – Drug Network .84 .000 
Depression .93 .005 
Anxiety .88 .000 
PTSD .85 .000 
Illness Perception .95 .042 
*. Lower bound of the true significance.  
a. Lilliefors Significance Correction 
 
5.4.4 Correlations  
An exploration of the correlations between the primary outcome and all the baseline 
predictors was carried out to minimise the number of predictors included in the 
regression model (Table 5.4). Scatterplots of all the variables were visually inspected to 
check the linearity of the relationship between injecting risk behaviour and all 
psychosocial factors measured. Given linearity was violated among all pairwise 
combinations, Spearman’s correlation was carried out to test the relationship between 
factors.
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Bivariate correlations (Table 5.4) showed that Injecting risk behaviour was significantly 
correlated to injecting frequency, ρ= .57 with p< .001, identification with family, ρ= -
.31 with p= .03, and identification with drug network, ρ= .46 with p= .001. Additional 
correlations were observed between secondary variables: injecting frequency was 
significantly correlated with group identification with drug network (ρ= .34, p= .014); 
group identification with family was significantly negatively correlated with anxiety (ρ= 
-.29, p= .043). 
The three mental health variables (depression, anxiety and PTSD) were intercorrelated 
with coefficients ranging from ρ= .67 to ρ= .82. These variables were also correlated 
with illness perception, with all coefficients ranging between ρ= .39 to ρ= .48 (Table 
5.4). 
Chi square tests of associations were used to check correlations between categorical 
baseline variables (Sex; Recruitment site; Intervention group; HCV genotype; Partner; 
Treatment pathway; SVR12 achieved; Drugs injected) and injecting risk behaviour and 
no correlations were found.  
 
5.4.5 Multiple regression (and bootstrap) 
A multiple linear regression was run to predict injecting risk behaviour from injecting 
frequency, identification with family and identification with drug network. The 
regression model explained 27% (R2) of the variance in injecting risk behaviour. The 
model was statistically significant, F(3,46)= 5.67, p= .002. Two of the variables had a 
substantial and statistically significant impact on injecting risk behaviour:  Injecting 
frequency (B= .01, p= .035), and group identification with drug network (B= .05; p= 
.027) (Table 5.5). 
The assumptions for linear regression were checked to assess bias within the model. 
Independence of error was inspected with the Durbin-Watson test (value of 1.71), 
which showed no cause for concern. Multicollinearity was checked via the Tolerance 
(above 0.2) (Menard, 1995), the VIF statistic (well below 10) (Myers, 1990) (Table 5.5) 
and the correlation coefficients among independent variables (all below |.4|). 
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Table 5.5: Regression coefficients table  
Coefficientsa 
 B SE β Lower 95% CI for B Upper 95% CI for B 
(Constant) 1.051 .138  .774 1.328 
Injecting  
Frequency 1 
.013 .006 .291* .001 .026 
ID - Family -.029 .022 -.167 -.075 .016 
ID - Drug Network .052 .023 .306* .006 .099 
Note: *p< .05. 
 
The eigenvalues also confirmed multicollinearity was not an issue, as each of the 3 
predictors showed most of their variance loading onto respectively different 
dimensions. 
However, casewise diagnostics showed that 8% of cases had a standardised residual of 
over +/- 2 (Table 5.6). More than 5% of the sample with standardised residuals over +/- 
2 is usually cause for concern.  
 






Injecting risk Predicted 
Value 
Residual 
2 2.96 2.60 1.52 1.08 
9 2.40 2.33 1.46 .88 
10 2.04 2.33 1.59 .75 
38 2.33 2.13 1.28 .85 
a. Dependent Variable: Injecting Risk 
 
Case 36 seemed to be problematic. Its Mahalanobis distance value was greater than 15 
and the leverage value was over 3 times the average leverage of 0.08 (Table 5.7). The 
DFBeta value for inject frequency was over 1 (1.21) (Table 5.8). The covariance ratio 
also showed deviation from its boundaries: .76-1.24 (calculated as upper= 1+ 
[3(k+1)/n] and lower= 1-[3(k+1)/n] where k is the number of predictors and n the 
sample size (Field, 2018)). Cases 2, 9 and 38 were all also outwith these boundaries. 
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Yet Cook’s distance was adequate in all of them, so none of these cases seemed to 
have an undue influence on the model. 
 
Table 5.7: Regression case summaries A 
 
Table 5.8: Regression case summaries B 
 
 
Case 36 was consented and seen for visit 1 the same day. He was known to the 
researcher because he used to beg between the university and the needle-exchange. 
He seems to be influencing the model because he had, by far, the highest weekly 
injecting frequency score of anyone in the sample. The range usually ranged between 
0 and 28 injections a week, but case 36 reported injecting 6 times a day (weekly score= 
42). He reported sharing with 1 other person both at the start and at the end of the 
IRQ. He was consented and the first visit was completed before he had been 
randomised onto the hepatitis C treatment trial (ADVANCE). His full bloods (which had 
been taken the day he completed visit 1) came back 2 weeks later as problematic and 
he was also incarcerated at the same time so he was lost to follow-up (and not treated 










36 36 15.96 .42 .33 

















ID - Family 
Standardize
d DFBETA 
ID – Drug 
Network 
2 2 .46934 .96999 -.29142 .66338 .16294 .24157 
9 9 .65622 .68817 -.31981 .21047 .20359 .39351 
36 36 1.24929 -1.33557 .51158 -1.20848 -.37503 .01739 
38 38 .68616 .74190 -.20159 -.37299 .12258 .57713 
a. Limited to first 100 cases. 
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researcher double checked during the visit, when he reported injecting so often, if the 
self-report was correct and he was adamant that it was an average amount for him. 
By visually inspecting the scatterplot of predicted standardised values against 
standardized residuals, it is clear that the assumption of homoscedasticity was violated 
and minor violations of linearity and normality were also observed. 
Given these considerations, the model was re-run with the bootstrap option (Table 
5.9).  Bias corrected and accelerated (BCa) bootstrapping estimates of the regression 
coefficients were calculated using 95% confidence intervals. The standard errors for 
the Beta values remained virtually the same for all three predictors. The analysis 
confirmed the statistically significant effect of group identification with drug network 
on injecting risk behaviour (B= .05; p= .033 [95% CI: .01, .11). However, both injecting 
frequency and group identification with family lost significance in predicting the 
dependent variable. 
 
Table 5.9: Regression with bootstrapping 
Bootstrap for Coefficients 
 B Bootstrapa 
SE p-value Lower 95% CI Upper 95% CI 
(Constant) 1.051 .123 .001 .781 1.286 
Injecting Frequency 1 .013 .009 .117 .002 .040 
ID - Family -.029 .023 .204 -.071 .018 
ID - Drug Network .052 .023 .033 .012 .101 
a. Bootstrap results are based on 1000 bootstrap samples;  
 
5.5 Discussion  
Injecting risk behaviour, defined in this study as sharing of injecting equipment, is a 
complex behaviour. The results of this study suggest that injecting risk is significantly 
associated with injecting frequency and group identifications. Further, although added 
to the tested model, the main effects of injecting frequency and group identification 
with family did not significantly add to the predicting model. However, group 
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identification with drug network was identified as a strong, significant predictor of 
sharing behaviour. 
The relationship between social factors and injecting risk behaviour has been widely 
documented (Day et al. 2005; Fraser et al. 2016; Latkin et al. 2011; Nasir & Rosenthal, 
2009; Shaw et al 2007).  Social networks involving drug use can consist of close friends, 
family, romantic and sexual partner, or simply of acquaintances. The general 
characteristics of these networks can be associated with risk-taking behaviour. Sharing 
of equipment is more common in larger networks (De et al. 2007; Heimer et al. 2014; 
Smith et al. 2017) and in environments with high acceptability of sharing behaviour 
(Bailey et al. 2007; McGowan et al. 2013; Neaigus et al. 2006). Other studies have 
found that the presence of multiplex relationships such as drug using sexual partners 
increases the likelihood of engaging in high-risk behaviours (Cox et al. 2008; Fraser et 
al. 2016; Gossop et al. 2002; Lakon et al. 2006; Medic et al. 2008; Roux et al. 2014; 
Unger et al. 2006; Zapka et al. 1993). This might be due to heightened social and 
instrumental support, e.g. pooling of money for drugs (Shahesmaeili et al. 2018), 
emotional or injecting support (Unger et al. 2006), or at times to increases in 
psychological and physical abuse, associated with receptive syringe sharing (Stoicescu 
et al. 2019). 
The results of this study are consistent with previous research that suggests social 
networks can negatively influence injecting risk taking (De et al. 2007; Dunn et al. 
2010; Shaw et al. 2007) yet they present new findings in regards to injecting drug use 
and group identification. Group identification is characterised by the subjective 
dimension of an individual’s sense of communal experience and psychological 
connection with fellow group members (Sani et al. 2015b; Tajfel & Turner, 1979). Some 
research has been carried out on the influence of group identification on substance 
use in adolescents and young adults (Savolainen et al. 2018; Sussman et al. 2000), 
yielding conflicting results. The current study, on adult injecting drug users, found that 
group identification with a drug network was a strong predictor of injecting risk 
behaviour, revealing that the stronger the sense of identification, the higher the 
likelihood that an individual was sharing injecting equipment. 
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Yet the association between social factors and engagement in risk behaviours has 
potential to be a positive one.  Some social associations, such as romantic 
partnerships, can become sources of social care and protection. They have the capacity 
to reduce risk behaviour, such as reducing injecting frequency (Chapter 31), and 
increasing a sense of acceptance, belonging and self-worth (Rance et al. 2017). 
Identification with a family nucleus can also promote healthy behaviour (Sani et al. 
2015a). A positive type of social capita can therefore improve risk-avoidant injecting 
behaviours (Kumar et al. 2016; Neaigus et al. 1996). Unfortunately the model tested in 
this study was unable to find a significant main effect of group identification with 
family on sharing behaviour. Nonetheless, the findings of this study uncover the 
potential negative impact of an individual’s identification with a social group such as a 
drug network.  
The current study did not find any significant associations between psychological 
factors and sharing of injecting equipment, which have been widely reported in the 
literature (Bailey et al. 2007; Broz et al. 2010; Cepeda et al. 2012; Gossop et al. 2002; 
Heimer et al. 2014b; von Hippel et al. 2018; Mackesy-Amiti et al. 2014; Neaigus et al. 
2006; Perdue et al. 2003; Roux et al. 2014). Perception of HCV also did not show a 
significant correlation with injecting risk behaviour. Perception of HCV, in a HCV-
positive population, emerged from the literature review as an important factor 
influencing HCV treatment and risk behaviour (Bailey et al. 2007; Fairnbairn et al. 2010; 
Langston et al 2016; Langston et al. 2017; Langston et al. 2018; McGowan et al. 2013; 
Wagner et al. 2010b; Zalai et al. 2015). There was, however, a significant association 
between mental health variables and the illness perception measure. A larger sample 
might have enabled an exploration of these variables in the regression model 
predicting injecting risk behaviour. 
  
                                                          
1
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5.5.1 Limitations  
The sample of this study was small. Green (1991) suggests that for a multiple 
regression the minimum sample required is 50+8k, where k is the number of 
predictors. The sample in this study did not reach this threshold. This might have 
influenced the assumptions of the regression test not being met. To overcome this, a 
bootstrap analysis was performed. A bootstrap analysis is a robust method of analysis 
that deals with tests assumptions not being met (Field, 2018). Given its ability to derive 
a sampling distribution from the sample itself, a core-principle of bootstrapping is that 
the sample needs to be large enough for this empirically derived hypothetical sample 
of 1000 to draw information from the original sample (Rousselet et al 2019). An 
original sample of 50 was considered a respectably sized sample for this function to be 
performed. 
A further limitation of the study is that, in order not to overload participants with 
questionnaires at visit 1 in the RCT, baseline questionnaires were split into two visits. 
The results presented in this analysis are measures taken on visit 1 only. Visit 2 saw a 
dropout rate of 36%, with a sample size of 32. A sample of 32 was considered too small 
to be able to result in reliable inferences about the data even with bootstrapping, 
given the skewed sampling distribution (Rousselet et al. 2019). This was unfortunate, 
as visit 2 included the second primary outcome of ADAPT, self-efficacy, in addition to a 
further 2 secondary measures of social influence, social connectedness and social 
norms. Some aspects of social influence were captured via group identification scales. 
Yet, self-efficacy was not. This is a limitation to the findings of this study as published 
literature evidences the association and predicting role of self-efficacy with/on 
injecting sharing behaviour (Bonar & Rosenberg, 2011; Cox et al. 2008; Gagnon & 
Godin, 2009; Gibson et al. 1993; Nasir et al 2009; Thiede et al. 2007; Wagner et al. 
2010a). On reflection, this construct should have been captured on visit 1. 
Future research should consider including a self-efficacy measure in the baseline visit. 
Given the highly correlated nature of the mental health scales, considerations should 
be made about the need to measure all variables as separate constructs. Interventions 
on social network identification to reduce sharing of injecting equipment should be 
designed and piloted with the PWID population.  
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5.5.2 Conclusions 
In conclusion, baseline data shows injecting risk behaviour to be associated with both 
individual-level and social-level factors. Mental health variables and HCV illness 
perception, although inter-correlated, showed no significant association with sharing 
behaviour. A significant effect of group identification with drug network on sharing 
behaviour was observed in the tested model. Although the study was not able to 
support findings from previously published literature on the relationship between 
mental health and risk-taking in PWID, the finding showcase the importance of one’s 
social network when sharing of injecting equipment occurs, in particular the 
identification of an individual with peers from a drug network. Identification with a 
social group, usually associated with improved health, may pose health risks 
depending on the type of group identification. Interventions on social networks are 
recommended to reduce sharing of injecting equipment.
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CHAPTER SIX: Study 3 – ADAPT Results 2  
A pilot randomised controlled trial to test a psychosocial intervention on 
self-efficacy to reduce injecting risk behaviour. 
This chapter reports the main findings of ADAPT. After exploration of the data, it 
focuses on presenting and describing such data in detail, using simple inferential 
statistics to investigate the effects on the use of implementation intentions with the 
specified population on self-efficacy and sharing of injecting equipment. 
 
6.1 Abstract 
Background: Injecting behaviour in people who inject drugs is the main risk factor for 
hepatitis C virus (HCV) infection. Self-efficacy has been shown to be associated with 
injecting risk behaviour. The risk of HCV reinfection in people who inject drugs (PWID) 
treated for HCV remains high when sharing of injecting equipment continues post-
treatment. This study explores the use of implementation intentions on self-efficacy 
and injecting risk behaviour among PWID on HCV treatment. 
Methods: This randomised controlled trial comprised 50 participants on treatment for 
HCV. Active randomisation tasks were performed on 32 participants so a modified 
Intention to Treat analysis was carried out with the strategy of last observation carried 
forward applied for one follow-up point (visit 3). Data were explored in detail. 
Randomisation and attrition checks were carried out. Correlational analysis was 
performed as well as simple inferential statistics to observe time differences within-
subjects and intervention effects on the two main outcomes (self-efficacy and injecting 
risk behaviour).  
Results: Correlation analyses showed strong correlations between self-efficacy, 
injecting risk behaviour, injecting frequency and group identification with drug 
network. Mann Whitney U tests showed no significant differences between control 
and intervention groups on the two main outcomes. Wilcoxon Signed Ranks showed 
no significant differences within subjects between Time 1 and Time 2 on the two main 
outcomes. Analysis of secondary outcomes revealed a significant difference in HCV 
perception between start and end of treatment. 
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Conclusions: Despite the large attrition rate and the small sample size, the data 
exploration highlighted some interesting relationships between the main outcomes 
(self-efficacy and injecting risk behaviour) and two secondary outcomes (injecting 
frequency and group identification with drug network). The intervention did not show 
significant effects on behaviour, but several limitations did not allow a full analysis of 
the dataset. The results highlighted the importance for harm reduction strategies to 
emphasise each piece of injecting equipment as a potential source of HCV. 
Additionally, the change in illness perception should be explored in future research as 
a potential predictor of HCV reinfection. 
 
6.2 Introduction  
As explored in previous chapters, hepatitis C (HCV) is a blood-borne virus that is 
estimated to chronically affect around 1% of the global population (World Health 
Organization - WHO, 2017a). Around 57% of people who inject drugs (PWID) in 
Scotland show antibody positivity, and an estimated 31% present an active infection 
(Needle Exchange Surveillance Initiative – HPS, 2019; Public Health England - PHE, 
2019). Injecting behaviour in PWID is the main risk factor for hepatitis C virus (HCV) 
infection (PHE, 2019). Spontaneous clearance of HCV infection and successful 
treatment of HCV infection do not seem to provide protective immunity against future 
infections (Falade-Nwulia et al. 2018). As PWID continue to engage in injecting risk 
behaviour after being treated, with one of the highest HCV reinfection rates being 
reported in Dundee as 21.5 per 100 person years (Schulkind et al. 2019), the National 
Health Service incurs costs for retreatment. Therefore, it is essential to examine 
injecting risk behaviours and psychosocial factors that are associated and predict such 
behaviours in order to intervene on such factors and reduce chances of future HCV 
reinfection. 
Literature suggests a number of psychological and social factors have been associated 
with injecting risk behaviour (thoroughly explored in chapters 1, 3-5). Of interest to 
this study, some literature has focused on the association between self-efficacy and 
injecting behaviour (Bonar & Rosenberg, 2011; Copenhaver & Lee, 2006; Cox et al. 
2008; Falck et al. 1995; Gagnon & Godin, 2009; Gibson et al. 1993; Kang et al. 2004; 
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Latka et al. 2008; Robles et al. 2004). As presented in Chapter 1, the Theory of Planned 
Behaviour (TPB) (Ajzen, 1991) is a model of behaviour change that highlights the 
influences of attitudes, societal norms and perceived behavioural control on 
behavioural intention and subsequently on behaviour itself. Perceived behavioural 
control is thought to have a direct influence on behaviour, and to consist of 
controllability and self-efficacy (Ajzen, 2002b), with self-efficacy being a person’s belief 
in their own ability to perform a specific behaviour or succeed at a specific task 
(Bandura, 1977; 1986). Implementation intentions have been used as an extension of 
the TPB to intervene on the gap between intention and behavioural action (Higgins & 
Conner, 2013), and research on implementation intention on behaviours and self-
efficacy has produced mixed findings (Chapter 22; Milne & Sheeran, 2002; Murray et al. 
2005, Rodgers et al. 2002; Webb & Sheeran, 2008). Using a volitional help sheet can 
provide participants with a structured approach to creating effective implementation 
intentions (Arden & Armitage, 2012). 
The aim of this chapter is to explore the effect of implementation intentions on self-
efficacy and injecting risk behaviour as no published study to date has investigated the 
use of implementation intentions on injecting drug behaviour with people who inject 
drugs.  
 
6.3 Methods  
The methodology employed in this study was the focus of Chapter 4, reported in 
accordance with the CONSORT 2010 statement (Schultz et al. 2010) and the TIDieR 
checklist (Hoffmann et al. 2014) so it will not be repeated here. This section will focus 
on the participants and the analyses. All regulatory approvals (University of Dundee 
sponsorship, NHS East of Scotland Research Ethics Committee, Research & 
Development NHS Tayside) were received in December 2017. Data collection took 
place between February 2018 and January 2020. The study was longitudinal, divided 
into visit 1 (start of treatment), visit 2 (mid treatment), visit 3 (end of treatment) and 
visit 4 (3-months follow-up). The data and results reported in this chapter refer to 
                                                          
2
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baseline visits 1 and 2 (referred to as Time 1: Baseline) and the 1-month follow-up visit 
(visit 3, referred to as Time 2: Follow-up) of the pilot RCT. Visit 4 (3-month follow-up) 




The trial’s target sample size was 67 participants (See chapter 4). A total of 82 people 
were approached for the study, and 52 participants were consented (See Figure 6.1). 
Two consented and did not have time to complete Visit 1, but never returned to 
participate in the study. Therefore, 50 participants were randomised in the study. The 
intervention and one of the main outcomes (self-efficacy) were completed at visit 2, 
which was still considered a baseline visit (Time 1) given that baseline measures had 
been split into 2 visits in the interest of time and to facilitate participants’ active 
engagement. After visit 1, the attrition rate increased at every study visit. Participants 
were withdrawn for different reasons. Eight participants completed the trial (16%); 22 
were lost to follow-up with unknown reason (LTFU= 44%); 9 people were withdrawn 
from their HCV treatment (18%); 8 people went to prison (16%); 1 participant was 
withdrawn as cognitively incapacitated due to being under the influence of heroin 
(2%); 1 participant was hospitalised (2%); 1 participant was in withdrawal and left half 
way through visit 3 and was then LTFU (2% - Visit 3 data completed as LOCF). The 
overall attrition rate was 84%. Attrition rate between Time 1 and Time 2 analysed in 
this chapter was 28.1%.  
 
6.3.2 Analysis  
Data was analysed using IBM SPSS Statistics 25. Descriptive analyses showed the 
characteristics of the sample at Time 1 and mean scores of the 2 main outcomes 
(injecting risk and self-efficacy).   
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Figure 6.1: Complete study sample size 
 
 
A modified intention to treat analysis (mITT) was employed for the analysis of this trial 
(Fisher et al. 1990; Gupta, 2011; Sabin et al. 2000; Streiner & Geddes, 2001). Given that 
the intervention was provided on visit 2, only participants who completed visit 2 were 
considered for the analysis (N=32). Following a Last Observation Carried Forward 
(LOCF) strategy, the last recorded observation was used in place of the missing data for 
the 9 participants who did not show for Time 2 (visit 3) (Gupta, 2011; Streiner & 
Geddes, 2001). 
6.3.2.1 Data exploration 
All variables were explored to characterise the sample and inspect data visually. Apart 
from age, social connectedness, depression and illness perception, all other variables 
showed quite severe levels of skewness and/or kurtosis, as confirmed visually with Q-Q 
plots and box plots and numerically with skewness and kurtosis values and Shapiro-
Wilk test statistics. Three types of data transformations were tried in order to 
normalise the distribution of the variables and reduce the number of outliers: a log 
(log10x), a square root (√x) and an inverse (1/x) transformation. None of these 
transformations normalised the data distribution. 
Non-parametric correlations (Spearman’s rho) were carried out to inspect correlations 







Target Screened for 
study 
Enrolled Visit 1 Visit 2 Visit 3 Visit 4 
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results in Chapter 5 suggested not all independent variables showed a relation to the 
dependent variable. 
6.3.2.2 Attrition checks 
Attrition tests were carried out to compare those who completed Time 2 (23) and 
those who only completed Time 1 (9).  They were also carried out to compare those 
who completed the full planned 4 visits (8) and those who did not (42), even though 
the data from visit 4 were not included in the main analysis. 
The assumptions for MANOVA were not even approximately met. Univariate tests 
were used: Mann-Whitney for age, injecting frequency, injecting risk, identification 
with family and drug network, depression, anxiety and illness perception; and Chi-
square for gender, genotype, site, treatment pathway, trial group, partner, SVR12, Post 
Traumatic Stress Disorder (PTSD) and drugs injected. 
The increase in Type I errors when performing multiple tests was not considered here, 
as almost all tests performed did not approach significance. Relationships among the 
variables are also ignored in these checks since it was not possible to run MANOVAs. 
6.3.2.3 Randomisation checks 
Randomisation checks were also carried out on the same variables using the Mann-
Whitney U and Chi-square tests to check for differences at baseline between 
participants in the intervention and control group. Both checks were carried out for a 
mITT (N=32) and a per-protocol analysis (N=50). In this case too, assumptions for 
running a MANOVA were not met, leading to multiple univariate tests which did not 
take into consideration intravariate effects and increased the chance of Type I errors. 
6.3.2.4 Main analyses 
In the study protocol, the main planned analysis was a MANCOVA, testing self-efficacy 
and injecting sharing risk as dependent variables, trial group as the grouping variable 
(intervention or control) and any correlated variables at Time 1 as covariates. 
MANOVA and MANCOVA (multivariate analysis of variance or covariance) make a 
number of assumptions but is generally quite a robust test that can deal with some 
assumption violation, especially a degree of skewness in data distributions. However, 
the small sample size, the number of outliers and the ceiling and floor effects of the 
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two dependent variables (self-efficacy and injecting risk) resulted in severe assumption 
violations. When all test assumptions were checked, the severe distribution 
asymmetry (univariate normality being a necessary condition of multivariate 
normality, which cannot be tested in SPSS IBM Statistics 25), the number of outliers 
(participants 3 and 40 for both variables, and participant 18 for self-efficacy only), the 
lack of linear relationship (between IRQ and SES both in the control and intervention 
groups) and the heterogeneity of variance-covariance matrices (Box’s test p=.009), 
made MANCOVA an unsuitable method. 
In order to allow some inferential analyses, a number of other options were 
considered:  
- One option would have been a non-parametric MANOVA or MANCOVA, but this is 
not available in SPSS 25.  Non-parametric MANOVA is available with R packages 
(e.g. coin package) but given the different software and coding necessary for this 
analysis, this option was not viable.  
- A new score was calculated for the 2 dependent variables as the Difference Score 
between Time 2 and Time 1 (IRQ_Score_v3 – IRQ_Score_v1= IRQ_Difference & 
SES_Score_v3-SES_Score_v2= SES_Difference) to check whether the respective 
scores presented a more normal distribution and fewer outliers. The distributions 
still had large skew and kurtosis and the number of outliers increased. A log 
transformation was tried but it did not improve the distributions. 
- A Generalised Linear Model (GLM) with a Gamma distribution was considered as it 
is a type of analysis widely used for continuous, non-negative positively skewed 
data, able to deal with heteroscedasticity. However, the dependent variable self-
efficacy had a strong negative skew (Skewness = -1.57, SE= .41, Shapiro-Wilk test 
statistic= .66, p<.001) which cannot be used in a GLM with a Gamma distribution. 
- A cross-Lagged model was also considered to assess the interplay between Time 1 
variables (injecting risk, self-efficacy, injecting frequency and identification with 
drug network) with the same repeated measures at Time 2. This is a type of 
structural equation model for information that has not been manipulated and is 
collected at two or more points in time to assess causality. However, the variables 
were measured in an experimental setting, and therefore had been manipulated, 
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and the approximate sample size required for this analysis of 10 cases per variable 
was 60% greater than the present sample size (Bentler & Chou, 1987; Nunnally, 
1967) rendering any results and conclusions unreliable. 
- Therefore, due to major obstacles in producing good quality, reliable hypotheses 
testing analyses, the main analyses on the sample were simple frequencies and 
descriptives in order to understand and characterise the sample results as well as 
possible. 
Some Mann-Whitney U and Wilcoxon Signed Rank tests were performed (despite 
multiple univariate tests not taking into consideration intravariate effects and 
increasing the chance of Type I errors), with the purpose of exploring effect sizes. 
 
6.4 Results  
6.4.1 Descriptive statistics and attrition checks 
Exploration of the Time 1 data was carried out to characterise the sample (Table 6.1). 
Means and standard deviations are presented for the full sample (N=32, Table 6.1) and 
divided between those who completed (N=23) and those who did not complete Time 2 
(N=9). The main attrition checks are also reported in Table 6.1. Secondary outcomes 
(social norms, social connectedness, identification with family, identification with drug 
network, depression, anxiety, PTSD, illness perception) were checked for Time 1 
differences and are not reported in the table. Table 6.1 shows that the values for 
completers and non-completers are similar, and no differences approaching statistical 
significance were found at Time 1 between those who completed and those who 
dropped out of the study. A full attrition check was also carried out on the whole 
ADAPT sample (N=50) presenting only 8 participants with a complete dataset and 42 
who dropped out before visit 4. No statistically significant differences were found 
between completers and non-completers at visit 1.  
137 
Chapter 6   
Table 6.1: Characteristics of the full sample and attrition checks 
Characteristics  Full sample (N=32) 
 
M             SD 
Completed (N=23) 
 
M             SD 
Dropped out (N=9) 
 
M             SD 
Mann-Whitney 
U test* p-value 
Age (years) 38.40 8.10 38.43 8.62 38.22 7.03 .621 
Weekly injecting  7.38 9.21 6.22 8.40 10.33 10.98 .212 
Injecting Risk 
Behaviour-IRQ (1-4) 
1.22 .39 1.18 .33 1.33 .54 .621 
Self-efficacy (1-7) 6.65 .58 6.69 .57 6.54 .63 .592 
  
N               % 
 
N               % 
 



























































































































































































































































1Sites= Cairn Centre is the main IEP in Dundee; Drumhar is the main IEP in Perth. 
2Treatment pathways: DOT= Daily Observed Therapy; 2/52= Fortnightly observed therapy; 
2/52+ = Fortnightly observed therapy with Psychological intervention (Adherence). 
3SVR12 Achieved= Sustained Virological Response (HCV undetectable, patient cured). 
* Significant at the 0.05 level (2-tailed). 
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Reliability analyses were carried out for the scales which had not been tested in 
Chapter 5 (given they were assessed at Visit 2 baseline). An exploratory factor analysis 
on all the measures was not possible as the sample size was too small for appropriate 
analysis. Cronbach’s α for all measurement showed good scale reliabilities (all above 
.7) (Table 6.2). 
 
Table 6.2: Visit 2 variable’s descriptives and reliability testing 
 
6.4.2 Randomisation checks 
Means and standard deviations for those who completed the intervention or control 
activity are presented in Table 6.3 and are divided by trial group (intervention and 
control). The randomisation checks on the main outcomes are also reported in Table 
6.3. Secondary outcomes (social norms, social connectedness, identification with 
family, identification with drug network, depression, anxiety, PTSD, illness perception) 
were also checked for baseline (Time 1) differences but are not reported in the table. 
No statistically significant differences were found at Time 1 between those who were 
randomised to the intervention and control groups. A full attrition check was also 
carried out on the whole ADAPT sample (N=50) which presented 23 participants in the 
control group and 27 in the intervention arm. This check was run to ensure the 
randomisation procedure was robust, even though 18 participants completed neither 
the intervention nor the control task. No statistically significant differences were found 
between intervention and control participants at visit 1. 
  
Characteristics (Range) M SD Cronbach’s α 
Self-efficacy (1-7) 6.65 .58 .76 
Social norms (4-28) 7.47 5.47 .77 
Social connectedness (8-48) 24.90 11.63 .90 
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Table 6.3 Characteristics of sample by intervention group (N=32) 
Characteristics  Intervention (N=14) 
 
M                   SD 
Control (N=18) 
 
M                   SD 
Mann-Whitney U 
test* p-value 
Age (years) 39.07 6.37 37.83 9.37 .896 
Weekly injecting 
frequency at Time 1 
4.93 8.70 9.28 9.38 .125 
Injecting Risk Behaviour 
(Range 1-4) 
1.10 .22 1.32 .47 .145 
Self-efficacy (Range 1-7) 6.84 .34 6.50 .69 .145 
  
N                    % 
 
















































































































































































1Sites= Cairn Centre is the main IEP in Dundee; Drumhar is the main IEP in Perth. 
2Treatment pathways: DOT= Daily Observed Therapy; 2/52= Fortnightly observed therapy; 
2/52+ = Fortnightly observed therapy with Psychological intervention (Adherence). 
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3SVR12 Achieved= Sustained Virological Response (HCV undetectable, patient cured). 
* Significant at the 0.05 level (2-tailed). 
 
6.4.3 Correlations 
An exploration of the correlations between the two main outcome and all the Time 1 
predictors was carried out to explore the relation between variables (Table 6.4). 
Scatterplots of all the variables were visually inspected to check the linearity of the 
relationship between injecting risk behaviour and self-efficacy with all psychosocial 
factors measured. Given linearity was violated among all pairwise combinations, 
Spearman’s correlation was carried out to test the relationship between variables.  
Table 6.4 shows bivariate correlations between the main outcomes and all Time 1 
predictors. In the table, the main outcomes are shown as injecting risk behaviour and 
self-efficacy.   
Significantly correlations were observed between a few variables. A higher level of self-
efficacy was associated with lower injecting risk behaviour, lower injecting frequency 
and a weaker identification with a drug network. A higher injecting risk was associated 
with a stronger identification with a drug network.  
Higher injecting frequency was associated with lower threat of illness perception; 
higher social connectedness was associated with higher identification with family and 
fewer PTSD symptoms; interestingly, social norms showed no correlation at all with 
identification with drug network. 
In chapter 5, the 3 mental health variables (depression, anxiety and PTSD) were all 
correlated using the data from all the 50 participants enrolled. In this analysis, using 
only the 32 cases that completed visit 2, the 3 mental health variables were all still 
positively and significantly correlated, as can be seen in the last 3 rows of Table 6.4.  
Chi-square tests of associations were used to check correlations between categorical 
Time 1 variables (sex; recruitment site; intervention group; HCV genotype; partner; 
treatment pathway; SVR12 achieved; drugs injected) and injecting risk behaviour 
(computed as a categorical variable), with no significant correlations found.
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Table 6.4: Spearman’s correlations between factors at Time 1 (n=32) 
*. Correlation is significant at the .05 level; **. Correlation is significant at the .01 level (2-tailed). 
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The correlations between categorical Time 1 variables and self-efficacy could not be 
checked with a point-biserial correlation, as self-efficacy was not normally distributed 
and presented outliers. The significance of these relations was therefore checked using 
a Mann-Whitney U test (Field, 2018) and showed no significant tests.  
The correlation between the main outcomes of self-efficacy and injecting risk was 
checked at Time 2, revealing the strong negative relationship was not sustained at 
follow-up (Spearman’s rho= -0.31, p=0.085). 
 
6.4.4 Exploration of injecting frequency  
Given the randomisation checks showed no significant differences between groups at 
Time 1, the description and exploration of frequencies in the data was carried out on 
the full sample at Time 1 (N=32).  
One third of the sample did not inject in the week preceding the mid-treatment visit 2 
(Table 6.5). The sample distribution, however, was very heterogeneous, as injecting 
frequency for the other two-thirds of the sample was spread between once a week 
and 28 times a week (or 4 times a day). 
 
Table 6.5 Weekly injecting frequencies 
Injecting Frequency 2 
                           Frequency             Percent 
0 11 34.4 
1 2 6.3 
2 3 9.4 
3 3 9.4 
4 1 3.1 
6 1 3.1 
10 1 3.1 
14 2 6.3 
18 3 9.4 
19 1 3.1 
21 2 6.3 
28 2 6.3 
Total 32 100 
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At Time 2 the score spread in the control group remained in the same range, even 
though fewer participants had not injected in the week prior to the visit, whilst in the 
intervention arm, the range of scores diminished, with most of the participants 
featuring at the lower end of the frequency scale (Figure 6.2). 
There were 3 measurements of injecting frequency as this was measured at every visit. 
All participants were current injectors but injecting frequency was quite 
heterogeneous across the sample. This is quite evident when reporting means and 
standard deviations for the 3 visits: injecting frequency at start of treatment visit 1 M= 
6.69 (SD= 8.42); injecting frequency at mid-treatment visit 2 M=7.37 (SD= 9.21), 
injecting frequency at end of treatment visit 3 M=6.5 (SD= 8.22). 
Nonetheless, a Friedman test for differences in injecting frequency within-subjects 
between the start, middle and end of HCV treatment on the full sample (N=32) showed 
no significant difference in injecting frequency over time χ 
 (2)= .33, p= .848). Wilcoxon 
tests were used to explore these findings and showed no differences in injecting 
between start and mid treatment (visit 1-visit 2) (T= 122, r = .05), between start and 
end of treatment (visit 1-visit 3) (T= 109, r = -.04), nor between mid and end of 
treatment (visit 2-visit 3) (T= 51.5, r = -.01). The effect size r was calculated according 
to Rosenthal’s (1991) formula    
 
  
 , where Z is the test score and N is the number 
of observations and r  is interpreted as: Small = .1, Medium = .3, Large= .5 (Field, 2018). 
A Mann-Whitney test for a difference in injecting frequency between the control and 
intervention arms at Time 2 was not significant (U= 81, z= -1.74, p= .091).  
Nevertheless, the effect size was r = -0.31 (medium, Figure 6.2), functions as a 
reminder that the test statistic and significance depend on N as well as any difference 
between the groups compared. 
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6.4.5 Exploration of injecting risk behaviour 
The injecting risk questionnaire was completed at Time 1 and Time 2 (See Thesis 
Appendix for copy of IRQ and see Chapter 4 for measure description and scoring). It 
measured on a 4-point Likert scale (1= never shared – 4= frequently shared) an overall 
sharing behaviour score by asking participants if in the past 4 weeks they had shared 
equipment, how many people they had shared with (repeated at the start of the 
questionnaire and at the end), and individually asking which singular equipment piece 
was lent and/or received for sharing. 
The exploration of the behaviour will initially be carried out on the overall injecting risk 
score, followed by the comparison between the self-reported number of people 
shared with at start and end of questionnaire. Scores on singular injecting 
paraphernalia are then examined, followed by the comparison between lending and 
borrowing of equipment. The difference between trial groups is then investigated on 
injecting risk at Time 2. 
6.4.5.1 Number of people shared with & injecting risk score at Time 1  
Time 1 scores were investigated on the full sample (N=32) in more detail than the 
overall IRQ score used as the main outcome. Injecting risk showed a marked floor 
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effect (Table 6.6) as almost two thirds of participants reported not sharing equipment 
at visit 1.  Tables 6.7a and 6.7b show self-reported number of peers with whom people 
had shared injecting equipment. The same question was asked at the start of the 
injecting risk and at the end of the injecting risk, after single item questions about 
receiving and lending each piece of injecting equipment (syringe, spoon, filter and 
water) had been asked. 
 
Table 6.6 Injecting risk score Time 1 Table 6.7a Reported number of people        






Table 6.7b Reported number of people 









The injecting risk score of 0, obtained from 20 participants, was (all but for one person) 
in line with the self-reported number of people at the end of the questionnaire, in 
which 21 people reported not sharing with anyone. A Wilcoxon Signed Rank, run to 
check for a difference between the self-reported number of people shared with at 
start and end of the injecting risk at visit 1, showed a significant increase (N=32, z 
=2.55, p=.011). The effect size r = .45 was large. 
 
Injecting risk 
Frequency       Percent 
1.00 20 62.5 
1.07 2 6.3 
1.20 1 3.1 
1.40 2 6.3 
1.47 1 3.1 
1.60 1 3.1 
1.73 3 9.4 
2.13 1 3.1 
2.60 1 3.1 
Total 32 100.0 
Number_Shared_start.1 
                       Frequency        Percent 
0 29 90.6 
1 2 6.3 
2 1 3.1 
Total 32 100.0 
Number_shared_end.1 
                      Frequency         Percent 
0 21 65.6 
1 5 15.6 
2 4 12.5 
4 1 3.1 
5 1 3.1 
Total 32 100.0 
146 
Chapter 6   
6.4.5.2 Singular injecting paraphernalia 
Because this change in self-report occurred after answering individual questions about 
injecting equipment, Table 6.8 explores the individual equipment items as individual 
sub-scores of the injecting risk questionnaire. 
 
Table 6.8 Singular injecting paraphernalia sharing 
 
The syringe sharing sub-score was the closest to the overall injecting risk score (M= 
1.22, SD=.39), and although the range of scores for sharing of spoons and filters was 
larger, the mean score was also quite similar to the overall injecting risk score. 
However, these results showed that sharing of water to inject was common, with the 
mean score of 3.37 (SD=1.13) with water being shared sometimes (=3) and frequently 
(=4) in a quarter of the sample. A quarter of the sample also scored over 1 (1=never 
sharing, anything above meaning sharing at varying degrees), and half the scores 
remaining closer to the lower end of the scale. This was the only injecting item that 
was measured by one scale item only. 
6.4.5.3 Examining lending and borrowing 
The injecting risk also allowed for differentiation between a lending-sharing score and 
a borrowing-sharing score. Most scores were 1(=never) for both lending and 
borrowing,  yet  4 participants delineated a difference between receptive-sharing and 
lending-sharing and 8 participants engaged in both types of sharing (Table 6.9). 
  
Singular injecting paraphernalia sharing characteristics 
 Number of scale 
items in sub-score 
Score Range Mean (SD) 
Syringe Sharing 9 1-1.67 1.09 (.17) 
Spoon Sharing 2 1-4 1.42 (.83) 
Filter Sharing 2 1-4 1.47 (.89) 
Water Sharing 1 1-4 3.37 (1.13) 
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Table 6.9 Crosstabulation (2x2) of paraphernalia lenders and borrowers at Time 1
  
Time 1: IRQ_lent * IRQ_borrowed 
 Not borrowing Borrowing Total 
Not lending 20 2 22 
Lending 2 8 10 
Total 22 10 32 
 
6.4.5.4 Sharing characteristics at Time 2 
Exploration of the same injecting risk characteristics at Time 2 showed a similar picture 
to those at Time 1, with most of the injecting risk scores at the lower end of the scale 
(Figure 6.3). The two trial groups were tested for any significant differences at end of 
treatment using a Mann-Whitney U test. No significant difference was found (U= 
122.5, z= -.184, p= .896), with r = -.03 a negligible effect. No statistically significant 
increase or decrease in injecting risk behaviour was observed within-subjects in the 
two trial arms between Time 1 and Time 2, the intervention group showing a small-to-
medium effect, whilst the control group approached a significant reduction with large 
effect (Wilcoxon Signed Rank: z= -1.87, p=.061, r = -.44). 
Also, at Time 2, the self-reported number of people with whom participants had 
shared ranged between 0 and 2 both at the start of the questionnaire and at the end. 
Two participants (one per trial group) switched from 0 to 1 after being asked about the 
sharing of each singular injecting equipment piece, with no significant difference found 
in the self-reports in the full sample between start and end of questionnaire (Wilcoxon 
Signed Rank z= 1.41, p=.157, r = -.25). 
The same number of people as Time 1 were not lending and not borrowing injecting 
equipment at Time 2. No participants reported only lending or only borrowing, with 12 
reporting doing both at Time 2 (See Table 6.10). No significant changes were observed 
within the full-sample (N=32) at the two time points (Wilcoxon Signed Rank test results 
respectively z= -.65, p= .513, r = -.12 for lent and z=-1.72, p=.085, r = -.3 for received), 
nor between control and intervention groups at Time 2 (Mann Whitney U test results 
respectively z= -.21, p= .896, r = -.04 for lent, and z= -.56, p= .722, r = -.1 for received). 
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Table 6.10 Crosstabulation (2x2) of paraphernalia lenders and borrowers at Time 2 
Time 2: injecting risk lent * injecting risk borrowed 
 Not borrowing Borrowing Total 
Not lending 20 0 20 
Lending 0 12 12 
Total 20 12 32 
 
6.4.6 Exploration of self-efficacy to refuse sharing 
Self-efficacy to reduce sharing was measured on a 7-point Likert scale (ascending 
confidence level). It was completed at Time 1 and Time 2 (See Thesis Appendix for 
copy of self-efficacy scale and see Chapter 4 for measure description and scoring). As 
presented in Table 6.11, the self-efficacy scores showed a ceiling effect (M=6.65, SD= 
.58), as two-thirds of the sample at Time 1 reported high levels of confidence in their 
own ability to refuse and resist sharing of injecting equipment. 
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1 – 4.99 0 0 0 
5 – 5.99 4 (22.3) 1 (7.1) 5  (16) 
6 – 6.99 5 (27.9) 2 (14.2) 7  (22) 
7 9 (50) 11 (78.6) 20  (62) 
Total sample 18 14 32 (100) 
 
At Time 2 self-efficacy scores remained very high, with the range increasing only due to 
two individuals, one in each trial arm (Outliers 19 and 40 in Figure 6.4). 
The two groups showed no significant difference at Time 2 (Mann-Whitney U= 161.5, 
z= 1.55, p= .180). However, the effect r = .27 was medium, a reminder that the group 
sizes were small. No statistical significant increase or decrease in self-efficacy was 
observed within-subjects in the two trial arms between Time 1 and Time 2. The effect 
size of the change for the intervention group was r = 0, whilst that of the change for 
the control group was r = -.25. 
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6.4.7 Exploration of identification with drug network 
The group identification with drug network scale was completed at Time 1 and Time 2 
(See Thesis Appendix for copy of group identification scale (with drug network) and see 
Chapter 4 for measure description and scoring). The scale measured identification on a 
7-point Likert scale (ascending identification level). The drug network group 
identification scores showed a wide spread throughout the scale, although most 
frequently scores clustered at the top ends of the range (Table 6.12), thus providing a 
centrally located mean with wide standard deviation (M=3.39, SD= 2.18). 
 
Table 6.12 Frequency scores for identification with drug network at Time 1 
Frequency (percentage) 
Identification with 
Drug Network  






1 – 1.99 4 (22.2) 6 (42.9) 10 (31.3) 
2 – 2.99 4 (22.2) 2 (14.2) 6 (18.8) 
3 – 3.99 2 (11.2) 3 (21.4) 5 (15.7) 
4 – 4.99 2 (11.2) 0 (0) 2 (6.2) 
5 – 5.99 1 (5.5) 1 (7.2) 2 (6.2) 
6 – 7 5 (27.8) 2 (14.2) 7 (21.8) 
Total sample 18 14 32 (100) 
 
At Time 2 the distribution of scores remained similar in both control and intervention 
groups (Figure 6.5). A Mann-Whitney U test showed no significant difference between 
control and intervention (U= 93.5, z= -1.25, p= .22, r = -.22); no difference was 
observed either within trial groups between Time 1 and Time 2, with Wilcoxon Signed 
Rank test results respectively: z=.26, p= .798, r = .06 for the control arm, and z= -.51, p= 
.609, r = -.14 for the intervention arm. 
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Figure 6.5 Boxplots of control and intervention scores at Time 2 for identification 
with drug network  
 
 
6.4.8 Secondary variables measured at Time 2 
The secondary outcome variables which were measured at different visits throughout 
the trial were explored even if no significant correlation between these variables and 
the two main outcomes (injecting risk behaviour and self-efficacy) were found at Time 
1. Differences between Time 1 and Time 2 in the full sample (N=32) were tested for 
with Wilcoxon Signed Ranks (Table 6.13). 
 
Table 6.13 Full sample Time 1-Time 2 differences in secondary outcomes  
Within-subjects Wilcoxon Signed Ranks tests 


















* Significant at the 0.05 level (2-tailed). 
 
Illness perception showed a significant decrease in time, whilst depression was not 
quite significant at 5%.  The effect sizes for illness perception and depression were, 
respectively, large (r = -.54) and medium (r = -.33). 
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These two variables were explored in more detail by trial group. Illness perception 
showed no differences between groups at Time 2 (U= 127.5, z= .06, p= .955, r = .01). It 
remained significantly different for both control and intervention groups from Time 1 
to Time 2.  
At Time 2, depression did not show any between-group differences either (U= 109, z= -
.65, p= .536, r = -.12). Within-group differences were checked with Wilcoxon Signed 
Ranks test which revealed no differences in time in the control group (z= -.8, p=.423, r 
= -.19), and a large significant difference in the intervention group by time (z= -1.96, p= 
.05, r = -.52).  This result was unexpected. The intervention was not targeting mental 
health variables. The time participants spent with the researcher was controlled for, as 
a time perspective inventory was explained and filled in with participants in the control 
group. The Time 2 between-group tests would suggest the time-control task was 
effective. Therefore this finding is considered accidental.  
No other variables showed between-group differences at Time 2. 
 
6.5 Discussion  
The results of this pilot RCT are exploratory in nature and allow the reader to gain a 
better understanding of the HCV-positive injecting population. The use of a volitional 
help sheet to create implementation intentions had not been tested in this population 
before (Chapter 2). The feasibility and fidelity of carrying out this intervention with this 
population will be discussed in chapter 8. Nevertheless, the intervention did not result 
in any detectable effect on self-efficacy nor sharing behaviour. 
In chapter 2, the effect of creating implementation intentions for substance use 
reduction on self-efficacy was explored and a pooled effect size of g=.16, p=.087 was 
reported. This result was pooled from studies on alcohol and tobacco smoking. The 
results of this trial are in line with those reported in chapter 2, as no significant effect 
was found on self-efficacy between- nor within-groups. The negative association 
between self-efficacy and sharing of injecting equipment has previously been explored 
in research with PWID, with literature highlighting the need for interventions to target 
risk reduction motivation and behavioural skills rather than using passive harm 
reduction education (Bonar & Rosenberg, 2011; Copenhaver & Lee, 2006; Cox et al. 
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2008; Falck et al. 1995; Gagnon & Godin, 2009; Gibson et al. 1993; Kang et al. 2004; 
Latka et al. 2008; Robles et al. 2004). Other behavioural interventions have reported 
promising results, such as a behavioural intervention improving harm reduction self-
efficacy in PWID (Pawa & Areesantichai, 2016) and motivational interviewing showing 
an increase in self-efficacy associated with a decrease in sharing of needles (Robles et 
al. 2004). In the current study, the measure of self-efficacy to reduce all equipment 
sharing suffered from a ceiling effect, with all participants reporting high levels of self-
efficacy to avoid sharing of all injecting equipment at Time 1. An improvement on the 
reported self-efficacy scores would have been quite difficult to detect, especially with 
such a small sample size. In addition, the inclusion of all injecting equipment in the 
study’s definition of sharing compared to sharing of needles only (Robles et al. 2004), 
might have impacted on people’s reporting of sharing as discussed below. 
 
6.5.1 Sharing of injecting equipment 
The results of the trial present a detailed picture of injecting behaviour, as a relatively 
stable and habitual behaviour, even throughout HCV treatment. Unlike results 
reported in Chapter 33 and other published literature (Caven et al. 2019), no change in 
injecting frequency was observed between start (visit 1), mid (visit 2) and end of 
treatment (visit 3). Previous studies have mostly been carried out on patients on 
treatment during the Interferon-era (Chapter 3; Alavi et al. 2015; Artenie et al. 2017; 
Midgard et al. 2017) with only one study reporting small reductions in injecting and 
sharing behaviour during DAA treatment (Artenie et al. 2020). The near-to-none side 
effects associated with DAA treatment might be resulting in no influence on patients’ 
ability to continue injecting. 
Sharing behaviour did not change over the course of the HCV treatment in this study. 
As one of the main outcomes of the trial, change was explored between intervention 
and control groups at Time 2, with no difference detected between the two groups. 
The reported scores of injecting risk behaviour suffered from a floor effect, with all 
participants reporting low levels of sharing of injecting equipment at Time 1. An 
improvement on the reported injecting risk behaviour scores (i.e. a reduction in 
                                                          
3
 Published in Journal of Viral Hepatitis: Malaguti et al. (2019): Doi: 10.1111/jvh.13009 
154 
Chapter 6   
scores) would have been quite difficult to detect, especially with such a small sample 
size. 
By dissecting the overall injecting risk behaviour score, a differentiation among 
injecting paraphernalia started to emerge. By asking about individual injecting 
equipment pieces, participants would be reminded that sharing of other paraphernalia 
other than syringes (such as water, pots and filters ) also contributed to HCV risk 
(Mathei et al. 2006). This allowed them to adjust the self-reported number of people 
with which they had shared equipment in the previous 4 weeks, resulting in a 
significantly increased number of ‘sharers’ between start and end of questionnaire. 
Unsurprisingly, linked to these results were the reported sharing behaviour sub-scores 
according to each piece of equipment, which showed water was the most shared and 
syringes by far the least shared pieces of equipment. These findings are supported by 
previous research, which shows spoons and water to be significantly more frequently 
shared than needles and syringes (Gaskin et al. 2000; Gossop et al. 1997), with as little 
as 10% of interviewed samples reporting not sharing water or filters during the 
previous year (Gaskin et al. 2000). Needle sharing has been associated by people to 
intimate partnerships, as it can be perceived as more intimate and intrusive than 
spoon or water sharing (Gossop et al. 1997; Unger et al. 2006).  
This study explored sharing of injecting equipment in the previous 4 weeks, with 
participants reporting some instances of sharing (one-third at Time 1 and one-fifth at 
Time 2). These findings and previous research show that PWID are aware of the health 
risks associated to sharing, in particular in this study’s sample which has been 
negatively affected by such risk behaviour (HCV infection), yet sharing continues to 
occur (Gaskin et al. 2000; Gossop et al. 1997). This might suggest that PWID hold a 
non-threatening perception of these negative consequences, such as HCV. 
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6.5.2 Change in illness perception 
The results of the study do indeed show that PWID hold mostly non-threatening 
perceptions of HCV. The findings show that between Time 1 and Time 2, irrespective of 
trial group, the perception of HCV became even slightly less threatening. This decrease 
in illness perception score suggests HCV becomes less threatening after having been 
through treatment. Literature suggests HCV diagnosis can be perceived as frightening 
whether or not people perceive a high degree of susceptibility to the infection 
(Dowsett et al. 2017; Fraser & Treloar, 2013). The common sense model (CSM) of self-
regulation of health and illness can be useful in order to understand this change in HCV 
perception (Leventhal et al. 1980; Leventhal et al. 1984; Safo et al. 2015). The CSM 
suggests that patients create an abstract representation of their illness, by interpreting 
factors such as the severity of symptoms and the socio-cultural context linked to the 
illness. These illness representations are both cognitive and emotional and inform the 
personal health threat and emotional response to the diagnosis and the illness itself. 
The illness is a change in the individual’s status quo, which drives forward a self-
regulatory process in order to return to such status.  This self-regulatory process 
includes engaging in behaviours, such as seeking treatment, which will aid the 
individual to return to their original status. This is the coping stage, which is usually 
shaped by two types of coping strategies: approach and avoidance. The final stage 
involves the appraisal of the chosen coping strategy, with return to the status quo or 
identification for the need to re-create an illness representation and/or coping strategy 
(Leventhal et al. 1980; Leventhal et al. 1984; Ogden, 2012). By undergoing HCV 
treatment, participants’ appraisals of their coping strategies at the end of their 
treatment would have been positive, considering the selected strategy as effective and 
rendering the illness less threatening given their experience of successful, and virtually 
side-effect-free, cure.  
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6.5.3 Attrition 
Recruiting to a full sample size and retaining the full sample are very common issues in 
RCTs. A review of trials funded by the UK Medical Research Council and the Health 
Technology Assessment Programme, showed that only 55% recruited to target, with 
45% of trials being awarded an extension, 44% failing to meet recruitment target and 
22% achieving less than 80% of their required sample size (Duley et al. 2018; Sully et al. 
2013). Another review of funded RCTs showed a mean attrition rate in RCT of 21.1% 
(Cooper et al. 2018). This study managed to recruit 74.6% of the required sample, 
though only 47.8% completed the randomisation tasks. This impacted heavily on the 
analysis presented in this Chapter, allowing mostly just descriptive analysis with 
inferential statistics which suffer from a high probability of Type I errors. Attrition rates 
also influenced the results, with a total attrition rate of 85% being well above the 
average for RCTs. If considering only those actually randomised to the conditions (visit 
2), the attrition rate fell to 28.1% for 1-month follow-up (visit 3/Time 2), and 75% for 4-
month follow-up (visit 4). The results reported in this chapter refer to visits 1 and 2 
(Time 1) and visit 3 (Time 2) with an attrition rate of 28.1%, average for longitudinal 
trials, behavioural trials, and trials that involve PWID. Mean attrition rates vary widely, 
with studies reporting 66% as a typical attrition rate for self-reported studies (Gratton 
et al. 2007; Manstead & Semin, 1999), 22.5% (Samo et al. 2016), 29% (Horyniak et al. 
2013) and 40% (Gindi et al. 2009) for longitudinal studies with PWID, 22.4% for 
behaviour change trials (Rigotti et al. 1997), and others (Crutzen et al. 2015) reporting 
a review of behavioural trials with pooled dropout rates of 18% in intervention 
conditions and 17% control conditions. 
In order to allow an intention-to-treat analysis, missing data was dealt with using a last 
observation carried forward (LOCF) strategy. LOCF is widely used in trial analysis plans 
although it presents both positive and negative aspects. LOCF can introduce bias ,as it 
implies no change (positive or negative) has occurred over the time of the trial and 
ignores the trend of the data prior to the final value (Streiner, 2008; Streiner & 
Geddes, 2001). However, it allows the assessment of effects of interventions on 
slightly larger samples by minimising the number of participants excluded from the 
analysis (Conroy et al. 2015; Streiner, 2008). Overall, the bias introduced by using LOCF 
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is considered acceptable in order not to exclude participants from the trial analysis 
(Streiner & Geddes, 2001). 
 
6.5.4 Limitations 
The sample size was a large limitation of this study. A small sample size reveals an 
underpowered study which in turn is subject to an increase in Type II errors. Therefore, 
multiple univariate tests (which are associated with increase in Type I errors) were not 
considered a problem as the analysis was severely underpowered and the two types of 
errors are inversely proportional.  The main MANCOVA test, which could not be carried 
out due to violation of assumptions, would also have been underpowered and would 
likely not have resulted in any meaningful results. 
Although the design of the trial was adapted at the start of the recruitment to try to 
minimise drop-out rates (reduction of questionnaire repetitions between visits and 
reduction of visits from 5 to 4 with longest follow-up reduced from 6 months to 3 
months), attrition rates remained high. 
As a pilot study, the results reported in this chapter are informative for future 
research. They highlight different practical aspects which need to be considered for 
future research planning with this population. The physical difficulty of one person 
running an RCT individually was evident specifically when there were two recruitment 
sites open simultaneously and at times when the researcher was not at the site due to 
meetings or trainings. A larger research team involving treatment nurses seeing the 
patients for their routine appointments might reduce the attrition rate. 
The number of questionnaires was too high. The results reported in this and in 
previous chapters will help guide future selection of psychosocial factors to be tested, 
alongside appropriate theories and models of behaviour change. 
The visits were too long, with participants repeatedly reporting they did not have time 
to stay when being asked to stay for a visit, until the window in which that visit was 
meant to take place would close and they would have to be withdrawn as lost to 
follow-up. This specific issue had been thought of during the planning stages, as, per 
protocol, participants were given protein drinks at each visit as an incentive to take 
part in the trial. During the trial, participants always attempted negotiations and 
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bargaining in order to receive more protein drinks than the usual amount of 4 per visit. 
This might suggest that the perceived benefits of participating in the trial did not meet 
the perceived costs (e.g. effort and time). 
 
6.5.5 Conclusions  
In conclusion, despite the large attrition rate and the small sample size, the data 
exploration highlighted some strong correlations between self-efficacy, injecting risk 
behaviour, injecting frequency and identification with drug network. No significant 
differences between trial groups and between baseline and follow-up were found in 
self-efficacy and injecting risk. Therefore, the intervention was not able to show 
significant effects on behaviour, but several limitations did not allow a full analysis of 
the dataset. The importance for harm reduction strategies to highlight each piece of 
injecting equipment as a potential source of HCV infection was evidenced by the 
results on the individual analysis of injecting risk behaviour. Additionally, the change in 
illness perception should be explored in future research as a potential predictor of HCV 
reinfection and as a target for intervention. 
159 
Chapter 6   





CONSORT 2010 Flow Diagram 
Assessed for eligibility (n= 82) 
Excluded (n= 30) 
   Not meeting inclusion criteria (n= 0) 
   Declined to participate (n= 28) 
   Other reasons (n= 2) 
Analysed  (n= 15) 
 Excluded from analysis (give reasons) 
 (n= 12) 
 -      Did not receive intervention 
Lost to follow-up (give reasons) (n= 25) 
 
Discontinued intervention (give reasons) (n= 0) 
Allocated to intervention (n= 27) 
 
 Received allocated intervention (n= 15) 
 Did not receive allocated intervention (give 
reasons) (n= 12) 
- Lost to follow-up before 
intervention was given 
 
Lost to follow-up (give reasons) (n= 19) 
 
Discontinued (give reasons) (n= 0) 
Allocated to control (n= 25) 
 
 Received allocated control (n= 18) 
 Did not receive allocated control task (give 
reasons) (n= 7) 
-      Lost to follow-up before control 
task was completed 
Analysed  (n= 18) 
 Excluded from analysis (give reasons) (n= 7) 
 





Randomized (n= 52) 
ENROLLMENT 
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Chapter Seven: Qualitative study 
A qualitative study investigating the lived experience of patients with HCV 
on DAA treatment. 
This chapter presents the small qualitative sub-study to ADAPT that was carried out 
with 5 participants enrolled on ADAPT whilst concluding or having concluded their HCV 
treatment. The interviews explored experience of diagnosis, treatment experience, 
occurrence of stigma, therapeutic alliance and illness perception. Qualitative 
exploration of the acceptability of use of implementation intentions with the 
population was not possible as none of the participants of this sub-study had 
completed the ADAPT intervention. 
 
7.1  Abstract  
Background: An estimated 1% of the global population is chronically infected with 
hepatitis C (HCV). Advances in pharmacological interventions have enhanced sustained 
virological response (SVR) rates and lowered side effects associated to treatment. 
These novel therapies have been implemented now for a number of years and this 
study aimed to provide updated understanding of illness perceptions and the lived 
experience of HCV treatment amongst people who inject drugs (PWID). 
Methods: Semi-structured interviews were conducted with 5 adults who injected drugs 
on HCV treatment. The interviews took place in two Injecting Equipment Provision 
(IEP) sites in Tayside, Scotland. Data was analysed using thematic analysis, applying an 
inductive approach with experiential and essentialist orientation, as it aimed to 
understand and voice the experiences and perspectives of participants. 
Results: Three overarching themes were identified in the interview transcripts: 1. 
“Changing illness perception”, which provided an insight into the journey that 
participants embarked on from diagnosis to end of treatment. It explored how their 
perception of HCV changed throughout treatment, from a dichotomy of ‘the great 
scare vs the great indifference’ to the ‘acceptance of individual and societal 
coexistence’ with the virus, to the view of a ‘de-stigmatised illness’; 2. “Shifting 
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agency”, presenting an internalised conflict of accepting and rejecting a sense of 
agency for individual behaviours, such as: a ‘socially responsible injector’; 
‘powerlessness in drug use’, as one is overcome by temptations; and ‘locus of control 
in treatment’ with healthcare staff actively providing choice and agency to patients; 3. 
And lastly, “Treatment adherence” which allowed participants to share what aided and 
hindered their treatment. 
Conclusion: Enhanced effectiveness and availability of HCV treatment is changing 
illness perception and social norms on treatment among people who inject drugs. 
Behavioural insights into sense of responsibility associated with diagnosis, sense of 
agency associated with treatment, and powerlessness associated with substance 




Hepatitis C (HCV) is a blood-borne virus that primarily affects the liver. Globally, the 
World Health Organization (WHO) estimates that 71 million people are chronically 
infected with HCV, which translates to around 1% of the global population (WHO, 
2017a). In the UK, approximately 214 000 people are infected with HCV (Public Health 
England - PHE, 2017a), with an estimated 1% of the Scottish population being affected 
(Health Improvement Scotland, 2017a). In Tayside, estimates posit that between 0.5-
0.6% of the resident population are affected by HCV. The most common transmission 
risk factor for HCV infection, in high-income countries such as Scotland, is injecting 
drug use, with around a half of all people who inject drugs (PWID) infected with HCV 
(PHE, 2019). The Needle Exchange Surveillance Initiative (Health Protection Scotland - 
HPS, 2019) in Scotland reports 57% HCV antibody positivity in people who inject drugs 
and attend needle-exchange services. This association between injecting drug use and 
HCV infection has produced a social stigmatisation of the condition and discrimination 
of those infected on multiple levels (Contreras & Jason, 2013; Treloar & Rhodes, 2009). 
The way in which the illness is perceived can have a variety of consequences on the 
experience of patients living with HCV (Jordan et al. 2013; Langston et al. 2016). 
Studies on the perception of HCV have focused on awareness and knowledge of the 
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virus (Cruz et al. 2018; El-Sayed et al. 2019; Owiti et al. 2015; Saleh et al. 2014), on 
effects of diagnosis (Fraser & Treloar, 2006), on treatment uptake (Mehta et al. 2008; 
Skolnik et al. 2019; Sublette et al. 2015) and on treatment outcome (Langston et al. 
2016), coping and adjustments (Langston et al. 2017; Langston et al. 2018; Zalai et al. 
2015). 
Most of the qualitative studies investigating the experience of patients living with HCV 
have been carried out in the Interferon era of treatment, which was associated with 
severe side effects and low treatment uptake (Butler, 2017; Grebely et al. 2011; 
Sublette et al. 2015; Treloar & Rhodes, 2009). The continuously changing landscape of 
available HCV treatments has improved not only sustained virological response (SVR) 
rates, but also diminished side effects associated with therapies (Pawlotsky et al. 
2015). More recent studies about the lived experience of patients engaging in the new 
direct acting antiviral treatments (DAA) revealed that societal and cultural 
understanding of the new therapies was not up to date (Whiteley et al. 2016; Whiteley 
et al. 2017). The interferon-free DAA regimens were introduced in 2015 with restricted 
use in clinical practice because of financial constraints (Whiteley et al. 2017). PWID, 
who represent the majority of HCV+ patients, were often still offered interferon 
treatments, as they did not clinically qualify for interferon-free treatments, mostly 
given to being diagnosed during early stages of infection and liver disease. Therefore, 
despite the start of the DAA-era, constructions and perceptions of the illness were still 
being influenced among PWID by the personal and peer knowledge and experience 
from the interferon treatment era (Whiteley et al. 2016; Whiteley et al. 2017). These 
perceptions continued to produce multiple barriers to treatment uptake and 
completion (Skolnik et al. 2019). 
This study aims to provide an updated understanding of illness perceptions and the 
lived experience of HCV treatment amongst PWID after access to DAAs had been 
broadened  (Healthcare Improvement Scotland and NHS National Services Scotland, 
2018; WHO, 2018d) and implemented in Tayside (Hickman et al. 2019; Inglis et al. 
2019; Radley et al. 2018). The findings aim to enrich behavioural insights into 
therapeutic uptake and retention and to enhance harm reduction strategies.  
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7.3 Methods 
7.3.1 Participants and procedure 
This study is the qualitative component of a larger study (ADAPT, See Chapter 4). All 
regulatory approvals (University of Dundee sponsorship, NHS East of Scotland 
Research Ethics Committee, Research & Development NHS Tayside) were received at 
the beginning of August 2019 (in the final stages of the ADAPT trial). All participants on 
the ADAPT trial that had concluded or were concluding their HCV treatment were 
asked if they would be interested in being interviewed about their experiences with 
HCV infection and treatment. All participants received verbal and written (in the form 
of a patient information leaflet) information about the qualitative study and were 
offered £10 cash to cover costs for travel and time commitment. After being 
consented, they were assigned a pseudonym to ensure anonymity. Only 5 participants 
were consented onto this study, exhausting the available population sample pool. In 
this paper, no claims are made that this number of participants can be used to 
generalise results, but there was an attempt to voice and highlight the importance of 
individual experience and perceptions of HCV infection and treatment. 
Recruitment was both planned and opportunistic, yet not biased by targeting any 
particular participant: all available participants were asked to take part in the 
interviews and all those approached agreed. Two of the 5 participants were seen for 
scheduled visits on ADAPT towards the end of their HCV treatment. Another 2 were 
seen opportunistically as they had concluded the ADAPT study and their HCV 
treatment but had accessed the IEP service whilst the researcher was on site. One 
participant had been released from prison and was contacted by one of the nurses, 
and whilst on the phone was asked if he’d be interested in participating in the 
interview, so a time and place were arranged. 
Semi-structured interviews were conducted between the end of August 2019 and 
December 2019 by one researcher. All interviews took place in a clinic room at the 
main IEP service in two different locations, four interviews in Dundee and one in Perth, 
where participants had received or were receiving HCV treatment and where they had 
previously been seen by the same researcher for the ADAPT trial visits. Therefore, the 
researcher conducting the interviews was acquainted will all participants prior to the 
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interview taking place.  
The interviews lasted between 15 and 20 minutes, with an average duration of 17 
minutes. They were audio-taped and transcribed Verbatim. The Verbatim transcription 
reported the same words and sounds produced by participants and the interviewer, 
including ‘ehm’ and ‘uh’ sounds. Where possible, words were spelled phonetically in 
order to adhere to the participants’ Scottish accents, and laughs and long pauses were 
reported in square brackets. A member of the research team checked the transcripts 
for accuracy against the recording.  
It was not possible to qualitatively explore the acceptability of using implementation 
intentions during the interviews. Four out of the 5 participants in this qualitative study 
had been randomised to the control group in the quantitative study component. The 
only participant randomised to the intervention group never completed the 
intervention as he was incarcerated after the baseline visit (with the intervention being 
carried out on visit 2). 
 
7.3.2 Analysis 
The data was analysed using thematic analysis. Thematic analysis was chosen because 
of its relative flexibility allowing for identification of semantic meanings in the data but 
also for interpretation and exploration of latent meanings and assumptions ‘hidden’ 
amongst the data (Braun & Clarke, 2006). A six-phase approach was applied to the 
thematic analysis (Braun & Clarke, 2006), which was carried out manually, i.e. without 
analysing software. Firstly, all 5 interview transcripts were individually read and reread 
by two authors (AM and FS) to get more familiar with the data. Transcripts were 
annotated during this process. Phase 2 involved the initial generation of codes. Both 
semantic and latent levels of meaning in the transcripts were coded. Interpretation of 
the content of the data was deemed effective to delve deeper into the hidden 
meaning behind participants’ narratives. Phase 3 involved the generation of themes. In 
this phase, it was particularly useful for the two researchers conducting the analysis to 
discuss the identified codes and potential themes. This discussion led to the generation 
of themes to make sense of the data, identifying where codes overlapped and when 
themes were recurring throughout transcripts. The codes and themes were discussed 
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by the two researchers to improve analysis accuracy and reduce bias. During phase 4, 
the developing themes were reviewed in the context of the full dataset. Quotes were 
selected from the individual transcripts and catalogued under themes and sub-themes 
or simply as standalone codes. The themes were then once again reviewed against the 
full dataset to ensure the data was fully captured in these findings. Phase 5 involved 
defining and naming themes, by ensuring they were focused, related to other themes 
and addressed the research question. Finally, phase 6 involved writing up the findings, 
which continued to involve analytical, procedural and conceptual thinking. This process 
continued the exploration of the themes, investigating their relation to each other and 
to the research question, in order to create a narrative supported by the data. 
The data coding and analysis (Phases 2 and 3) was mainly inductive, using a bottom-up 
approach to allow analysis to be driven by the content of the data. It is, however, 
important to recognise the inherent bias of the researcher who knew the participants 
and had carried out the quantitative component of this research, therefore being 
influenced by concepts and topics which had been or were being concurrently 
discussed with participants in ADAPT, presenting a degree of deductive influence to 
the analysis. The analysis orientation was experiential and essentialist as it aimed to 
understand the experiences and perspectives of participants, with the researcher 
making sense and giving voice to what the participants reported and trying to 
understand how the participants themselves made sense of their own experience of 
living with HCV and being treated (Braun & Clarke, 2006).  
An experiential orientation allows the participants’ views, meanings, perspective and 
experiences to be explored by the participant themselves as they use language to 
reflect internal categories of understanding. It allows the researcher to hear from the 
participant directly how they see, perceive and understand the world around them 
(Braun & Clarke 2013; Mcleod 2011; Reicher 2000). The polar aspect to the 
experiential orientation is the critical one, which interrogates the meanings and 
experiences voiced by the participants, exploring them through the way narratives are 
phonetically and semantically constructed, through factors that influence them, and 
particular meanings and representations hidden behind the data. In this orientation, 
the interpretation carried out by the analyst is given more weight than the 
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interpretation carried out by the participants when they voice their experience (Braun 
& Clarke 2013; Mcleod 2011; Reicher 2000). 
An essentialist method of analysis reports the reality lived by the participants, their 
meaning and experiences, with a belief that these are natural phenomena. The 
opposing method of analysis, constructionism, seeks to understand the socially 
constructed reality of events, meanings and experiences and how these are 
constructed using language as a vessel interpretation (DeLamater & Hyde, 1998). 
Although this study was the qualitative component of a larger study, the design of the 
two studies was concurrent, as both ran at the same time, recruitment took place 
contemporarily and analysis was run independently. The concurrent design was 
selected in order to investigate convergence of results yet allowing both datasets and 
analyses to be independent from one another. The results from the quantitative 
component and those of this qualitative component will be integrated in the 
discussion chapter (Chapter 8). 
 
7.4 Results 
All 5 participants were white Scottish. One was female and 4 male, which closely 
represents the female gender split in the quantitative component of the trial (24%). 
They were all current injecting drug users when consented on ADAPT. Mean age was 
33.4 years old (range 23 – 41 years old), slightly younger than the quantitative 
component of the trial with mean age of 37.4 (range 22-55). Genotype 3 to genotype 1 
ratio was 3:2, mirroring the exact genotype ratio in the quantitative component of the 
trial. All 5 participants achieved a sustained virological response 12-weeks post 
treatment. Three overarching themes and 8 themes were identified in the interviews 
and are presented below.  
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7.4.1 Changing illness perceptions 
7.4.1.1 The great scare VS the great indifference 
The participants reported dichotomous perceptions of HCV as an illness when they 
were diagnosed, some frightened by the diagnosis, with the test result being a life 
defining moment, whilst the others indifferent as if nothing had changed. All 
participants were clients of the needle-exchange, with harm reduction messages being 
instilled habitually and most of them being tested regularly for blood-borne viruses 
(BBVs). Despite this, for some, HCV was an unexpected diagnosis. A sense of unrealistic 
optimism left participants scared and in disbelief: 
 
“Oh I felt, my legs went all jelly, and and, I was upset. Ehm. Gobsmacked. I 
couldn’t believe it.” David, 33 (years old) 
“I just, I want to come in and get tested because I knew I was injecting [but] I was 
shocked. [...] Cause like, I wasn’t expecting to have it [...] I was kinda 
thinking like ‘Uhhhh!’, took aback, a back seat, and was like ‘oh no’. And I 
was, I was scared.” Laura, 23 
 “Yeah, yeah, I was scared. I had a, a horrible feeling all the time, and and I was 
wondering to myself what, what is it? [...] I was, I was putting it down to 
anxiety, just putting, putt, Pushing it to the side and that, And then it got 
real, come on and got tested and everythin’” Jason, 41 
 
Whilst on the other hand, some participants felt the diagnosis was just confirmation of 
something they knew already, portraying a sense of indifference to their condition: 
 
“Ken what, at the time I wasnae really shocked cause I was daeing stupid things 
with needles and [...] I think I thought I knew I had it, just cause of stupideh 
things I waes doing.” Peter, 32 
“Ken what? Deep down I think I ken I had it anyway, so it wasnae any surprising 
news.” Gordon, 38 
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However, the perception of HCV as an illness transformed throughout the participants’ 
experience of living with the illness and treating it. This shift in perception was 
particularly marked at the end of the treatment, when the perception dichotomy 
seemed to have swapped: those scared of HCV having dealt with their fears and 
learning from their treatment experience; whilst those indifferent being wary of the 
health consequences of having HCV, suggesting a positive influence of being in contact 
with healthcare staff: 
 
“I think..Yeah it could be a lot scarier, it could be a lot scarier. Like you say 
interferon and that if it was still at that stage it could be a lot scarier. But 
because the treatment is easy..Ehm I mean I, I, I’m not playing down hep C, 
I know it’s a bad thing. But the treatment that’s there for us is excellent, it’s 
excellent “ Jason, 41 
 “Aye. I never even, it never seemed to affect my everyday life hevin’ it like, but 
kennin’ that it was, that it was there and it was, doing your liver in. Then at 
least, at least I could have stopped that, ken what I mean” Gordon, 38 
 “Means everything to be honest with you [being HCV-free]. Yeah. It was either 
life or death eh. And sometimes. Cause it’s gonna kill you in the end, ken.” 
Peter, 32 
 
7.4.1.2 Acceptance of individual and societal coexistence  
At a personal level, there seemed to be a shift in illness perception in light of an ‘easy’ 
treatment experience, and, at times, after a comparison with other BBVs. There was a 
sense of having HCV as being normal, because it did not have negative effects on 
everyday life: 
 
 “I’ve been injecting, I’ve been an IV user all my life, well not all my life. But 
through ma, adult life. Ehm, And I never, never had anything like this 
before. But it’s nothing, nothing eh too bad, it’s curable. And with the 
medication obviously, which is quite, quite amazing. [...] It’s...just feel 
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normal. Get up in the morning. Take my tablet. Nothing’s different.” David, 
33 
 “In a, in a way I waes kinda glaed it was hep C [yeah?] nothing else, ken what I 
mean..oh, God no, HIV or anything.” Jason, 41 
 
Yet, a feeling of resignation transpired for the sense of ubiquity of HCV at population 
level among PWID, which increases the risk of getting infected again as the virus 
presents itself as unavoidable: 
 
“Ken what it’s just normal now. Eh.[...] Eh. You no get rid of it. Ken, It’s always 
gonna be there, is it. [you got rid of it] Eh, it’s keeping it staying like that 
though. Cause too many people got it. People that dinnae ken they got it.” 
Peter, 32 
 “It’s like, mes mes, mest people I think, that, bang up probably got it and dinnae, 
dinnae know [...] eh. Sometimes is easier just to put the blinders up.” Jason, 
41 
 
7.4.1.3 De-stigmatised illness 
The sense of ubiquity of the virus in the population, which produced negative 
perceptions on one’s own sense of agency and powerlessness against the infection, 
also seemed to have a positive effect on reducing stigma towards the illness: 
 
“I dinnae think it’s as much as a, a deal now as it used to be, cause like, it used to 
be “ah stay awae from him he’s got hep” but it’s not like that anymair. Like, 
every 3 or 4 people that’s used drugs have probably had it or have it or 
have had it before, so..it’s not so bad now. Like few years back it was well 
mair stigmatised than it is now. Now people think right well I can get 
treatment in 6 weeks and that will be awae.[...]I dinnae think, they still 
dinnae want it, but they ken that it’s an easier treatment. So they’re not as 
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scared of it, but then again hep C is hep C it still ruins your liver so I dinnae 
think naebody wants it, ken what I mean. That’s it.” Gordon, 38 
“Yeah people could judge, yeah.  You don’t know who’s out there that will judge 
you. Nah fe, fe I’ve had it, I’ve been been alright. Nobody’s judged me. 
Nobody’s ehm not been any stigma about it” David, 33 
 
However, one participant reported experiencing stigmatising behaviour among his 
family members, who did not use drugs. He linked the behaviour to ignorance on the 
subject:  
 
“I told my mum and my sister.  But I was feel, I was getting, eh like, my mum, 
mum was geein’ us a certain cup and I was thinking to myself how come I 
keep on getting the exact same cup every single time I come in here, ken 
what I mean. And, And I figured oot, cause..[had hep C] Yeah, But I 
understand that cause my mum, I think my mum had to look it up on the 
internet and stuff cause when I first told us she was like ‘what’s that?’” 
Jason, 41 
 
7.4.2 Shifting agency 
7.4.2.1 Socially responsible injector 
The de-stigmatised nature of HCV among PWID in this study made it possible for 
participants to be open about their diagnosis with their peers. This required a high 
degree of agency, as participants were taking the responsibility of informing peers and 
allowing them to make informed decisions (about sharing drugs and injecting 
equipment). This seemed to create an image of socially responsible injector, but it also 
allowed the participants themselves to shift the sense of responsibility of having the 
virus to others, by letting their peers make that informed decision to share injecting 
equipment (so if they acquired the virus they could not have blamed the participants): 
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 “No I’m honest with people. If I’m having, like [a charge with someone else] 
Yeah, like, I’ll say to them , like look I’m not gonna lie, but hep C. I says, but 
I’m on treatment for it, so.” Laura, 23 
“I would tell them. Ken, especially if they were gonna use I was, I’d say to them 
“look I’ve got Hep you cannae use wi’ me, you gotta get yer ain stuff”. So in 
that respect it put me in position to need to tell certain people, ken? But. 
And. [they would react like..]“Well at least you telt us” ken, cause I never 
got told.” Gordon, 38 
“But eh.. he, heving hep C, jee you get people that go aboot that got it and they 
won’t tell anybody that they got it, ken like I would tell people if I had it. 
Ken what I mean, I’d say ‘listen, listen I’ve got hep C, so if you’re wantin’ to 
ge’ a hit, ge’ a hit, but if you’re no, if you dinnae, you got first I go whatever 
ken? but I just get people that don’t even tell you they got it, in the middle 
of the treatment and then they tell you they’ve got it and then you’re like 
‘what, what’s the point in that?’ it’s stupid.” Jason, 41 
 
Although the decision to share equipment was bestowed upon their peers (creating 
the socially responsible injector), the openness about their diagnosis put the 
participants at increased risk when injecting equipment sharing did occur. There was a 
sense of duty for sero-sorting, given their own HCV status was known, coupled with a 
sense of safety because they were not infecting anyone else: 
 
“Like, we used clean needles, like everything is clean. It’s just like, soocking up of 
the pot. I do A’s [friend] first and then I do mine. So that it’s safe.” Laura, 23 
 “They would go first; they would, they wouldnae go awa’ [laughing] they would 
go first [laugh]. [did you know if they had it? Did they know if they had 
it?(HCV)] No, they didn’t know if they had it..” Jason, 41  
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7.4.2.2 Powerlessness in drug use 
Shifting the sense of responsibility away from the self was also part of the reasoning 
why participants continued to use drugs and put themselves at risk. This 
powerlessness was particularly evident for Peter and Jason, who described how 
difficult it was to fight temptation due to their social environment: 
 
“Just need to stay awa’ fae the needles. That’s my fucking problem eh.[or get 
clean ones] I do all the time but when you’re rattling you’re feeling that 
shite and somebody’s got a pin, like my ex girlfriend, I think it was her eh, 
sharing needles and, not caring. But. Naething to dae. I dinnae want to 
[share], but It just happens, eh. [...] See what happens when I go into town 
now. Bump into people and they think you’re back into it. And. Nah, I’ve 
had enough of it eh. I need to gi’ up. Drugs are for mugs eh. {But] Eh, 
naewhere to stay and, staying wi’ fucking idiots, and end up jagging. Stupid 
eh. [temptation] It’s always there, it’s always there, it’s always gonna be 
there. [inaudible] the mentality to say no. I cannae do it eh” Peter, 32 
“Cause environment is a big thing. Because in S. lane [hostel 1] it was all people 
just on drugs and there’s door here door there, door there and door there. 
And everybody, 2 different people selling drugs in they 4 doors. So you’re 
like Phf.  Just you’re facing it awe the time. So when I got moved up there 
[hostel 2] I was like ‘oooh bliss, bliss’ [It must be really difficult] Yeah it is. 
Especially if you have nae money and aeverybody’s running around rattling 
and you’re like..ken” Jason, 41 
 
7.4.2.3 Locus of control in treatment 
The nurses providing the HCV treatment, notwithstanding wanting to treat as many 
people as possible, applied trauma-informed principles to their practice. They built 
safe, trusting and collaborative relationships with the patients, and facilitated their 
choices over their own treatments, about whether they wanted to be treated or not, 
thus empowering the participants and handing them the responsibility for their own 
173 
Chapter 7   
treatment. This helped shift the participants’ locus of control from external to internal. 
In a social environment where often these participants have little agency, due to 
substance use services using negative operant conditioning to control behaviours, they 
commented on the sense of free will they felt in regards to obtaining HCV treatment: 
 
“Yeah. Cause they did say, like, you don’t have to take it. We’re not forcing you to 
take it. But if you take it, then, you could get rid of it. And I was like, I want, 
I want rid of it.” Laura, 23 
“No it was kinda mair or less saying that if you want the chance there it is, yeah 
here it is, tak it if you want it, if you dinnae want it then [it’s your own 
decision] yeh yeh yeh. [...] this is your treatment yeah that’s it yeah” Jason, 
41 
 
Jason also felt responsible to champion the HCV treatment and reduce his peers’ 
anxieties: 
 
“Oh brilliant. It’s great. It’s brilliant. It’s, It’s quite funny now you hear people 
saying ah ah chatting to them ‘now I’ve got hep C’ and I’m like ‘dinnae 
worry about it, C. [nurse] will sort you oot, and the rest will sort you oot, 8 
weeks done, 12 weeks it’ll be gone, it’s brilliant’. Say you gotta tell people 
ken I suppose to help people after they’re all like ahhh pure all that worried 
about it ken.” Jason, 41 
 
7.4.3 Treatment Adherence 
7.4.3.1 Facilitators 
Facilitated by the internal locus of control experienced in relation to their treatment, 
participants perceived treatment as being easy to take, with no issues arising in 
relation to attending for the dispensing of medication and/or adhering to the daily 
dosage. The sense of freedom of having a choice was present throughout the 
treatment:  
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“You knew that when your 2 weeks were up your last 2 pills were gone so you 
need mair anyway. So if you wanted to continue the treatment you’d, you’d 
have to come around to take the pills anyway, so it was easy in that 
aspect.” Gordon, 38 
 
Participants spoke about how easy the treatment was and therefore easy to forget one 
was on any medication at all. It had no effects on day-to-day life and most reported 
having strategies and forming habits in order to remember to take the tablets: 
 
 “Nothing. Nae side effects. Honestly, nothing, noth. I cannae think of..[...] It was 
just like not being on anything aye, there were nae side effects that I could 
remember, whatsoever.” Jason, 41 
“It’s easy, easily forgotten, Ehm sometimes if you’s no there. I’ve got them on my 
bedside cabinet so when I wake up in the morning I’ll take it.” David, 33 
“Aye, aye cause they were always in my top drawer where my socks were so 
that’s was..every time I opened the drawer I would see them so I would 
remember to take them. [And] you knew that when your 2 weeks were up 
your last 2 pills were gone so you need mair anyway. So if you wanted to 
continue the treatment you’d, you’d have to come around to take the pills 
anyway, so it was easy in that aspect.” Gordon, 38 
 
Vicarious experience also facilitated treatment adherence, as knowing what the 
treatment was like before starting it, or knowing how bad older treatments 
(Interferon-based) had been in comparison to the newer treatments (DAAs), allowed 
participants to create outcome expectancies about treatment: 
 
“So obviously because K’s [partner] gone through treatment and cleared it up and 
that. I done it, I’m doing it as well [...] Plus plus I’m quite optimistic it’s 
going to work for myself. Cause I knew it worked, I knew this is gonna, this 
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is gonna work for myself. Yeah. So, if it doesn’t work then it’ll be.. Not 
happy [laugh]” David, 33 
“I got the new treatment eh so, I was only, I was only taking the tablets so, so it 
was fine to me. Didnae really make any difference to my everyday life. Ken 
like that eh, that other stuff, interferon aye, nothing aye nothing like that 
ah!” Gordon, 38 
 
Experienced peers, the nurses and the staff of the IEP service all provided a supportive 
role and facilitated treatment: 
 
“What helped me? My fiancé, yeah, definitely my fiancé. Pushed me. Which was 
a good thing. [And] Staff at clinic. Always supportive and welcoming. 
[inaudible] ‘Oh I’ve not seen you here in a while’ I says ‘yeah’, how you 
doing and things like that, so it’s. [...] always chatting to me, and wanting 
to know how you are, and things like that, yeah” David, 33 
 
The accessibility and familiarity of the IEP service allowed participants to feel at ease 
about getting treatment, in an environment they knew, with people they had seen 
before, whilst also providing a level of anonymity given the variety of services offered 
under one roof: 
 
“[getting treatment in IEP] Oh, it’s made it, made it easier here, a lot easier yeah. 
Cause I know a lot of people in here” David, 33 
“Cause I was here for my drug treatment anyway, so...so it was easy just to pop 
in, and every time I had an appointment I could pop in and check up, ken 
what I mean. What the score was with the results or that, so aye.” Gordon, 
38 
“Yeh, straight away, nane, nane of this you right you have to go here and dae this 
and then dae this and dae this. [...] Eh, when I came in here at least I knew 
people fae coming in here fae needles and that, at least I had a, at least I 
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knew your faces at least. Yeah I had a relationship with yous at least. So, so 
it was a lot easier coming in here eh. I think if I’d have to go to a chemist or 
somethin’ I’d be a bit freaked oot. [would you prefer the chemist now that 
you are on daily methadone pick-up?] No I’d rather it’d still be here [yeah]. 
Eh. Cause it’s quiet, it’s out the wae, naebaedy knows kinda thing, ken what 
I mean.” Jason, 41 
 
7.4.3.2 Barriers 
For some participants accessibility could be a barrier to treatment, given the service 
had defined opening hours (Monday-Friday 9am-5pm). Laura (on daily pick-up) 
reported HCV making her feel fatigued. This affected her sleep and her ability to pick 
up her medication daily: 
 
“Just slept in [...] Annoying...cause I don’t know all the times that yous close at, 
like, everyday. I ran down, every day I was running down and then it was 
like, ‘closed’, [laughs]” Laura, 23 
 
Forgetting to take the tablets was a problem mentioned by the participants who were 
dispensed with a fortnightly dose. Having little to no effect on daily life, forgetting to 
take the medication was irregular but common across the sample: 
 
“It was probably just sitting there and seeing the bottle and night and just go and 
remember. Cause you forget cause it’s that easy you know” Peter, 32 
 
The size of the tablets was commented on by most participants, being referred to as 
“horse tablets” by Gordon, but it did not affect the participants in a negative way. Near 
to no side effects were reported by participants, with only one participant reporting a 
headache that didn’t last long enough to put him off getting treated: 
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“A wee bit of a headache, nausea at first, first eh tablets, yeah, but then that 
went away, died down. And it just levelled down.” David, 33 
 
7.5 Discussion 
Qualitative approaches have helped to understand the lived experience of HCV 
throughout the years as HCV treatment was in the process of being optimised 
(Dowsett et al. 2017; Treloar et al. 2013a; Whiteley et al. 2017). Studies on the lived 
experience of HCV in patients on treatment have previously been carried out when the 
DAA treatments were still novel and patients had little experience of them, presenting 
a general lack of personal and peer knowledge given interferon-based treatments 
were still at the forefront of patients’ minds (Whiteley et al. 2017). This study provides 
an updated understanding of illness perceptions and the lived experience of HCV 
treatment amongst PWID a couple of years after access to DAAs was broadened in 
Scotland  (Healthcare Improvement Scotland and NHS National Services Scotland, 
2018; WHO, 2018d) and implemented in Tayside (Hickman et al. 2019; Inglis et al. 
2019; Radley et al. 2018).  
 
7.3.1 Change in illness perception and de-stigmatisation 
The perception of HCV as an illness presented itself as a fluid concept in this study’s 
findings. The changing perception provided an insight into the journey that 
participants embarked on from diagnosis to end of treatment. Two polar reactions to 
diagnosis were observed in the data. The reaction of disbelief and shock is present in 
literature from all therapeutic eras (Dowsett et al. 2017; Fraser & Treloar, 2013; 
Whiteley, 2017). Those who were shocked and scared by their diagnosis, tended to 
present a level of unrealistic optimism about their susceptibility to the virus. Although 
they were aware of some degree of susceptibility, as suggested by them engaging in 
regular testing arranged annually, they still held the belief that becoming infected was 
not going to happen to them. Unrealistic optimism is a common trait observed in the 
general population and published literature suggests that those with unrealistic 
optimism tend to undermine their actual risk, worrying less about negative 
consequences and applying fewer risk reduction strategies, which might actually lead 
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PWID to an increased susceptibility to infection (Harris & Middleton, 1994; Weinstein, 
1982). The opposite reaction, that of indifference, is observed in previously published 
literature even during the interferon-era of treatment (Rhodes & Treloar, 2008; Roy et 
al. 2007; Wozniak et al. 2007), and is associated with a perception of susceptibility to 
the infection based on past behaviour and knowledge about the virus. The perceived 
susceptibility was also linked to the belief that HCV was ubiquitous in the PWID 
population, creating the perception of HCV being an unavoidable and accepted 
consequence of injecting (Rhodes et al. 2004; Rhodes & Treloar, 2008; Roy et al. 2007; 
Wozniak et al. 2007). The ubiquitous nature of the virus coupled with the absence of 
any symptoms brought on by the virus, led participants to accept the virus as 
coexistent, both in their body and in their social network, without affecting their will 
and motivation to be treated and cured. The data suggests that this internal and 
external coexistence may have produced a de-stigmatisation of HCV as an illness 
among PWID. Participants’ reports of no experiences of stigma was a novel finding 
compared to the vast amount of literature that focuses on the terrible lived 
experiences of stigma among HCV-positive PWID (Fraser & Treloar, 2013; Treloar et al. 
2013a; Treloar & Rhodes, 2009; Whiteley et al. 2017). When asked about the 
experience of any stigma, participants in this study mostly focused on the experiences 
relating to HCV mentions or conversations with their peers. This would suggest there 
has been a reduction in stigma about HCV infection among PWID. One of the 5 
outcomes established by the Scottish Government (2015a) in their updated framework 
on sexual health and blood borne viruses (BBV) specified a need for a societal attitude 
change towards sexual health and BBV to become more positive, non-stigmatising and 
supportive. The results of this study would seem promising in this respect, yet no firm 
conclusions on improvements on stigma and attitudes towards HCV can be drawn at a 
societal level given these were not mentioned by participants, because absent, 
forgotten or not considered worth mentioning. The de-stigmatising theme presented 
referred to attitudes and stigma among PWID only. De-stigmatisation among PWID 
might be the result of more effective treatment with fewer side-effects and of the 
relative widespread nature of HCV within the PWID population in Scotland with 
reports of 57% HCV antibody positivity in PWID who attend needle-exchange services 
(HPS, 2019; Rhodes & Treloar, 2008). Participants did not feel shame associated with 
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their HCV status, possibly because they believed most of their peers either had or had 
previously had it, in addition to the fact that they were on treatment and efficiently 
coping with it (Langston et al. 2017; Langston et al. 2018; Zalai et al. 2015). 
 
7.3.2 Shifting agency 
The process of de-stigmatisation encouraged participants to be open about their 
condition with their peers. The findings on shifting agency presented an internalised 
conflict of accepting and rejecting responsibility for individual behaviours. Agency is 
the capability to make free choices and act independently (Barker, 2002). The ‘socially 
responsible injector’ presented in Plumridge and Chetwynd (1998) discourse analysis 
revealed the moral intricacies of lending and borrowing injecting equipment among 
peers and the concept of shifting agency.  A discourse of moral exoneration for 
lenders, who were altruistically lending because of the need of peers, meant 
borrowing came with the duty to accept the consequences of one’s own decisions; yet 
borrowing was exonerated from moral culpability too because of the individual’s 
powerlessness in front of the need to consume drugs to annul withdrawal symptoms 
(Plumridge & Chetwynd, 1998). The interesting aspect of the findings in this study’s 
cohort is that participants introduced the concept of the ‘socially responsible injector’ 
as the actor, the lender of the transaction. However, in reality the ‘socially responsible 
injector’ came to signify the openness about one’s infection status, the lending of 
equipment and drugs but also the social responsibility about letting the ‘borrower’ use 
first, putting the lender at risk of further infection: a sort of ‘ultimate socially 
responsible injector’. The sense of powerlessness described by Plumridge and 
Chetwynd (1998) was also voiced in this study’s findings, with a shift in responsibility 
and perceived behavioural control. Temptation was too hard to fight and social 
environment was the primary culprit, shifting away the moral culpability from the self 
and assigning it to the social environment, with temptation becoming a social 
production (Gyarmathy et al. 2009; Muñoz et al. 2015; Rhodes et al. 2005; Rhodes & 
Treloar, 2008, Sherman et al. 2001).  
Even though for drug use the sense of agency was rejected through a loss of willpower 
in front of temptation and locus of control being placed externally, this was not the 
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case for HCV treatment. This was perceived differently due to the healthcare staff 
providing it. The nurses providing treatment for participants applied trauma-informed 
principles to their practice (NHS Education for Scotland, 2017). They built safe, trusting 
and collaborative relationships with the patients, and allowed them to choose freely 
whether to get treatment or not, allowing participants to build agency. This helped 
shift the participants’ locus of control from external to internal. In healthcare settings, 
PWID are often custom to having very little agency, due to substance use services 
using negative operant conditioning to control behaviours. Opiate Substitution 
Therapy (OST), for example, is supervised, controlled, restrictive and part of a system 
that allows the provider to control the individual by the means of punishing strategies 
(Duff, 2013; Earnshaw et al. 2013; Fraser, 2006). This type of power dynamic between 
provider and patient offers little chance for patients to increase their agency and 
internalise the locus of control. The approach that the nurses applied when offering 
treatment allowed participants to experience a sense of free will and choice, and 
allowed them to act independently, welcoming a sense of ownership over the desire to 
be cured and a sense of agency over their treatment (Braun et al. 2018). Involving 
individuals in their own treatment has been shown to improve outcomes and 
experience (NHS England, 2014; Vahdat, 2014). This study’s findings suggest that 
National Health Services’ recommendations of involving patients in their own care 
(NHS England, 2014) and utilising a trauma-informed approach (NHS Education for 
Scotland, 2017) ought to be implemented as they could improve PWID’s experience of 
general and specialist health services. 
 
7.3.3 Treatment barriers and facilitators 
On the topic of health service improvement, participants also shared the factors that 
facilitated or hindered their treatment. Previous research has widely reported on 
barriers and facilitators of HCV treatment (Dowsett et al. 2017; Mehta et al. 2008; 
Skolnik et al. 2019; Treloar et al. 2013a), as understanding these factors is 
indispensable to improving experience of treatment for patients and increasing 
treatments delivered to the population. The perspectives of people living with, and 
getting treated for, HCV are key to developing evidence-based clinical and policy 
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decision and better patient-centred healthcare (Dowsett et al. 2017). The findings of 
this study indicated a tendency for participants to report facilitators to their treatment 
more often than barriers, as generally the treatment was perceived as easy and 
immediately available. They perceived facilitators of treatment to be mostly of social 
nature. Patient-provider relationship, linked to the previously discussed trauma-
informed approach used by the nurses to build safe, trusting and collaborative 
relationships with the patients, allowed participants to have choice, control and a 
sense of agency over their treatment. This helped them to be confident in forming 
personalised habits in order to remember to take tablets daily. They built knowledge 
of their treatment and experienced virtually no side-effects, generating the belief of an 
easy treatment, especially in those whose peers experienced HCV treatment using 
Interferon and socially shared such an experience. This exchange of experiences 
relating to previous treatment led to vicarious experience becoming an important 
facilitator. In Bandura’s (1977) work on self-efficacy, vicarious experience is one of the 
most important factors involved in building confidence in one’s own ability to perform 
a behaviour, together with mastery experience, persuasion and affective/physiological 
feedback. Knowing a peer who had gone through the same treatment and had been 
cured built the positive belief in the participants that they would also have been able 
to experience a successful treatment. In addition, the familiarity of the location where 
the treatment was provided was reported in the findings as a major facilitator, with co-
location of services, familiarity of setting and familiarity with staff (admin, healthcare 
and IEP) playing an important role in facilitating treatment. Co-location of substance 
use and HCV treatment services has previously been reported in the literature as an 
important factor in facilitating HCV treatment.  It helps patients to avoid stigmatising 
and discriminatory experiences in unfamiliar healthcare facilities (in particular hospital 
settings) and patients’ familiarity with the environment and the staff reduces potential 
anxiety and discrimination since trusting and positive relationships are already 
established (Harris et al. 2013; Treloar et al. 2013b). 
Findings on barriers to treatment were scarce in this study and they focused on more 
logistic factors (compared to the more social nature of facilitating factors). Accessibility 
of the service, although reported mostly as a facilitator because it was a known 
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physical and social environment, could also act as a barrier because of its defined 
opening hours (9am to 5pm), which were perceived by some as restrictive. The ease of 
the therapy, also a facilitator, could work against patients as they would forget they 
were on any medication at all and therefore forget to take the tablets. To combat this, 
all participants had strategically stored tablets in places (contextual cues) that would 
automatically function as daily reminders (such as bed side tables or sock drawers) in 
order to facilitate forming a daily habit. Habit formation allows actions to become 
automatic, with automaticity in turn reducing the cognitive load and the need for 
motivation or conscious action (Gardner et al. 2012; Lally & Gardner, 2011). All 
participants in the study achieved an SVR, which would suggest the strategic reminders 
and habits that they formed facilitated adherence and cure. 
The lack, or very mild presence, of side effects and the ease of the DAA therapy 
influenced participants’ change in illness perception throughout the course of 
treatment. Perceptions and knowledge of Interferon treatment, which heavily 
influenced illness perception and treatment uptake in previous literature (Skolnik et al. 
2019; Whiteley et al. 2016; Whiteley et al. 2017), has remarkably reduced in this 
population, with knowledge and perception prior to HCV diagnosis and treatment now 
influenced by social norms of HCV ubiquity and relative ease and availability of 
treatment.  
 
7.3.4 Future research and limitations of the current study 
Further research should focus on whether this perception of HCV and HCV treatment 
influences HCV reinfection rates, as the illness continues to be considered ubiquitous 
yet non-threatening. An update on societal attitudes toward HCV in the established 
DAA era should also be the focus of further research, as stigma and attitudes were only 
mentioned at peer-level in the current study. 
The study presents a number of limitations. The study sample was very small, yet 
sufficient for the methodology applied. Thematic analysis was chosen because of its 
relative flexibility allowing for identification of semantic meanings and interpretation 
of latent meanings and it does not require a large sample size as its aim is to give voice 
to people’s lived experiences. In addition, the 5 participants were considered to be 
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closely representative of the PWID population accessing treatment and IEP services, as 
presented in the demographic characteristics result section. Participants were from 
two Scottish cities in the Tayside region, which has an estimated lower prevalence of 
HCV compared to the rest of Scotland and in which interferon-free DAA treatment has 
been available for several years to the PWID population through clinical trials and 
standard care. The two Scottish cities are relatively small in size (of between 50 
thousand and 150 thousand inhabitants). The networks of people who use drugs are 
therefore geographically and socially restricted, which facilitates communication and 
shared knowledge among peers, which might have impacted on the shift of HCV 
perception, given vicarious experience of DAA treatments would have been quite 
common amongst the sample. In addition, as stated in the methods section, the 
interviewer was acquainted with all 5 participants as they had taken part in the 
quantitative component of the trial. This prior established relationship might have 
influenced answers to questions of experience of treatment, such as all participants 
reporting more facilitators than barriers to their treatment. 
 
7.3.5 Conclusions 
In conclusion, the findings enhance the available understanding and knowledge 
surrounding the perception of HCV as an illness in PWID and their lived experience of 
treatment. The rapidly improving treatment effectiveness and availability in Scotland 
has, for the first time with this study’s findings, shown that illness perception and 
social norms on HCV treatment are changing accordingly among PWID. Behavioural 
insights into sense of responsibility associated with diagnosis, sense of agency 
associated with treatment but powerlessness associated with substance temptation 
and HCV ubiquity will aid therapeutic uptake and retention for people who inject drugs 
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Supplementary File 7.1 
 
Interview schedule for ADAPT sub-study  
 
1) Tell me a bit about what it’s like for you to have hepatitis C.  
2) What was your experience of hepatitis C diagnosis? 
3) What led you to seek treatment? 
4) Tell me about the barriers you have encountered to get treatment. 
5) What has facilitated getting you onto treatment? 
6) What does getting treatment mean to you? 
7) What has been your experience of treatment? 
8) What was your relationship like with the nurses who gave you treatment? 
9) Tell me about the barriers you have encountered whilst on treatment. 
10) What has facilitated your adherence to treatment? /taking your tablets? 
11) What would it mean for you to be hep C - free?  





Interferon vs DAA if experienced both + reinfection 
Illness perception – feeling during diagnosis 
Stigma (from self or others) 
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Chapter Eight: Discussion 
This chapter presents an overall discussion of the results presented in the thesis. It 
aims to integrate the findings of studies 3 and 4 into one final discussion. The 
concurrent design of these two studies allows the analysis of the convergence, 
divergence or contradiction of the findings of the two datasets in an overall discussion, 
presenting the implications of these findings, the limitations of the studies and 
suggestions for future research. The chapter also aims to provide narrative reflections 
on lessons learnt from planning and carrying out the study with a population which is 
traditionally considered to be ‘hard-to-reach’, people who inject drugs (PWID) (van 
Baelen et al. 2020). 
 
8.1 Primary study findings: creating implementation intentions with 
PWID 
Models of behaviour change such as the Theory of Planned Behaviour (Ajzen, 1991) 
highlight the importance of intention to perform a behaviour as a direct predictor of 
the behaviour itself. However, intentions do not always translate into actions 
(Prestwich et al. 2006; Sheeran, 2002). Implementation intentions are used to change 
behaviour by enabling individuals to recognise a high risk situation, committing to an 
action and automatically and unconsciously implementing their intention when the 
specified environmental cues are encountered (Aarts et al. 1999; Brandstätter et al. 
2001; Prestwich et al. 2006). Cognitive models of addiction, such as that described by 
Tiffany (1990), propose that drug use is triggered by cues of automatic action. 
Implementation intentions could therefore be used to redeploy these attentional 
triggers to automatically activate a counter behaviour (Prestwich et al. 2006). In this 
study, the behaviour being countered was sharing of injecting equipment.  Higher 
levels of polydrug use, in particular using heroin on top of benzodiazepines and 
amphetamines, predicts more recent and frequent needle sharing with a greater 
number of people (Darke & Hall, 1995; Darke et al. 1992; Darke et al. 1995). 
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8.1.1 Using a volitional help sheet 
The volitional help sheet (VHS) was introduced to the participants by the researcher, 
who explained what the exercise involved and offered the pen to the participant. The 
researcher explained that detailed on the VHS are some situations in which people can 
find themselves when they end up sharing equipment. Some situations may be 
applicable and some may not, and participants could skip those that did not apply. In 
addition, if they were able to think of a situation in which they shared equipment that 
was not on the list, they were asked to add it at the end of the situation list. Similarly, 
the solutions were presented as an assortment of solutions which people might devise 
to avoid sharing of injecting equipment. Some solutions might not be applicable 
personally and, if so, they were not to use them. If they could think of any of their own 
personal solutions which were not on the list, they should add them to the end of the 
solution list. The researcher read the solution list to give participants an idea of what 
was listed and then the situations were presented one by one. No participants added 
any situations or solutions to the lists. A number of the stated situations and solutions 
did not apply to all participants. 
The VHS was used as an intervention tool rather than a data collection device, so every 
participant that completed the VHS was offered the opportunity to take it away with 
them. A handful of participants did so, but most of them just asked for the VHS to be 
kept in their case report form.  
On two occasions the participant did not wish to carry out the intervention. One did 
not understand the exercise and felt overwhelmed. Limited engagement is sometimes 
associated with fear of disclosure of low literacy (Easton et al. 2013) and literacy 
cannot be assumed with patients from any background and patients are often 
reluctant to disclose any difficulties. Therefore, the researcher offered to go through 
the VHS with the participant and complete it together. The participant agreed to 
continue but the links between the situations and the solutions were drawn by the 
researcher. The other participant simply refuted they would ever be in a position in 
which they would need to share equipment and stated the exercise did not apply to 
them. Interestingly, this participant was the only one to become reinfected with 
187 
Chapter 8   
hepatitis C (HCV) (with a different genotype) out of the whole sample during the full 
follow-up period, up until the database was locked (28th April 2020). 
Several participants found one solution fitted most situations: “Then I will do 
something else instead of injecting”. Being flexible and using alternatives to injecting 
when consuming drugs is regarded as a protective harm reduction strategy. When 
injecting can only occur via sharing of paraphernalia, temporary smoking or snorting of 
heroin can help to avoid blood-borne virus (BBV) infections (McGowan et al. 2013). 
A few participants also found that some situations did not apply to them, as in they 
would not feel the need to share equipment if they were in that situation. Yet a lot of 
them described one situational example of a time in which they were most likely to 
share: “If I am tempted to share equipment when I am under the influence of other 
drugs”.   
 
8.1.2 Effects of the intervention on self-efficacy to refuse injecting sharing and on 
sharing behaviour 
In chapter 2 the use of implementation intentions on use of substances and self-
efficacy showed statistically significant small-to-medium effects of the intervention on 
alcohol use and cigarette smoking and a small effect on self-efficacy that did not reach 
significance. The significance of effect sizes provides information about how precise 
the sample-based estimates are (Ellis, 2010). These results were helpful to estimate 
the ADAPT sample size, but did not eliminate the risk of Type I error. There were no 
published studies on the use of implementation intentions with people who inject 
drugs on sharing behaviour so there was still a risk of finding a false positive effect of 
the intervention. When it came to analysing the results, however, the main issue faced 
was the lack of statistical power as a consequence of the small sample size and its 
associated risk of finding a false negative effect of the intervention (Type II error). 
Carrying out multiple univariate analyses, which is associated with an increase in Type I 
error, was therefore not considered a problem, as the risk of a false negative effect 
was still more substantial than that of a false positive one. The results confirmed these 
suspicions, as for both self-efficacy and sharing behaviour the null hypotheses of no 
difference between control and intervention groups were retained.  
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The results of the self-efficacy outcome highlighted the importance of the group sizes. 
Self-efficacy was not significantly different in the two groups at follow-up, but it did 
show a substantial effect size. When analysing this further for time differences in the 
two groups, it was clear the intervention group showed no change in self-efficacy over 
time, whilst the control group showed a small-to-medium decrease in self-efficacy 
scores between baseline and follow-up. Therefore, although implementation 
intentions did not increase self-reported levels of self-efficacy, it is unclear whether 
the intervention helped maintain participants’ level of self-efficacy to refuse sharing 
throughout a 4-week period. A complete sample size in this trial would have allowed 
the analysis of this hypothesis.  
Other behavioural interventions have reported positive results on self-efficacy and 
PWID (Pawa & Areesantichai, 2016; Robles et al. 2004), yet the current study would 
suggest that the behavioural intervention functioned as risk limitation rather than as 
active instrument producing positive change. 
The results for sharing behaviour showed a negligible effect size, regardless of the 
small sample. When delving deeper, the control group was approaching a significant 
large reduction in sharing, whilst the intervention group showed a non-significant 
small-to-medium increase. A full sample and its retention in the study would have help 
to better understand the differences in sharing behaviour between groups and time. 
Previous literature does not present the use of implementation intentions to reduce 
sharing of injecting equipment so no comparison can be drawn; however, literature 
would suggest that participants that receive HCV treatment without the addition of a 
behavioural intervention, show changes in injecting behaviour, supporting the 
reported effect size in the current study (Chapter 3; Alavi et al. 2015; Artenie et al. 
2017; Artenie et al. 2020; Midgard et al. 2017). Although most literature produced 
evidence of a change in injecting behaviour during the interferon-era of HCV treatment 
without the use of a purposely designed behavioural intervention (Chapter 3; Alavi et 
al. 2015; Artenie et al. 2017; Midgard et al. 2017), one study reported small reductions 
in injecting and sharing behaviour during DAA treatment (Artenie et al. 2020). 
These findings stand in contrast to the results reported in the meta-analysis in chapter 
2, which suggested a medium effect of implementation intentions on substance use 
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behaviour and a small and non-significant effect on self-efficacy in non-clinical 
populations (i.e. general population and students). Additionally, at baseline self-
efficacy and injecting risk were highly negatively correlated (an inversely proportional 
relationship), the higher the self-efficacy, the lower the self-reported sharing 
frequency. The results of the univariate analyses would suggest the strength of this 
correlation not to be sustained at follow-up, with the control group showing a 
reduction in self-efficacy but also a reduction in sharing behaviour, whilst the 
intervention group showed a very slight increase in sharing whilst maintaining a 
constant self-efficacy level. These results were confirmed by testing the relationship 
between self-efficacy and injecting risk at Time 2 (follow-up). 
The results of the quantitative study would benefit from clarification via a larger study, 
to more confidently report the intervention effects. However, the results that were 
found were convergent to those of the qualitative study for the injecting risk outcome. 
No difference was observed in the quantitative study between baseline and follow-up 
and participants in the qualitative study reported their injecting behaviour not to have 
changed during treatment. There was no or weak evidence for injecting frequency and 
sharing of injecting equipment changing over time during HCV treatment, both in the 
presence or absence of creating implementation intentions.  
Self-efficacy, however, was not described as such by participants in the qualitative 
study. What the study did find was that participants spoke about a sense of 
powerlessness in front of temptation, especially when under the influence of other 
drugs. This qualitative theme converged with the quantitative study when participants 
anecdotally recognised their highest-risk situation for sharing in the volitional help 
sheet as that of being under the influence of other substances. But the theme also 
completely contradicts the participants’ self-efficacy scores. A sense of powerlessness 
can be conceptualised as a complete lack of the belief in one’s own capability to 
perform a behaviour or control internal states (Lim et al. 2018; Wallston et al. 1987) 
and can present a link to low self-efficacy. These contradicting results are explored in 
the proceeding section. 
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8.1.3 Temptation, powerlessness and impulsivity 
The common recognition of participants for being under the influence of other 
substances as the highest risk situation for sharing injecting equipment could help 
explain the main study findings. Albeit reporting low levels of sharing behaviour and 
high levels of self-efficacy to refuse sharing, being under the influence of other 
substances could be moderating the strong negative correlation between self-efficacy 
and sharing behaviour.  As seen previously, polydrug use predicts needle sharing with a 
greater number of people (Darke & Hall, 1995; Darke et al. 1992; Darke et al. 1995). 
Previous research also shows that PWID are aware of the health risks of sharing 
equipment, yet sharing continues to occur irregularly for the majority of people 
(Gaskin et al. 2000; Gossop et al. 1997). This might suggest that sharing of injecting 
equipment could be characterised as sporadic, impulsive and non-rationalised. The 
reported sense of powerlessness of participants in front of temptation supports this 
view of the behaviour. A high self-efficacy to refuse, instead, requires conscious and 
non-impulsive processing of situational information coupled with conscious volition 
(Hofman et al. 2008).  
Many health promotion campaigns and harm reduction messages seem to portray 
people who inject drugs as rational and health-conscious beings who are 
autonomously responsible for their risk-taking actions (Fraser, 2004; Miller, 2005; 
Rhodes & Treloar, 2008).  These assumptions of reflective processing capabilities are a 
common element of many models of behaviour change. They tend to assume cognitive 
appraisals and cost-benefit analyses to be associated with volitional control and 
willpower over reasoned goal-directed behavioural decisions (Hofman et al. 2008). Yet 
the results discussed so far paint the picture of a behaviour (sharing of injecting 
equipment to consume illicit drugs) which is unplanned, impulsive, subject to the 
individual’s cognitive capacity in the moment, physical capacity if/when in opiate 
withdrawal, coupled with a sense of powerlessness in front of temptation and the 
complete loss of willpower due to an absolute need to consume substances. 
Dual-system models, such as the framework presented in Figure 8.1, attempt to 
integrate the orbitofrontal reflective predictors of behaviour (those reasoned goal-
directed behavioural decisions) with the amygdala-dependent impulsive influences 
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(Bechara et al. 2006; Strack & Deutsch, 2004). They assume there are two different 
systems which process information and produce either impulsive or reflective forms of 
behaviour (Bechara et al. 2006; Hofman et al. 2008; Strack & Deutsch, 2004). 
 
Figure 8.1 Dual-system framework of behaviour change prediction  
 
Source: Hoffman et al. 2008 
 
Chronic drug use reduces neural processing of the frontal regions of the brain, involved 
in executive functioning, decision making and appraisal of future consequences 
(Jentsch & Taylor, 1999). The dysfunction in the frontal lobes is also associated with an 
increase in impulsivity. Impulsivity, however, has also been identified as a pre-existing 
vulnerability marker for substance use disorders (Verdejo-García et al. 2008), 
confirming a correlation between impulsivity and drug use but rendering unclear the 
direction of the relationship and making it difficult to infer causality. Nevertheless, 
published literature has shown moderating effects of impulsivity on implementation 
intentions effectiveness (Churchill & Jessop, 2010; Hofman et al. 2008). Evidence 
shows that implementation intentions can be effective in patients with frontal lobe 
dysfunction (Lengfelder & Gollwitzer, 2000) and in patients in opiate withdrawals 
(Brandstätter et al. 2001) when they are creating intentions to perform everyday 
activities. This evidence presented a good rationale for the present study, to test 
implementation intentions in a drug-using population. 
Implementation intentions were specifically used in the current study because of their 
automatic activation of goal-directed responses as a result of unconscious 
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environmental cues (Gollwitzer & Sheeran, 2006; Hofman et al. 2008; Webb & 
Sheeran, 2007). If sharing of injecting equipment is also considered an impulsive, non-
reflective behavioural process, then it might be the case that implementation 
intentions are ‘fighting’ for a space in the ‘Impulsive Precursors’ system with the well-
established automatic impulsive reactions associated with illicit drug attentional cues. 
Although implementation intentions are automatically triggered by environmental 
cues, those same environmental cues are also triggering an effortless associative 
cluster for drug consumption, which has a positive ‘hedonic’ value associated to it (the 
hedonic value will be discussed in the subsequent paragraphs). 
Furthermore, in chapter 2, implementation intentions were defined as self-regulatory 
processes which take the form of ‘if-then’ plans and facilitate the attainment of goals 
and behaviour change (Gollwitzer, 1993). The automatic and unconscious nature of 
implementation intentions might be reduced by the self-regulatory nature of the plans 
themselves. Evidence shows that effective self-regulation requires willpower and 
control over thoughts emotions impulses and behaviour (Baumeister et al. 1994), yet 
conflicting goals such as a desire to abstain from injecting risk behaviour coupled with 
a physical need to use an illicit substance to reduce withdrawals symptoms, result in 
self-regulatory failures (Prestwich et al. 2006). Self-regulation is a limited resource. 
When self-regulatory failures occur, there is an ego-depletion and an increase in the 
vulnerability of an individual to act impulsively (Baumeister et al. 1994; Prestwich et al. 
2006). Additionally, further factors such as cognitive load, emotional distress and 
substance intoxication, all commonly observed among people who inject drugs, have 
been associated with self-regulatory disruption (Hoffman et al. 2008). 
An observation not currently stated in theories and evidence is that drug-taking is, in 
itself, a form of self-regulation.  Deficits in the ability to self-regulate emotions, 
thought and behaviour have been shown to be associated with the initiation and 
escalation of illicit drug use (Kober, 2014; Wong et al. 2013). Drug taking can be 
perceived as a positive hedonic associative cluster (Hofman et al. 2008). However, the 
body’s tolerance to substances, emotional dysregulation and the nature of addiction 
itself, can transform chronic drug taking from a pleasure-seeking activity to a pain-
avoidant one (Kober, 2014; National Institute on Drug Abuse, 2020). This is highlighted 
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by the incentive-sensitisation theory, which posits the existence of two different brain 
circuits associated with ‘wanting’ and ‘liking’ (Berridge & Robinson, 2016). People’s 
first experiences of drug taking could be argued as being hedonistic, with the reward 
(drug) being both wanted and liked (although difficulties with emotional regulation 
skills could also suggest that the first instances of drug taking are a form of self-
regulatory strategy in itself). Long-term drug-taking quickly transforms into a need to 
self-regulate and return to the status quo. Incentive salience (‘wanting’) is a form of 
motivation generated by robust neural systems which include mesolimbic dopamine. 
The actual pleasurable reward consumption (‘liking’) is controlled by smaller and more 
fragile neural systems which are not dependent on dopamine (Berridge & Robinson, 
2016).  According to incentive-sensitisation theory, drug addiction is a result of the 
amplification of incentive salience as a result of triggering cues which do not amplify 
the ‘liking’ system. This amplification is, in turn, a result of neural sensitisation of 
dopamine-related motivation systems (Berridge & Robinson, 2016).  
These motivational processes produce hypersensitivity to substance-related cues, i.e. 
attentional bias, which both implicitly and explicitly influence an individual’s decision-
making process (Cox et al. 2006; Field et al. 2006; Robinson & Berridge, 2003). The 
environmental stimuli which arouse incentive salience, are the same which 
implementation intentions try to engage to automatise a self-regulatory response 
which is in direct opposition to the dominant tendency of the consumption of a 
substance (Palfai, 2006; Rachlin, 2000). Self-regulatory abilities can be increased, and 
automaticity of selected self-regulatory processes can be enhanced, through practice 
and planning (Fitzsimons & Bargh, 2004; Palfai, 2006). Practice and planning require 
effortful, conscious decision-making to support the repeated use of skills (such as the 
VHS ‘solutions’). However, creating plans such as those when forming implementation 
intentions, allows individuals to mentally simulate practice and enables the automatic 
execution of goal-directed behaviours (Gollwitzer, 1999; Palfai, 2006; Prestwich et al. 
2006). The findings of the current study did not provide evidence for the successful use 
of implementation intentions to reduce sharing of injecting equipment and to increase 
self-efficacy for refusing sharing of injecting equipment. A one-off session creating 
implementation intentions in this study was not enough to provide the necessary 
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repeated practice to replace the dominant automatised ‘solution’ (sharing and drug 
consumption) with the desired non-sharing ‘solutions’. 
 
8.2 Other study findings 
8.2.1 Group identification 
Identification with a drug network was explored in Chapter 5 as a strong predictor of 
sharing behaviour. Chapter 6 showed that no change in group identification was found 
in the trial groups at follow-up. Levels of sharing also remained similar suggesting the 
trend of the correlation was stable over time. Evidence shows that social networks can 
have negative influences on injecting risk taking (De et al. 2007; Dunn et al. 2010; Shaw 
et al. 2007). The qualitative results slightly diverged from those of the quantitative as 
group identification with drug network did not feature heavily. When discussing the 
sense of powerlessness in drug use the influence of social networks was clear, though 
there was no explicit mention of identification with a group of peers using drugs. The 
sense of communal experience was present in the participants’ descriptions of why 
they would share equipment or give into temptation to use drugs, but there did not 
seem to be an overt psychological connection with peers. 
Social Identity Theory suggests that an individual’s sense of self is the product of the 
membership to various social groups (Tajfel & Turner, 1979). This produces social 
identities which influence people’s behaviours, perceptions, values, norms, goals and 
relationships (Haslam, 2014; Tajfel & Turner, 1979). Typically a social identity approach 
would propose group identification as a social cure (Jetten et al. 2017). This was 
evidenced in previous literature on injecting drug users and the general population 
(Chapter 3; Kumar et al. 2016; Neaigus et al. 1996; Rance et al. 2017; Sani et al. 2015a). 
It is also evidenced by the importance of social groups and social connectedness for 
substance recovery, particularly in social groups that do not support substance use and 
are able to support a social identity change (Best et al. 2010, Zwiayk et al. 2009). 
However, the results of the present quantitative study, in which group identification 
with drug network became a social curse, contradict those of the social identity 
approach that suggest group identity as a social cure (Jetten et al. 2017). Strong 
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identification with a group which is considered socially deviant, such an injecting drug 
users, has been evidenced to increase general social exclusion and stigma coupled with 
reduced self-esteem, health and wellbeing (Best et al. 2016; Savolainen et al. 2018; 
Schofield et al. 2001; Sussman et al. 2000). By identifying more strongly with a group, 
members internalise group norms (Best et al. 2016) and the group norms of drug 
networks might be a negative influence. However, the social norms regarding sharing 
of injecting equipment reported by participants (Chapter 6) were mostly critical of 
sharing of injecting equipment and were not correlated with identification with drug 
network, with no differences found by group or in time.  
 The findings on group identification in the quantitative study and peer facilitation of 
drug use in the qualitative study suggest a potential negative impact of a social identity 
on health behaviour. These findings coupled with the evidence discussed above, 
present the picture of social groups and identification as a bipolar force which can 
influence individuals both positively and negatively. This suggests integration of health 
and social psychological intervention should be explored to facilitate social identity 




8.2.2 Changing illness perception 
Perception of HCV as an illness was explored in both the quantitative and qualitative 
studies; the perception of the illness presented as a fluid and changeable concept in 
both the quantitative and qualitative studies, suggesting a degree of convergence of 
results. At Time 1, participants overall did not hold threatening perceptions of HCV. 
Some aspects of illness perception, such as concern and emotional impact, scored as 
mildly threatening. The wide standard deviation of the illness perception score was 
obvious in the qualitative study which showed two polar reactions to diagnosis and 
perception of illness threat at baseline. Similar reactions have been observed and 
evidenced in published literature. Some patients displayed disbelief and shock to their 
diagnosis (Dowsett et al. 2017; Fraser & Treloar, 2013a; Whiteley, 2017); whilst other 
patients were aware of their susceptibility and displayed indifference and a degree of 
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expectation to an eventual and inevitable diagnosis (Rhodes & Treloar, 2008; Roy et al. 
2007; Wozniak et al. 2007).  
In both the quantitative and qualitative studies, however, no matter the degree of 
threat participants had assigned to HCV at baseline, at follow-up they reported a 
decrease in perceived threat of the illness. These results were confirmed in Chapter 6 
with significant differences found in illness perception scores between Time 1 and 
Time 2 irrespective of the trial group. This decrease in illness perception suggests HCV 
becomes less threatening after undergoing treatment. As explored in Chapter 6, the 
common sense model (CSM) of self-regulation of health and illness (Figure 8.2) was 
useful to understand this change in HCV perception (Leventhal et al. 1980; Leventhal et 
al. 1984; Samo et al. 2015). 
 
Figure 8.2 Leventhal’s Common sense model of self-regulation  
Adapted from Ogden 2012 
 
When asked about HCV symptoms, participants generally reported very few if any. 
Some would report not knowing they were ill; others reported feeling tired or ‘having a 
feeling’ something was wrong. For those who were shocked at their diagnosis and 
worried about the infection, basic knowledge of the virus was slightly lacking; they 
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knew the causes of the infection, but could not relate that to their own behaviour. 
They also presented a degree of unrealistic optimism (Harris & Middleton, 1994; 
Weinstein, 1982), believing they were taking good precautions against infections. In 
other participants, the ubiquitous nature of the virus, coupled with the absence of any 
symptoms, led participants to be acceptant and indifferent towards the virus, with an 
acknowledgement of the perceived susceptibility and causes of the virus (Rhodes et al. 
2004; Rhodes & Treloar, 2008; Roy et al. 2007; Wozniak et al. 2007). 
All participants had started on HCV treatment by the time they were enrolled onto the 
study, so they were aware of DAA treatments, of the successful cure rate of the 
treatment, the timeline of the illness/treatment and any consequences of the virus if 
left untreated, as all this information had been provided to them by the nurses before 
commencing on treatment. 
The second stage of the CSM model comprises the self-regulatory coping strategies 
that drive the individual to seek a return to their status quo, their un-infected self. In 
the present studies, this stage was uniformly an approach coping strategy, with all 
participants seeking and engaging with HCV treatment (Leventhal et al. 1980; 
Leventhal et al. 1984; Samo et al. 2015).  
The final stage involves the appraisal of the selected coping strategy. This is the time at 
which participants were interviewed for the qualitative study and when they 
completed the follow-up illness perception score for the quantitative study. The 
significant reduction in illness threat suggest that participants’ appraisal of treatment 
(their selected coping strategy) was positive and effective. The un-infected status quo 
had been achieved and the illness representation had been modified according to their 
successful experience of treatment (Leventhal et al. 1984; Ogden, 2012) 
 
8.2.3 Trauma and trauma-informed care 
Interesting divergent results of the two studies, quantitative and qualitative, regarded 
trauma, a topic that developed from different viewpoints but that ultimately 
converged towards mutual implications for practice. A plethora of evidence associates 
traumatic experiences with substance use disorders, and specifically traumatic 
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experiences and injecting drug use (Dube et al. 2003; Felitti, 2003; Huang et al. 2011; 
Kerr et al. 2009; Khoury et al. 2010; Ompad et al. 2005; Pearce et al. 2008; Quinn et al. 
2016; Roy et al. 2003). Felitti’s (2003) study on Adverse Childhood Experiences (abuse, 
neglect, household dysfunction) pinpointed the origins of addiction in traumatic 
experiences in childhood. 
Experience of trauma is common. Scottish evidence indicates that up to 20% of 
children experience sexual abuse, one in six 11-17 year-olds experience severe 
maltreatment and 20% of women experience domestic abuse (NHS Education for 
Scotland, 2017). For some populations experience of trauma is even higher. The World 
Health Organization estimates that 75% of people who attend substance use services 
have experience of trauma (Krug et al. 2002), with other evidence suggesting up to 
80% of people who inject heroin have experienced childhood trauma (Wang et al. 
2010). The findings of the present study found 76% of the sample self-reported 
symptoms of posttraumatic stress disorder at baseline, in line with the available 
evidence on prevalence in this population. 
NHS Education for Scotland (2017) launched a training framework to transform 
psychological trauma and up-skill the Scottish Workforce enabling everyone, at 
different skill levels, to understand and respond to the needs of people affected by 
trauma. All healthcare should be provided in a trauma-informed way. However, 
healthcare services, including substance use services, tend to assume controlling, 
supervised and restrictive strategies, including negative operant conditioning to 
control behaviours, when caring for PWID (Duff, 2013; Earnshaw et al. 2013; Fraser, 
2006). When considering that between 75 and 80% of PWID have experienced trauma, 
this type of power dynamic between provider and patient offers little chance for 
patients to increase their agency and internalise the locus of control, in addition to 
increasing the possibility of developing damaging patient-practitioner relationships 
(NHS Education for Scotland, 2017). 
The qualitative study findings showed that the approach that the viral hepatitis nurses 
applied when offering treatment to study participants respected the trauma-informed 
values of working with patients affected by trauma. It allowed participants to 
experience a sense of free will and choice, allowing them to act independently, 
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welcoming a sense of ownership over the desire to be cured and a sense of agency 
over their treatment (Chapter 7; Braun et al. 2018). There is evidence that actively 
involving individuals in treatment can improve outcomes and experience of treatment 
(NHS England, 2014; Vahdat, 2014).  
Unfortunately, no outcome measures regarding trauma-informed working were 
collected in the quantitative study, so these observations and findings are drawn from 
the qualitative interviews. These are outcomes that should be researched further to 
enable the understanding of, and facilitate the implementation of, trauma-informed 
work at a systems level to improve the experience of PWID engaging with general and 
specialist health services. 
 
8.3 Recruitment  
Failure to recruit to target is the top reported inefficiency in UK registered trials (Duley 
et al. 2018). Reviews of funded RCTs show only 55% of studies recruit to their required 
sample size, with 44% failing to meet target and 22% achieving less than 80% of their 
target sample size (Duley et al. 2018; Sully et al. 2013). The current study managed to 
recruit 74.6% of the required sample, although only 47.8% of the target sample 
completed the randomisation tasks. This led to significant restrictions on the strength 
and generalisability of the analyses. 
 
8.3.1 Settings 
Recruitment took place in two injecting equipment provision (IEP) services (Dundee 
and Perth). Participants were receiving their HCV treatment at these IEPs. The 
accessibility and familiarity of these locations facilitated treatment: participants’ 
familiarity with the environment and the staff reduced potential anxiety and 
discrimination (Harris et al. 2013; Treloar et al. 2013b). It allowed participants to avoid 
unfamiliar healthcare settings which can be perceived as stigmatising and can be 
associated to discriminatory experiences (Harris et al. 2013; Treloar et al. 2013b). 
The co-location of the treatment clinics and the IEP service allowed participants to 
collect injecting paraphernalia whilst visiting the service for their HCV treatment. This 
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was highly encouraged given the target population for the treatment was active drug 
users and the nurses were keen to adopt a holistic approach to the care they offered. 
It is possible, however, that this might have played a part in the low uptake and 
retention of this study. Visits for the ADAPT study were between 20 and 30 minutes, 
sometimes longer when participants were very talkative. By asking them to participate 
and give up their time, the researcher was also delaying their drug taking. Delaying 
gratification can have a substantial impact on substance users’ physical and cognitive 
wellbeing. The best example that can be provided in the study is that of participant 32. 
This participant was being seen for their third visit. Half way through the visit they 
asked to stop the visit as they were in withdrawal and physically unable to stay in the 
room any longer. The study visit had stopped them from leaving the IEP service 
straight after being dispensed his HCV treatment to inject heroin. The protein drinks 
offered at the end of each visits were obviously not beneficial enough for him to stay 
an extra 5 or 10 minutes to finish the visit. Incentives such as the protein drinks and 
monetary reward will rarely triumph over immediate heroin gratification.  
Previous research has found that heroin users delay discounting rates are twice those 
of non-addicted controls, with discounting rates positively correlated with impulsivity 
traits (Kirby e al. 1999). Delay discounting refers to the choice an individual makes to 
receive a reward of reduced value in the present compared to a higher value reward in 
the future (Kirby et al. 1999). As rewards become more remote, their present value 
decreases. For some participants, the present value of the protein drinks they would 
receive after 20/30 minutes of research visit was negligible, or in fact negative, when 
considering physical and cognitive gratification from illicit substance use had to be 
delayed. In addition, the participants were receiving protein drinks from the nurses for 
their HCV treatment too, so part of the reward had already been obtained. 
 
8.3.2 Issues and obstacles 
The first obstacle was identified in the characteristics of the physical environment. The 
main IEP service in Dundee where recruitment took place, the Cairn Centre, is an 
integrated service for harm reduction and BBV care. A third sector agency (Gowrie 
Care) manages the site and provides the IEP service. NHS nurses tend to the physical 
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harm reduction needs of patients, such as caring for injecting-related injuries, and use 
clinic rooms to test patients for BBVs and treat HCV infections. The service is placed 
within a ground floor space, with 5 sitting spaces and 2 clinical rooms. The clinical 
rooms need to be available for clinical purposes, and the 5 sitting spaces in the office 
are used by 3 Gowrie Care staff and 2 or 3 nurses every day. This meant there was no 
space for the researcher to stay in the needle-exchange, to be visible and easily 
approachable when potential participants came in.  Within the same building there 
was a large office on the second floor with NHS node points. This office was vacant so 
the researcher used this space daily to be physically present in the building. Yet given 
the physical separation (2 floors, locked doors, flights of stairs) of these offices, 
researcher visibility was poor, and nurses had to proactively ask patients if they were 
interested in participating and contact the researcher to join them on the ground floor. 
Another obstacle was identified in the recruitment process. Active HCV infection was 
an inclusion criterion for the study. The sponsor of the study did not allow the 
researcher to approach the potential participants herself because of medical 
confidentiality, but required the nurses providing the HCV treatment to ask patients 
for their consent to speak to the researcher about the ADAPT study. If they agreed, the 
researcher would see them immediately after their HCV treatment visit to explain the 
study and ask if they wanted to participate. This required nurses to remember to ask 
patients if they wanted to speak to the researcher. At the start of the trial this was 
identified as a substantial obstacle to successfully recruiting participants.  
In order to facilitate patients’ attendance for HCV medication dispensing, the nurses 
did not assign appointment timeslots for patients but just asked them to come in 
during opening hours on specific days. This allowed participants to attend when it 
most suited them, empowering them and allowing them to take control of their own 
treatment. It also meant that, at times, a participant was missed because the 
researcher was seeing another participant or was away at a meeting or training. 
Nurses would employ strategies to remind participants to attend for their treatment. 
They would verbalise the reminder at each patient visit; they would write on the 
medication packaging the date the patient was expected to return for further 
dispensing; they would phone the patients directly if they had failed to showed up on 
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the assigned day by lunchtime; and lastly, if patients were on a prescription for opiate 
substitution therapy (OST) at a pharmacy, they would phone that pharmacy to ask if 
the patient had already collected their OST and, where they hadn’t, would ask the 
pharmacist to remind clients to attend the IEP service. 
Issues arose when recruitment opened in the second site (Drumhar, Perth – over 20 
miles from Dundee). As an individual researcher was running the trial, she could not be 
in both the recruitment sites at the same time. The researcher discussed with the 
nurses which day was the busiest in the Perth clinic for HCV patients and they agreed 
she would attend the second site every Thursday. In order not to miss participants 
from the main site in Dundee on Thursdays, she ran through the trial materials with 
two of the nurses and asked them if they felt comfortable being on the trial’s 
delegation log. This allowed the trial visits to be completed by the 2 nurses. Over the 
course of the trial, a total of two end of treatment visits (visit 3) and one final visit (visit 
4) were completed by the nurses. 
 
8.3.3 Strategies to increase recruitment and retention 
The Health Behaviour Change Competency framework developed by Dixon and 
Johnston (2010) describes a route MAP that does not utilise behaviour change models 
but assembles the 93 behaviour change techniques from Michie’s (2013) Taxonomy 
into three main routes to behaviour change: Motivation development, Actions & 
control, and Prompts & cues (MAP). Albeit this framework and route map are mostly 
NHS Education for Scotland to upskill healthcare staff in health behaviour change, the 
researcher found it useful in order to develop strategies to change the behaviour of 
nurses to increase recruitment and retention in the ADAPT trial.  
Nurses were very motivated to recruit participants in the HCV treatment trial, mostly 
driven by motivation to treat and cure patients. Due to their passion for patient 
welfare, it was apparent that they were also motivated to help the researcher recruit 
to the ADAPT trial in order to reduce instances of sharing of injecting equipment, but 
also from intrinsic curiosity around the psychosocial factors measured in the trial. The 
researcher and the nurses discussed the best plan (Action) to enable recruitment to 
ADAPT. When patients attended, the nurses would explain briefly that there was a 
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study conducted by a psychology student to aid behaviour change. If they agreed to 
see the researcher, the nurses would reach her by phone (mobile number) and she 
would see patients immediately. 
So the Motivation and Action components of the behaviour change framework were 
present. What the researcher identified as missing were prompts and cues. Prompts 
rely on the automatic and associative cognitive system to change behaviour, which 
was identified as the target component to facilitate the desired behaviour. Prompts 
were introduced in the physical and social environment at different stages.  
Initially the researcher added a post-it with her name and phone number above the 
telephone by the PCs used by the nurses in the office and clinical rooms. Potential 
participants were still being missed, so the researcher added another prompt by using 
the nursing team’s diary. Nurses on shift would check the diary first thing in the 
morning so the researcher added her name next to the patients that were booked in. 
By keeping on top of patient’s treatment schedule for participants that had been 
consented onto ADAPT, the researcher would then socially prompt the nurses by going 
to speak to them during the working day about the specific participants she wanted to 
see. 
One of the nurses (the one working most with these patients) then decided to create 
their own physical environmental cue by adding a blank matrix to the medicine cabinet 
from which patient were dispensed their HCV medication, in order that the researcher 
could add the patients ADVANCE participation number (the medicinal trial) for the 
patients she needed to see that week. The researcher would update this daily in case 
someone had not shown up on their scheduled day. This prompting worked for a 
while, but then the nurses got too used to seeing the prompts on the cabinet and 
stopped paying attention to the numbers written on them. 
Consequently, the researcher decided to use social prompts as the next strategy to 
increase recruitment and retention. She would stay in the needle-exchange every 
morning until the nurses arrived to work to socialise and to request to the nurse on 
shift to see selected participants. During the working day the researcher would also 
return to the needle-exchange as an additional cue and to specifically enquire whether 
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any of the patients had attended. The nurses often reported that patients would 
attend but refuse to see the researcher because of time constraints. 
The last strategy applied was the most successful one. A further environmental cue 
was added to the individual patients’ dispensing logs. The researcher would add a 
post-it inside the patients’ file at the start of each week for any consented participants 
she needed to see. As the nurses opened the file and recorded the dispensing, they 
were prompted to phone the researcher whilst the patient had just been dispensed 
(fortnightly doses) or was still consuming their daily dose (daily dispensed). 
The optimal option for recruitment would have been for the researcher to be 
physically present in the needle-exchange area the whole time. As this was not 
possible given space restrictions, the described trial and error of prompts resulted in 
the selection of the best available cues to enhance recruitment and retention. 
8.3.3.1 Contingency management  
As discussed previously, participants were offered protein drinks at the end of each 
visit. Among the HCV-positive injecting population, these protein drinks have gained 
value over the years as they were provided in concomitance to HCV treatment. During 
the Interferon-era of treatment, the protein drinks served a physiological purpose. As 
the DAA-era of treatment started, the protein drinks became a form of contingency 
management. 
Contingency management refers to providing patients with rewards such as vouchers, 
privileges or modest financial incentives to increase health promoting behaviours 
(Department of Health and Social Care, 2017; National Institute for Health and Care 
Excellence - NICE, 2007b). It is one of the few psychosocial interventions actively 
recommended within NICE guidelines because of the strong evidence supporting it.  
Anecdotally, the protein drinks were not solely used for the purpose of consumption. 
They were also sold on the street. This, indirectly, drastically increased their value as a 
form of contingency management. However, the protein drinks were provided with 
the patients’ HCV treatment so, in turn, the value of the reward for the ADAPT study 
reduced. The ADAPT visits were longer and participants were already in possession of 
protein drinks after being dispensed HCV treatment. Some participants felt that there 
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was no need to stay longer to get another few protein drinks, whilst other still 
appreciated the extra bottles. 
The small cash reward provided in the qualitative sub-study was substantially more 
attractive. Participants were keen to take part in the interview, even though they were 
told it would take around 30 minutes. In this case, the value of the reward, albeit not 
in the present moment but in the immediate future, was considered worth the effort 
and wait. This delayed (monetary) gratification might have been considered beneficial 
because of a possible anticipated future gratification (in the form of drug use). 
Ethical considerations were given in regards to the provision of monetary incentives. 
Some research suggests that compensation to PWID should be provided in vouchers or 
food (Ritter et al. 2003). This is because monetary incentives are believed to attract 
PWID for the economical gain rather than the willingness or interest in participating in 
research, impairing voluntary consent (Ritter et al. 2003). There are also 
preconceptions about the way PWID will use the monetary incentives, i.e. to buy illicit 
drugs, placing researchers and ethics committees in a moral conundrum (Murdoch & 
Caulfield, 2016). However, research has shown that, although there is a lack of these 
preconceptions for the general population, 30% of participants in RCTs from the 
general population state money as the main motivator for participating and that less 
than 5% of participants thought of money as a coercive incentive (Byrne et al. 2012; 
Murdoch & Caulfield, 2016). Therefore, avoiding monetary incentives only in research 
with PWID reinforces negative stereotypes and stigma towards this population, 
preconceiving participants as untrustworthy (Murdoch & Caulfield, 2016). 
8.3.3.2 Lost to follow-up 
Attrition rates in RCTs are common, with mean attrition falling between 21.1% and 
66% (Cooper et al. 2018; Gindi et al. 2009; Gratton et al. 2007; Horyniak et al. 2013; 
Manstead & Semin, 1999; Rigotti et al. 1997; Samo et al. 2016). The current study 
showed an even higher overall attrition rate of 84%. 
As explored in Chapter 6, there were different reasons why people were lost to follow-
up (LTFU). The cost-benefit analysis of time employed to complete a visit and the 
protein drinks incentive was undoubtedly one of the reasons why participants were 
LTFU. The researcher believes this cost-benefit analysis was one of the explanations for 
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some of the twenty-two participants that were lost to follow-up for unknown reason 
(LTFU= 44%). Nine people were withdrawn from their HCV treatment (18%) because 
they did not attend their dispensing appointment for up to 7 days after their assigned 
date (Inglis et al. 2019). HCV is capable of developing viral resistance to treatment 
(Sagnelli et al. 2018) so this mechanism was put in place to reduce emergence of DAA 
resistance among HCV-positive participants. Eight people went to prison (16%). Their 
HCV treatment was continued via the prison healthcare facilities but the ADAPT study 
could not take place in prison. One participant was withdrawn as cognitively 
incapacitated due to being under the influence of heroin (2%). One participant was 
hospitalised due to severe injecting-related injury (2%). One participant was in 
withdrawal and left half way through visit 3 and was then LTFU (2% - Visit 3 data 
completed as LOCF).  
Visit disruptions were also common with staff in the needle-exchange looking for 
available rooms or recovery workers, social workers, and at one time even police, 
looking for the people being seen in the study. This was considered the nature of the 
population under investigation and strategies could not be employed to reduce the 
interruptions and study drop-outs. 
8.3.3.3 Time and repetition  
After the first few participants had been recruited to the trial, the first repeated 
measures took place. Some participants commented on the length of the visits and the 
repetitiveness of some of the measures. The researcher discussed this feedback with 
her supervisors and the decision was taken to amend the protocol to facilitate 
participants’ engagement. Amendment 02 (AM02), reported in Chapter 4, was 
submitted to shorten the first two visits and reduce the repetition of some of the 
measures taken at both these visits. 
 
8.3.4 Substance influence: assessing cognitive and physical capacity 
The researcher was aware of the issue of substance influence on the ability of 
participants to give informed consent and to complete study visits. As a population 
which is characterised by the use of both prescribed and illicit opioids, 
benzodiazepines, and often other substances, expecting the participants to be fully 
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sober would have been unrealistic and would have lacked ecological validity. PWID are 
able to perform daily tasks under the influence of substances and this ability differs 
individually person to person (Aldridge & Charles, 2008). Therefore, the researcher did 
not assess intoxication categorically, but assessed the level of intoxication using her 
experience of working with the population to appraise excessive influence and 
intoxication. Three examples of excessive influence are described below. 
On one occasion, a follow-up visit was interrupted and the little data that had been 
collected was deleted, as the participant showed severe levels of heroin influence and 
the nurses were called. Naloxone was offered to the person, who refused it. On 
another occasion, a potential participant was being seen for consent. Heavy 
benzodiazepine intoxication became quickly apparent, so the researcher could not 
take inform consent and instead offered the person a cup of coffee and sat with him to 
ensure his health and safety. A third example relates to assessing physical capability 
due to withdrawal symptoms. As presented in the LTFU section, one participant left 
half way through visit 3 because he was experiencing heroin withdrawals. He was not 
capable of sitting physically still, was sweating and agitated albeit very lucid. The 
researcher asked him if he wanted to stop. He was grateful she had asked and left. 
Cognitive capacity was also assessed for the qualitative study, as participants were 
required to reflect and express their lived experience of HCV. All the participants that 
were approached, consented and interviewed were not incapacitated by undue 
influence. However, conducting the qualitative interviews proved quite difficult. As 
discussed in the section on trauma-informed care, PWID are used to controlling, 
punitive and, at times, stigmatising experiences of healthcare services. As a 
population, they are not generally used to being asked about their thoughts and 
opinions, not to reflect on situations and feelings or to be involved in their own care 
plans (other than in research settings). In addition, chronic drug use reduces neural 
processing of frontal regions, impairing cognitive function (Dregan & Gulliford, 2012; 
Jentsch & Taylor, 1999; Severtson et al. 2012). When prompted to say more, 
participants would generally just repeat what had been said or not develop the topic 
any further, producing a series of short interviews. However, the analysis proved the 
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interviews to have been fruitful, engaging and generating stimulating content (Chapter 
7). 
 
8.4 Implications for clinical practice 
Direct implications for practice cannot be stated regarding the intervention as the 
results on the effect of implementation intentions are not reported with confidence, 
but some implications can be reported for secondary outcomes and findings. 
Harm reduction staff and viral hepatitis nurses should implement routine enquiry 
about all individual injecting paraphernalia (e.g. water, filters, spoons) when asking 
active injectors whether they have put themselves at risk. Asking clients and patients 
about sharing in general terms results in a significantly lower number of self-reported 
sharing contacts, compared to asking the same question after enquiring about each 
individual injecting equipment piece. The findings showed that water continued to be 
the most shared equipment piece and that participants would not recall water sharing 
as a risk until specifically being reminded about it, as supported by previous literature 
(Gaskin et al. 2000; Gossop et al. 1997).  
The strong significance of identification with a drug network as a predictor of injecting 
sharing behaviour also has implications for practice. Since usually identification with a 
social group is associated with improved health, these findings are a reminder that 
some forms of social identifications may pose health risks depending on the type of 
group people are identifying with. Substance use practitioners, BBV practitioners and 
harm reduction staff should ask patients and clients about their strength of 
identification with a social group that injects drugs. This will help them assess the 
degree of individual risk for each person.  
The viral hepatitis nurses and the harm reduction staff in the needle-exchanges have 
been made aware of these results and their implications for practice. 
  
209 
Chapter 8   
8.5 Strengths and limitations of the study 
8.5.1 Strengths of the study 
Although literature has called for the use of implementation intentions with people 
who use drugs for some time now (Gagnon & Godin, 2009; Palfai, 2006; Prestwich et 
al. 2006), the results of chapter 2 showed no such studies had been carried out and 
published. ADAPT is the first study to use implementation intentions as an intervention 
to reduce risk behaviour in people who inject drugs.  
The methodology devised for the study was sound (Chapter 4). Most of the outcomes 
selected were previously developed and validated measures. Where previously 
published scales were not available or appropriate, adaptations of validated scales 
were made to ensure the quality of the measurements collected. Using validated 
measures reduces research waste and allows more scientific evidence to be collected, 
disseminated and critically evaluated (McDowell, 2006). The randomisation in the trial 
was also very rigorous, as demonstrated by the randomisation checks reported in 
chapter 6.  
The intervention was innovative for a variety of reasons. Firstly, the intervention was 
carried out with people who inject drugs. Although one study reported using 
implementation intentions with people who used drugs in opiate withdrawal 
(Brandstätter et al. 2001), the participants in the study were asked to form 
implementation intentions to create a curriculum vitae rather than to change or 
reduce their substance use behaviour. In addition, they were patients admitted to a 
hospital for detoxification and were not currently injecting. No studies to date have 
reported the use of this intervention with actively injecting drug users. Furthermore, 
the implementation of the intervention was carried out with a clinical population as 
the participants were all on treatment for HCV.   
This leads onto the second innovative aspect of ADAPT. Since 2013, both the UK and 
the Scottish Governments have produced legislation to facilitate the integration of 
health and social care (Department of Health and Social Care, 2013; Scottish 
Government, 2015b). ADAPT was integrated in a needle-exchange setting and with a 
viral hepatitis service, increasing the holistic approach to health, care and support 
needs of patients that required HCV treatment (Department of Health and Social Care, 
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2013).  
Lastly, the integration of ADAPT within a third sector needle-exchange and an NHS 
clinical team, enabled the researcher to develop multidisciplinary ties. The researcher, 
a health psychologist, was collaborating with the nursing and medical team of the viral 
hepatitis service, the gastroenterology service, the harm reduction service, in addition 
to public health workers from the sexual health and BBV managed care network, the 
clinical psychologist in the substance use service and the third sector harm reduction 
staff. Multidisciplinary working allows professionals to learn about colleagues’ 
activities and roles which can improve communication (Finkelman, 2006). It also allows 
for collaboration between disciplines which improves quality of care and increases 
professionals’ knowledge and skills (Finkelman, 2006; Ndoro, 2014). 
 
8.5.2 Limitations of the study 
Limitations of the study (ADAPT and the qualitative sub-study) were discussed 
individually in each chapter and most of the obstacles and issues encountered during 
the study were discussed in the preceding paragraphs. However, an overall discussion 
of limitations is presented here. 
The main limitation of ADAPT was the difficulty to recruit to target and to retain 
participants in the trial. The design of the trial was adapted during the study and 
different recruitment strategies were employed to increase recruitment and minimise 
drop-out rates. Despite this, the target sample was not reached and attrition rates 
remained high throughout the study. This issue resulted in the impossibility to run the 
planned multivariate analyses in chapter 6. It also meant that one of the secondary 
research questions could not be investigated, as the outcome for the longevity of the 
intervention effectiveness 4 months post-intervention (i.e. 12 weeks post HCV 
treatment) presented too many missing data. 
To deal with missing data and allow for a degree of the planned modified intention-to-
treat analysis, a Last Observation Carried Forward (LOCF) strategy was applied. This 
strategy is widely used in clinical trial analyses plans but it can introduce bias as it 
implies no change has occurred over time for participants that have been lost to 
follow-up. It also ignores data trends prior to drop-out (Streiner, 2008; Streiner & 
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Geddes, 2001). These negatives aspects are thought to be offset by the advantages of 
using this strategy. It allows for testing of the effects of the intervention on a larger 
sample, minimising the participants excluded and therefore the research waste 
associated with the trial (Conroy et al. 2015; Streiner, 2008). 
In order to keep the time of research visits to under 30 minutes, the baseline measures 
and the interventions were divided into 2 visits (visit 1 – start of treatment & visit 2 – 
mid treatment). This resulted in a loss of data as 18 participants did not return for visit 
2, not allowing the analysis in chapter 5 to include one of the main outcomes (self-
efficacy) and some of the secondary outcomes (social connectedness and social 
norms). A sample of 32 was considered too small to be able to result in reliable 
inferences about the data even with bootstrapping, given the skewed sampling 
distribution and that bootstrapping cannot be used as a justification for a small sample 
size (Rousselet et al. 2019).  Therefore the association and predicting role of self-
efficacy on injecting risk behaviour, evidenced in published literature, could not be 
tested (Bonar & Rosenberg, 2011; Cox et al. 2008; Gagnon & Godin, 2009; Gibson et al. 
1993; Nasir et al 2009; Thiede et al. 2007; Wagner et al. 2010a). 
Despite dividing the baseline measures and attempting to keep the visits to under 30 
minutes, the visits were too long for the population in the study and the number of 
questionnaires and measures was too high. Participants repeatedly reported they 
would not have time to stay for a visit. This issue was pre-empted in the planning 
stages and incentives were put in place to increase recruitment and retention. The 
incentives were not enough to serve this purpose. These limitations and the results 
reported in these chapters will, however, help inform and guide future selection of 
psychosocial factors to be tested, alongside appropriate incentives and contingency 
management strategies to aid recruitment and retention. 
The sample size of the qualitative sub-study was also small, due to the pool of available 
participants diminishing towards the end of the trial. Although the sample size 
presented in chapter 7 was considered adequate for the methodology applied, a larger 
sample would have helped consolidate the results. 
A further limitation was the initial lack of familiarity of the population (needle-
exchange clients) with the researcher. As discussed above, around 80% of this 
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population has experience traumatic events. Experience of trauma can affect people’s 
trust in others (NHS Education for Scotland, 2017). As the researcher was not offering a 
treatment or a service and was simply asking personal questions about consumption of 
illicit drugs and intimate mental health and social details, issues with trust might have 
influenced people’s decisions for taking part in the study and returning for future 
visits. The lack of initial familiarity might have also influenced participants’ self-
reported responses. As some of the outcomes were of a sensitive nature (injecting risk, 
trauma, depression, anxiety), the validity and reliability of the self-reported outcomes 
might be limited. For example, some participants might not have wanted to disclose 
traumatic experience to the researcher after only meeting them once. Nonetheless, 
evidence shows that behavioural self-reports of people who use drugs are reliable and 
valid when compared to biomarkers, collateral interviews and criminal records (Darke 
et al. 1998). No such evidence has been produced for self-reported psychosocial 
outcomes. 
Finally, the effect of implementation intentions was only tested at a 4-week follow-up. 
Evidence shows that sustained behaviour change is commonly defined as 6 months 
since the initial behavioural modification (Prochaska & DiClemente, 1983). A 6-month 
follow-up was initially planned, but given the difficulty in retaining participants, it was 
amended to a 4-month follow-up as participants were expected to attend in this 
timeframe for the conclusion of their HCV treatment. Despite the change the attrition 
rate was extremely high and it did not allow any meaningful analysis of the data. 
 
8.6 Directions for future research  
This chapter has so far presented a number of ‘lessons learnt’ which will help improve 
and guide future research with this population in this setting. ADAPT showed that 
implementation intentions can be created with people who actively inject drugs and 
are on treatment for HCV. The effectiveness of the intervention, however, could not be 
reported with confidence given the small sample which was analysed. The large effect 
size observed for self-efficacy indicates that implementation intentions could aid self-
efficacy to remain high over time. The effects of the intervention on sharing behaviour 
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were less clear. The effect sizes reported suggest a larger trial would increase the 
understanding and confidence of the results reported and would likely find interesting 
results. 
Additionally, the contradicting results on self-efficacy and powerlessness in the 
quantitative and qualitative studies suggest that the self-efficacy measure used, 
adapted from Martin’s (1995) Self-Efficacy Scale for Drug Avoidance and 
recommended by the European Monitoring Centre for Drugs and Drug Addiction, had 
questionable validity and reliability. The administration of this scale to a large sample 
of PWID would allow a factor analysis to identify item factor loadings and result in the 
modification of the scale. 
Future research should consider conducting all main outcomes and interventions in 
the first baseline visit with people who inject drugs to ensure all main measures are 
captured in the first instance. Additionally, given the highly correlated nature of the 
mental health scales, considerations should be made about the need to measure all 
variables as separate constructs. If possible, the outcomes should be integrated in 
patients’ treatment visits and collected by nursing staff that have already established a 
therapeutic relationship with the patients and that are more likely to see patients 
returning for their treatment. Further considerations in regards to incentives for 
participants should be given in order to increase recruitment and retention. 
Interventions on social network identification to reduce sharing of injecting equipment 
should be designed and piloted with the PWID population. The change in illness 
perception should also be explored in future research as a potential predictor of HCV 
reinfection and as a target for intervention. 
 
8.7 Conclusions 
This pilot randomised controlled trial demonstrates that it is feasible and acceptable to 
create implementation intentions with people actively injecting drugs and on 
treatment for HCV. It reveals major difficulties with retaining PWID in a longitudinal 
trial not allowing firm conclusions in regards to the effectiveness of implementation 
intentions in reducing sharing of injecting equipment. However, it does suggest that 
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the behavioural intervention functioned as risk limitation rather than as active 
instrument producing positive change in regards to the self-efficacy outcome. A larger 
study is needed to confirm and consolidate these findings. 
Despite the small sample size, ADAPT revealed some interesting secondary results. 
First, it identified the strong influence of identification with a drug network on 
injecting sharing behaviour. Group identification, usually associated with improved 
mental and physical health outcomes, was exposed as a negative influencing factor of 
drug using behaviour. Second, the importance of enquiring about each singular piece 
of injecting paraphernalia when assessing injecting risk was highlighted as an essential 
aspect of risk assessments for staff working in harm reduction, substance use and viral 
hepatitis. Last, the changing perception of HCV throughout treatment was thoroughly 
explored and it suggest HCV risk increases as patients undergo treatment and as 
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